IMS Canada

Helping you stay
2006 Canadian Pharmaceutical ahead of the curve
2006 Canadian Pharmaceutical Industry Review

ABOUT IMS HEALTH
Operating in more than 100 countries,
IMS HEALTH®
16720 Trans-Canada Highway
Kirkland (Québec) H9H 5M3
Industry Review
IMS Health is the world’s leading provider (514) 428-6000
The Canadian pharmaceutical marketplace is complex and ever changing and 2006 was no
exception. Outperforming the global market in terms of growth, Canada held its position as the
of market intelligence to pharmaceutical 6755 Mississauga Road, Suite 200 8th largest market. Rebounding from drug safety concerns and picking up momentum through
and healthcare stakeholders. With $2 billion Mississauga, Ontario L5N 7Y2 a shifting product mix of biotech, generics and specialty offerings, Canada is forecasted to
in 2006 revenue and more than 50 years of (905) 816-5000 grow at a compound annual growth rate of 7.7% between now and 2011.
industry experience, IMS offers leading-edge http://extranet.imshealthcanada.com
Concurrent to this period of positive growth, challenging market conditions prevail. There is
business intelligence products and services sustained pressure to contain costs, fewer new products to launch and large patent expiries
that are integral to clients’ day-to-day that have the potential to reduce the brand name franchises to the tune of over $1 billion
operations and to the delivery of quality in 2007. To succeed in this environment requires the right strategic plan, effective execution
and the courage to invoke evidence-based change when conditions demand.
healthcare worldwide.
With management and investors keeping a close eye on the bottom line, there is little margin
for error. By partnering with IMS, clients gain the most comprehensive and reliable information,
analytics and consulting expertise to optimize the return on their sales force deployment and
marketing plan investment. IMS provides clients with the confidence to act guided by
evidence-based plans – helping them get the most out of every lifecycle phase.
Contact your IMS representative to learn more

about IMS offerings or visit our client website:
IMS Health Montreal: (514) 428-6000

Toronto: (905) 816-5000
Web: http://extranet.imshealthcanada.com
Helping you stay

ABOUT IMS HEALTH
IMS HEALTH®
Industry Review


Toronto: (905) 816-5000
MARKET INFLUENCERS
• Health Canada raising standards
for drug trials
• Pipeline gaps created due to lack
of new blockbusters
• Primary care growth is outpaced
by specialist-driven therapies
• Generics, oncology and biotech
grow in double digits
• Delays in public formulary
market access
• Regulators, payers and patients
increasingly weigh drug-risk/benefit
IMS SOLUTIONS
The intelligence to plan, build and tune
portfolios for success – setting the course
for the future. 2
Launch and Growth 3Maturity
• Determine investment levels
for new product research
•
•
Evaluate new markets, therapies
and acquisitions
Identify products to develop
and license
MARKET INFLUENCERS
•
•
Government cost containment initiatives
reduce spending
Governmental pressure for optimal
4Decline
• Optimize pricing and reimbursement therapy and post-marketing surveillance
strategies • Provincial formularies accelerating
• Assess market value and competition the shift to new generics
• Establish appropriate customer • Pipeline gaps due to patent expiries
segmentation strategies
• Balance resources across brands IMS SOLUTIONS
• Leverage health economics MARKET INFLUENCERS The confidence to make timely,
smart decisions that enhance efficiency,
• Slower adoption of new products
productivity and return on investment
• Growth in non-retail distribution
in sales and marketing.
• Physician access increasingly restricted
and return on detailing declining • Ensure thorough sales diagnostics
• Patients becoming influencers in • Optimize resources and align territories
product selection • Develop ideal customer segmentation
and call plans
IMS SOLUTIONS • Manage sales team performance
The insight to accelerate commercial launch and compensation
success and maximize the lifetime value of • Track and analyze competitors’ pipeline
a product or brand. • Demonstrate post-launch compliance
and outcomes
1Pre-Launch •
•
Assess market and competitive situation
Review market potential and forecasts
Create effective launch plans and
monitor uptake
•
•
Evaluate success of co-marketing
strategies
Plan for patent expiry
IMS
helping you
• Plan, optimize and evaluate ongoing
promotional mix throughout the
•
•
Optimize sales force deployment
Manage the overall lifecycle lifecycle
MARKET INFLUENCERS
• Health Canada raising standards
for drug trials
• Pipeline gaps created due to lack
of new blockbusters
• Primary care growth is outpaced
by specialist-driven therapies
• Generics, oncology and biotech
grow in double digits
• Delays in public formulary
market access
• Regulators, payers and patients
increasingly weigh drug-risk/benefit
IMS SOLUTIONS
The intelligence to plan, build and tune
portfolios for success – setting the course
for the future. 2
Launch and Growth 3Maturity
• Determine investment levels
for new product research
•
•
Evaluate new markets, therapies
and acquisitions
Identify products to develop
and license
MARKET INFLUENCERS
•
•
Government cost containment initiatives
reduce spending
Governmental pressure for optimal
4Decline
• Optimize pricing and reimbursement therapy and post-marketing surveillance
strategies • Provincial formularies accelerating
• Assess market value and competition the shift to new generics
• Establish appropriate customer • Pipeline gaps due to patent expiries
segmentation strategies
• Balance resources across brands IMS SOLUTIONS
• Leverage health economics MARKET INFLUENCERS The confidence to make timely,
smart decisions that enhance efficiency,
• Slower adoption of new products
productivity and return on investment
• Growth in non-retail distribution
in sales and marketing.
• Physician access increasingly restricted
and return on detailing declining • Ensure thorough sales diagnostics
• Patients becoming influencers in • Optimize resources and align territories
product selection • Develop ideal customer segmentation
and call plans
IMS SOLUTIONS • Manage sales team performance
The insight to accelerate commercial launch and compensation
success and maximize the lifetime value of • Track and analyze competitors’ pipeline
a product or brand. • Demonstrate post-launch compliance
and outcomes
1Pre-Launch •
•
Assess market and competitive situation
Review market potential and forecasts
Create effective launch plans and
monitor uptake
•
•
Evaluate success of co-marketing
strategies
Plan for patent expiry
IMS
helping you
• Plan, optimize and evaluate ongoing
promotional mix throughout the
•
•
Optimize sales force deployment
Manage the overall lifecycle lifecycle
The
Canadian
Pharmaceutical Industry
at a Glance
From leading companies and products, to the top molecules and classes, this 25th edition of Canadian
Pharmaceutical Review provides an overview of market performance in Canada, as measured by IMS Health
information services.
The publication provides key industry metrics using four key IMS databases that profile drugstore and
hospital purchases, prescription volume activity, diagnoses and treatment therapies, promotional activity and
expenditures, and the generics market.
This publication also features an executive analysis of the global and Canadian pharmaceutical market
performance. A brief description of the IMS services that were used to generate this review can be found
in the Appendix, as well as a list of manufacturer abbreviations and a glossary.
The information contained in Canadian Pharmaceutical Industry Review 2006 is reserved for the exclusive use of IMS
clients. All reproduction rights reserved.
©
IMS Health 2007
Table of Contents
Table Page
Executive Summary 5
I. Corporations and Manufacturers 17

Leading 50 Corporations by Total Ethical Purchases 1 18
Leading 50 Manufacturers by Share of Totla Ethical Purchases, Drug Stores vs. Hospitals 2 23
Leading 50 Manufacturers by Ethical Drug Store Purchases 3 25
Leading 50 Manufacturers by Ethical Hospital Purchases 4 27
Leading 20 Manufacturers and Top Five Products by Ethical Purchases 5 29
Leading 50 Manufacturers by Total Ethical Prescriptions 6 33
Leading 20 Manufacturers and Top Five Products by Total Ethical Prescriptions 7 35
Leading 20 Manufacturers and Top Five Products by Detailing Activity 8 39
Leading 20 Manufacturers and Top Five Products by Journal Ad Expenditures 9 43
II. Products and Molecules 47

Top 50 Products by Total Ethical Purchases 10 48
Top 50 Products by Ethical Drug Store Purchases 11 50
Top 50 Products by Ethical Hospital Purchases 12 52
Top 25 Molecules in Top 15 Therapeutic Classes by Total Ethical Purchases 13 54
Brand-Name Products Launched by Total Purchases 14 58
Top 50 Products by Total Prescriptions 15 60
Top 15 Products by Total Ethical Purchases, Canada vs. United States 16 62
Top 50 Molecules by Total Prescriptions 17 63
Top 50 Ethical Products by Total Promotional Dollars 18 65
III. Therapeutic Classes 67

Top 15 Therapeutic Classes and Leading Manufacturers by Total Ethical Purchases 19 68
Top 15 Therapeutic Classes and Leading Manufacturers by Ethical Drug Store Purchases 20 71
Top 15 Therapeutic Classes and Leading Manufacturers by Ethical Hospital Purchases 21 74
Top 15 Therapeutic Classes and Leading Brand-Name Manufacturers by Total Ethical Purchases 22 77
Top 15 Therapeutic Classes and Leading Generic Manufacturers by Total Ethical Purchases 23 81
Top 15 Therapeutic Classes and Leading Brand-Name Manufacturers by Total Prescriptions 24 85
Top 15 Therapeutic Classes and Leading Generic Manufacturers by Total Prescriptions 25 89
15 Fastest and Slowest Growing Therapeutic Classes (larger than $10 Million)
by Total Ethical Purchases 26 93
Top 15 Therapeutic Classes and Leading Corporations by Journal Ad Expenditures 27 94
Top 15 Therapeutic Classes and Leading Corporations by Detailing and Sampling Activity 28 97
2 Table of Contents
IV. Diagnoses and Therapies 101
Profile of Leading Diagnoses 29 102
Profile of Leading Recommended Drug Therapies 30 103
V. Generic Manufacturers 105
Leading 10 Generic Manufacturers and Top Five Products by Ethical Purchases 31 106
Leading 10 Brand and Generic Drug Manufacturers and Top 5 Provinces by Ethical Prescriptions 32 108
Share of Prescription Market by Province, Brand vs. Generic Manufacturers 33 112
Total Ethical Purchases for the Five Leading Generic and Brand Manufacturers by Province 34 113
Top 25 Generic Molecules and Top Five Products by Total Ethical Purchases 35 117
10 Fastest Growing Brand and Generic Manufacturers (larger than $10 million)
by Total Ethical Purchases 36 122
Appendix 123
IMS Health Information Services 124
Manufacturer Abbreviations 126
Glossary 127
Table of Contents 3
Executive
Summary
Global Pharmaceutical Market
Sales by Region
The global pharmaceutical market recorded $593.4 billion in total ex-manufacturer sales on 6.3% growth, or a
US $32 billion increase in the year ending September 2006. This is well short of the four-year compound average
growth rate (CAGR) of 9.1%. (See Figure 1) There are key market events that have shaped the pharmaceutical
industry in 2006 and are expected to change the market dynamics in 2007. These include the introduction of
the Medicare drug benefit in the US; patent loss and generic introduction for blockbuster products, new product
adoption not keeping pace with the loss of patent protection by established products; specialty and niche products
playing a larger role; continued efforts by local governments to reduce drug spending and manage patient access
to branded pharmaceuticals, and regulators, payers and consumers carefully weighing the risk/benefit factors of
pharmaceuticals. The factors that have affected the global marketplace have largely been the same ones that have
slowed growth in the US and Canadian markets.
Figure 1
Total Sales for the World Audited Market 12 Months Ending September 2006
World Audited Market U.S.$ Bil MAT Sept. 2006 % Market Share 2006 Growth (%) 2006 Growth (%) CAGR 2001-05
Latin America 27.1 4.6 13.4 13.5

Asia/Africa/Australia 50.4 8.5 10.4 11.6
Japan 56.9 9.6 1.4 3.4
Europe 176.8 29.8 5.4 8.5
North America 282.2 47.6 6.6 10.3
Worldwide 593.4 100.0 6.3 9.1
10 Key Markets 478.0 80.6 5.6 8.6
Source: IMS Health. MIDAS
The 10 leading markets (US, UK, Canada, France, Italy, Germany, Japan, Spain, Brazil and China Hospital) recorded
US $478 billion in sales on 5.6% growth for MAT September 2006. (See Figure 2) This growth rate was down
from 5.9% in 2005. The slowing growth of these key markets has been largely responsible for the overall market
slowdown. The contribution of these 10 regions to the market’s incremental growth slipped to 67% in MAT
September 2006, down from 84% just two years ago.
The drivers of the growth in the 10 leading markets of today’s pharmaceutical industry are much different from
what they were in 2002. 2001 and 2002 were arguably the years when new product launches started to have a
declining impact on market growth. In MAT September 2006, new products contributed 2.4 percentage points
of the overall market’s growth and had the largest positive impact on market growth, adding an estimated
US $10.9 billion to the market.
6 Executive Summary
Figure 2
Sales and Growth in 10 Leading Markets 12 Months Ending September 2006
U.S.$ Bil Growth (%)
10 Key Markets 478.0 5.6

US 267.1 6.5
Canada 15.1 7.8
Japan 56.9 1.4
China* 10.3 12.9
Brazil** 8.6 13.9
Major Europe 120.0 4.2
Germany 31.4 2.6
France 32.8 3.9
UK 19.9 2.6
Italy 20.2 6.8
Spain 15.6 7.3
*Hospital Market Only, % Growth, Constant $ **Pharmacy Market Only

Leading Global Corporations

The top 10 corporations recorded US $274.8 billion in total ex-manufacturer sales, a very modest 5% growth for the
12 months ending September 2006. (See Figure 3) The growth of these companies fell short behind the total market’s 6.3%
rate and their 9.5% historical growth rate (2001-2005). Market share has also slipped by 0.7 percentage points since 2005.
Figure 3
Top 10 Corporations 12 Months Ending September 2006
Rank U.S.$ Bil MAT Sept. 2006 % Market Share 2006 Growth (%) 2006 Growth (%) CAGR 2001-05
Worldwide 593.4 100.0 6.3 9.1

1 Pfizer 47.5 8.0 -2.7 6.1
2 GlaxoSmithKline 36.3 6.1 5.6 5.6
3 Novartis 30.9 5.2 7.2 14.3
4 sanofi-aventis 30.3 5.1 0.3 12.1
5 AstraZeneca 25.9 4.4 10.7 7.5
6 Johnson & Johnson 25.5 4.3 -0.1 11.9
7 Merck & Co. 24.9 4.2 6.6 4.6
8 Roche 21.9 3.7 15.4 12.6
9 Abbott 16.3 2.7 5.4 10.3
10 Amgen 15.3 2.6 19.1 30.3
Top 10 274.8 46.3 5.0 9.5
Executive Summary 7
Leading Global Products
Cholesterol reducer Lipitor remains the world’s leading product for the year ending September 2006. (See Figure 4)
Lipitor recorded US $13.4 billion in total global pharmaceutical purchases and grew by 4.6%; fell short of the MAT
September 2005 growth of 9% and its historical four-year CAGR of 15.8%. Aranesp was the fastest growing brand
(34.8%) among the top 10. Falling sales by Zocor and Zyprexa (previously ranked #2 and #3) and slowing Norvasc
sales (#4) allowed Nexium to leap forward by two rankings to become the second-leading global brand.
Figure 4
Top 10 Brands by Global Pharmaceutical Sales
Leading Brands U.S.$ Bil MAT Sept. 2006 % Global Sales 2006 Growth (%) 2006 Growth (%) CAGR 2001-05
1 Lipitor (atorvastatin) 13.4 2.3 4.6 15.8

2 Nexium (esomeprazole) 6.4 1.1 17.6 100.5
3 Plavix (clopidogrel) 6.2 1.0 7.0 37.6
4 Seretide/Advair (fluticasone/salmeterol) 6.1 1.0 11.7 54.6
5 Norvasc (amlodipine) 5.0 0.8 0.1 5.4
6 Zocor (simvastatin) 4.7 0.8 -15.6 0.7
7 Zyprexa (olanzapine) 4.7 0.8 -2.6 9.7
8 Aranesp (darpepoetin alfa) 4.6 0.8 34.8 542.4
9 Risperdal (risperidone) 4.4 0.7 11.8 15.5
10 Enbrel (etanercept) 4.3 0.7 20.2 43.4
Total Leading 10 Brands 59.8 10.1 7.2 21.2
Source: IMS Health Midas. MAT Sep 2006
8 Executive Summary
United States Market Performance
The US market recorded US $274.9 billion in purchases (at trade level) for the year ending December 2006. The
market grew by 8.3% or US $23.1 billion over the previous year, up from 5.4% in 2005 but fell short of its historical
four-year compound average growth rate of 10%. Growth was slower with MAT to September 2006 at only 6.8%,
but year-end growth shot to 8.3%. US sales dollar growth was up sharply in 2006, the first increase since 2001.
Retail Channels accounted for 71.4% of total US purchases and grew by 7.7%. The Institutional Channels accounted
for 28.6% and grew by 9.9%.
Direct-to-Consumer Advertising
For the 12 months ending September 2006, U.S. pharmaceutical companies spent an estimated record $4.53 billion
on direct-to-consumer advertising (DTCA). (See Figure 5) Promotion is shifting away from traditional physician
focus and toward the consumer. DTC grew by 10.8% in 2006, up by 4.8 percentage points from MAT September
2005. DTC dollar growth was due to television and magazine increased expenditure over the last three years.
Public perception of pharmaceutical companies was worse in 2005 than in 1997, but public perception of the
pharmaceutical industry improved in 2006.
Driving this growth was the emerging realization that DTC has positive Return-on-Investment (ROI). Across the
25 therapeutic markets that were investigated by IMS, ROI was positive for a majority of the 49 brands, specifically,
90 percent of brands in the study demonstrated positive ROI.
Figure 5
Direct-to-Consumer Advertising Expenditures 1997 to MAT September 2006
$5 50%
U.S.$ Bil
DTC Advertising $
Growth
40%
$4
30%
$3
20%
$2
10%
$1
0%
$0 -10%
1997 1998 1999 2000 2001 2002 2003 2004 2005 MAT
Sep. 06
Source: IMS Health & TNS Media Intelligence/CMR: Integrated Share of Voice Service, January 2007
Executive Summary 9
Internet Pharmacy Market Performance
Cross-border sales to the US originating from Canadian Internet pharmacies (IP-US) have been on a steady
and continuous decline for several quarters. In 2006, the IP-US sales volume estimates dropped by 49.7% to
$211.3 million CDN. There were 227 cross-border outlets operating in Canada in the fourth quarter of 20061.
Internet pharmacy locations are concentrated in Manitoba, Ontario, British Columbia and Alberta, with very
few outlets in other provinces.
Some of the key factors affecting cross-border sales include:
• A strong Canadian dollar
• Introduction and success of Medicare Part D, a new Medicare prescription benefit plan introduced in the US.
• Increased competition from overseas pharmacies
• Continued success of supply restrictions imposed by manufacturers
• Negative press around counterfeit and foreign drugs entering the US market
• Increasing penetration of generics in the last few years. Generic drugs accounted for slightly more than half
of all IP-US sales in 2006
1 Internet pharmacy sales figures compiled by IMS Health are estimates based on pharmacy purchases not including retail markups
or dispensing fees.
10 Executive Summary
Canadian Market Performance
Drug Store and Hospital Purchases

Pharmaceutical consumption measured through Canadian retail and hospital purchases grew by 7.8% (or
$1.29 billion) in 2006, totaling $17.8 billion in ethical1 purchases. (See Figure 6.) Growth was slightly higher
than the 7% rate posted in 2005 but it fell short of the 9.5% four-year compound average growth rate recorded
between 2001 and 2005. Market growth in 2006 was largely spurred by strong fundamental demand, a healthy
growth of the hospital sector and the rebound performance from drug safety concerns which helped accelerate
market growth.
Figure 6
Canadian Drug Store and Hospital Purchases 2006

$18
U.S.$ Bil
$15
$12
$9
$6
2006 Purchases Growth (%) Market Share (5) 4-Year CARG (%)
Total $17.80 billion 7.8 100.0 9.5

$3 Drug Stores $15.72 billion 7.4 88.3 9.7
Hospitals $2.07 billion 11.5 11.7 8.5
$0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Source: IMS Health. Canadian Drug Stores and Hospital Purchases.
1 The term “ethical” refers to products that are only available in retail and hospital environments and often require a prescription.
Executive Summary 11
Leading Therapeutic Classes in Drug Store and Hospital Purchases
Of the 50 general therapeutic classes, the 10 leading classes achieved $11.74 billion in total ethical purchases
and accounted for 66% of the total market. (See Figure 7) The top 10 classes grew by 7.7% over 2005 (6.3%).
The contribution of the top 10 classes to the industry’s incremental growth has increased by over six percentage
points. However, current growth is 1.6 percentage points below its historical four-year CAGR of 9.3%.
The growth of the leading 10 classes has been eclipsed by the aggregate of all other classes, which rose by 8.2%
and accounted for the remaining $6.05 billion in market purchases. However, these classes also fell short of their
historical four-year CAGR of 9.9%.
Figure 7
Leading Therapeutic Classes in Drug Store and Hospital Purchases 2006
Rank Therapeutic Class Total Purchases ($ Millions) Growth (%) CAGR % 2001-05
1 Cardiovasculars $2,470 6.2% 8.8%

2 Psychotherapeutics $1,742 8.9% 9.8%
3 Antihyperlipidemic Agents $1,671 8.7% 12.8%
4 Antispasmodics $1,318 7.2% 9.2%
5 Oncology $871 18.8% 17.0%
6 Analgesics $783 8.9% 13.7%
7 Bronchial Therapy $758 5.0% 9.7%
8 Anti-infectives $757 0.6% 3.6%
9 Hormones $690 -1.2% 5.4%
10 Anti-arthritics $683 15.7% 3.2%
Top 10 Total $11,743 7.7% 9.3%
All Other Classes $6,047 8.2% 9.9%
Total Ethical Market $17,790 7.8% 9.5%
Source: IMS Health. Canadian Drug Stores and Hospital Purchases
Top 10 Pharmaceutical Corporations by Sales

The leading 10 corporations recorded $9.89 billion in total ethical retail and hospital purchases. Their performance
is illustrated in Figure 8; together, they accounted for a market share of 55.58% and grew by 7.3% in 2006 –
2.7 percentage points short of its four-year CAGR. The growth of the aggregate of all other corporations rose
by 8.5% surpassing the rate of the leading corporations. The top 10 corporations’ share of incremental growth fell
by 8.35 percentage points, down to 51.9%. Because these companies account for over half of all industry volume,
their slowing growth has affected overall industry growth. The main reasons for the lagging performance of most of
the leading corporations included: loss of patent protection; muted performance from new drugs; cost containment
initiatives; Health Canada raising the standards for more drug safety data; and provincial formularies accelerating
the shift to new generics.
Figure 8
Canadian Ethical Market Top Ten Corporations, 2006
Rank C$ Bil MAT Dec. 2006 % Market Share 2006 % Growth 2006 CAGR 2001-05
CANADA $17.79 100.0 7.8 9.5

1 Pfizer 2.35 13.20 4.3 8.7
2 AstraZeneca 1.17 6.59 4.6 8.9
3 Apotex Inc 1.10 6.19 16.1 14.9
4 Johnson & Johnson 1.05 5.93 0.5 14.6
5 GlaxoSmithKline 0.99 5.59 3.3 1.4
6 sanofi-aventis 0.68 3.80 8.1 12.8
7 Novartis 0.67 3.79 6.2 9.2
8 Wyeth 0.65 3.63 10.8 13.1
9 Lilly 0.62 3.49 8.7 14.2
10 Roche 0.60 3.38 27.7 12.2
Top 10 $9.89 55.58 7.3 10.0
Source: IMS Health Canada. Canadian Drug Stores and Hospital Purchases.
Market Access
On an annual basis, the average time to listing has grown since 2000, with a compound average growth rate of 7%
between 2000 and 2006. The average TTL was 586 days (19.5 months) in 2000, rising to 866 days (29 months) in
2006. Meanwhile, the number of drugs achieving either full or restricted listing status has dropped by 4%, between
2000 and 2006.
The Common Drug Review (CDR) reviews recommendations based on decisions made by the Canadian Expert
Drug Advisory Committee (CEDAC) – an independent advisory body of health and other professionals with
relevant expertise. The CDR began accepting submissions on September 1, 2003. All provinces with the exception
of Quebec participate in the CDR process.
As reported in the February 2007 edition of IMS Health’s Provincial Reimbursement Advisor (PRA), CDR
received a total of 90 submissions by January 19, 2007. Fifty-nine (65.5%) were deemed complete on the initial
submission and ten brands (Iressa, Replagal,VFEND [initial and resubmission], Tarceva, Caduet, Pantoloc M, Sutent,
Nexavar and Myozyme) had been granted priority review. Sixty-two products had completed the full CDR process
as of January 19, 2007, with an average total time in the CDR process of 187 calendar days (about 135 business
days). That is on the upper limit of CDR’s targeted total time of between 99 and 129 business days. A total of 247
out of 274 listing decisions by participating federal and provincial plans were concordant with CDR/CEDAC
recommendations. (See Figure 9) Participating drug plans have followed the CDR recommendations 90% of the
time. It must be noted, that a large number of products that have received a final CDR recommendation have yet
to receive a provincial listing decision.
Figure 9
Provincial Drug Benefit Formulary Listing Status of Products Processed by Common Drug Review
(Updated to January 19, 2007)
Number of Listing Average Time to Concordance with

Decisions Published Number of Listings Listing (TTL) - Days Historical TTL - Days CDR Recommendation
British Columbia 42 10 654 450 32/42

Alberta 23 11 403 406 22/23
Saskatchewan 36 17 415 346 34/36
Manitoba 25 13 469 551 24/25
Ontario 13 13 252 494 12/13
New Brunswick 33 17 609 592 32/33
Nova Scotia 44 15 373 428 36/44
Prince Edward Island 8 8 753 744 8/8
Newfoundland & Labrador 25 16 400 352 25/25
Non-insured Health Benefits 25 17 524 348 22/25
Quebec* 44 30 438 374 30/40
* Quebec does not participate in the Common Drug Review. As such, Quebec’s performance is not included.
Source: CDR Recommendations: www.ccohta.ca.
Provincial Listing Status: Provincial formulary bulletins through January 19, 2007.
IMS Health Canada. Provincial Reimbursement Advisor (PRA), FAME
Generic Market Performance
In 2003, 2004 and 2005, the growth of generic manufacturers outpaced that of brand companies. 2006 was
no exception, with the generic sector recording $3.2 billion in total purchases, on 13.6% growth. (See Figure 10)
This helped to push the generic share of the total market up one percentage point to 18%. The remainder belongs
to the brand sector, which grew by a modest 6.6% in 2006, up to $14.6 billion. On the retail side, the generic
sector’s 12.1% growth doubled that of the brands at 6.3%. Retail generic growth was spurred by several major
brand-name drugs (Risperdal, Effxor XR, and Altace) facing generic competitors.
Hospitals have traditionally been a stronghold for the brand sector and that remains true; brands accounted
for 88.4% of the hospital market. Although brand manufacturers benefited from excellent growth in oncology
pharmacotherapy and vaccines, the 8.9% growth of hospital brand purchases was outpaced by the generic sector’s
36.4% growth. The generic hospital growth was driven by the oncology class where two products were generacized
in 2006 – Pfizer’s Camptosar, and AstraZeneca’s Casodex which had five generic copies in February 2006.
Figure 10
Generic Purchases – Drug Stores and Hospitals 2006

$3.5
U.S.$ Bil
$3.0
$2.5
$2.0
$1.5
2006 Purchases Growth (%) Market Share (5) 4-Year CARG (%)
$1.0
Total $3.20 billion 13.6 100.0 15.8
Drug Stores $2.96 billion 12.1 92.5 16.8
$0.5
Hospitals $0.24 billion 36.4 7.5 5.1
$0.0
1998 1999 2000 2001 2002 2003 2004 2005 2006
Source: IMS Health. Canadian Drug Stores and Hospital Purchases
Corporations
andManufacturers
T1 Leading 50 Corporations by Total Ethical Purchases
4-yr Avg
Ethical Compound
Rank Rank Rank Rank Rank Purchases % Share % Change Evolution Growth Rate
2002 2003 2004 2005 2006 2006 ($000s) of Market Over 2005 Index 2006 2002-06
Total Ethical Market 17,816,652 100.0 7.9 100 8
1 1 1 1 1 Pfizer 2,353,000 13.2 4.4 97 7

Pfizer 2,138,864 90.9 4.4 100 8
Pfizer Consumer Health Care 214,132 9.1 3.5 99 -2
Bioadvantex Pharma 5 0.0 ****** ****** ******
4 3 2 2 2 AstraZeneca 1,172,092 6.6 4.6 97 8

AstraZeneca 1,172,092 100.0 4.6 100 8
6 6 5 5 3 Apotex Inc 1,101,172 6.2 16.1 108 15

Apotex Inc 1,101,172 100.0 16.1 100 15
5 4 3 3 4 J&J 1,054,695 5.9 0.5 93 11

Janssen-Ortho Inc 805,421 76.4 -0.4 99 13
Lifescan 117,545 11.1 5.7 105 8
McNeil Consumer 109,347 10.4 -0.1 99 1
J&J 22,382 2.1 10.7 110 5
2 2 4 4 5 GlaxoSmithKline 994,406 5.6 3.4 96 1

GlaxoSmithKline 959,117 96.5 3.6 100 1
GSK Consumer 35,289 3.5 -2.0 95 -2
9 9 8 7 6 sanofi-aventis Canada 675,831 3.8 8.1 100 10

sanofi-aventis Canada 648,749 96.0 7.6 100 10
Dermik 21,447 3.2 17.1 108 22
Sanofi-Pasteur 5,635 0.8 44.1 133 43
8 7 7 6 7 Novartis 674,155 3.8 6.2 98 8

Novartis Pharma 620,320 92.0 6.9 101 9
Novartis Consumer Health Care 43,118 6.4 -0.2 94 -5
Novartis Nutrition 7,195 1.1 10.9 104 16
Ciba Vision Optics 3,522 0.5 -24.3 71 -14
11 10 9 9 8 Wyeth 646,549 3.6 10.8 103 13

Wyeth Pharmaceuticals 554,184 85.7 12.6 102 15
Wyeth Consumer Health Care 92,365 14.3 1.0 91 2
18 Corporations and Manufacturers

4-yr Avg
Ethical Compound
12 12 10 10 9 Lilly 620,957 3.5 8.7 101 12

Lilly 582,992 93.9 7.8 99 10
Lilly Icos 37,966 6.1 25.1 115 ******
14 14 13 13 10 Roche 600,857 3.4 27.7 118 17

Roche 600,857 100.0 27.7 100 17
10 11 12 12 11 Abbott 553,494 3.1 8.3 100 5

Abbott PCD 326,417 59.0 7.7 99 6
Abbott SPD 103,392 18.7 17.5 108 3
Abbott Nutrition 77,788 14.1 3.5 96 2
Abbott Diabetic Care 45,897 8.3 2.5 95 4
7 8 11 11 12 Bristol-Myers Squibb Canada 552,067 3.1 1.7 94 2

BMS-Sanofi 335,039 60.7 11.1 109 22
BMS Pharma 163,614 29.6 -12.2 86 -10
Mead Johnson 39,925 7.2 6.9 105 3
Linson Pharma Inc 9,819 1.8 -11.2 87 -34
Westwood Squibb 3,671 0.7 -42.4 57 -23
3 5 6 8 13 Merck Frosst 514,780 2.9 -14.5 79 -13

MS&D 274,445 53.3 -19.2 95 3
Frosst 240,334 46.7 -8.4 107 -23
16 17 15 14 14 Novopharm 485,092 2.7 8.3 100 18

Novopharm 485,092 100.0 8.3 100 18
13 13 14 15 15 Schering-Plough 446,659 2.5 8.9 101 8

Schering Health Care 446,659 100.0 8.9 100 8
27 22 21 20 16 Amgen 373,366 2.1 23.9 115 44

Amgen 373,366 100.0 23.9 100 44
18 16 16 18 17 Genpharm Pharma 365,097 2.0 9.4 101 15

Genpharm Pharma 365,097 100.0 9.4 100 15
Corporations and Manufacturers 19

4-yr Avg
Ethical Compound
17 18 17 17 18 Pharmascience 360,525 2.0 1.7 94 10

Pharmascience 265,325 73.6 -0.9 98 11
Squire Pharma Inc 32,541 9.0 9.5 108 9
Paladin 25,570 7.1 23.7 122 11
Pendopharm 24,263 6.7 1.5 100 0
Dominion Pharmacal 12,483 3.5 1.0 99 20
Pharmel 343 0.1 -5.2 93 -30
19 19 18 16 19 ratiopharm Inc 359,381 2.0 0.4 93 16

ratiopharm Inc 347,380 96.7 0.6 100 17
Rougier Pharma 12,001 3.3 -4.4 95 0
15 15 19 19 20 Bayer Inc 349,911 2.0 13.2 105 4

Bayer Pharma 328,842 94.0 13.6 100 4
Bayer CCD 21,069 6.0 8.2 96 1
21 21 22 22 21 ALTANA Pharma Inc 305,761 1.7 14.0 106 16

ALTANA Pharma Inc 305,761 100.0 14.0 100 16
20 20 20 21 22 Boehringer Ingelheim 298,852 1.7 10.9 103 13

Boehringer Ingelheim 298,852 100.0 10.9 100 13
23 24 23 23 23 Purdue Pharma 238,858 1.3 18.5 110 19

Purdue Pharma 238,858 100.0 18.5 100 19
22 25 24 24 24 P&G Pharmaceuticals Canada Inc 196,876 1.1 11.1 103 11

P&G Pharmaceuticals Canada Inc 186,274 94.6 12.1 101 12
P&G Health Care 10,602 5.4 -3.4 87 -3
32 32 31 28 25 Sandoz Canada Inc 185,429 1.0 74.5 162 32

Sandoz Canada Inc 185,429 100.0 74.5 100 32
34 33 33 32 26 Novo Nordisk Canada 117,131 0.7 27.7 118 19

Novo Nordisk Canada 117,131 100.0 27.7 100 19
26 28 28 27 27 Berlex Canada 116,920 0.7 9.6 102 4

Berlex Canada 116,920 100.0 9.6 100 4

4-yr Avg
Ethical Compound
28 27 26 26 28 Private Label 107,507 0.6 -0.1 93 5

Private Label 107,507 100.0 -0.1 100 5
30 30 27 29 29 Roche Diagnostics 105,146 0.6 -1.1 92 6

Roche Diagnostics 105,146 100.0 -1.1 100 6
31 31 32 30 30 Serono Canada Inc 100,871 0.6 9.4 101 5

Serono Canada Inc 100,871 100.0 9.4 100 5
29 29 29 31 31 Akzo 93,964 0.5 2.2 95 2

Organon 93,964 100.0 2.2 100 2
25 26 25 25 32 Biovail Corporation International 83,669 0.5 -34.4 61 -6

Biovail Pharma 83,669 100.0 -34.4 100 -6
71 62 41 39 33 Cobalt Pharma 77,403 0.4 48.2 137 90

Cobalt Pharma 77,403 100.0 48.2 100 90
40 37 35 35 34 Servier Laboratories 75,193 0.4 22.8 114 18

Servier Laboratories 75,193 100.0 22.8 100 18
24 23 30 38 35 Lundbeck Canada Inc 74,621 0.4 34.8 125 -11

Lundbeck Canada Inc 74,621 100.0 34.8 100 -11
35 34 34 33 36 Leo Pharma Inc 69,776 0.4 3.0 95 10

Leo Pharma Inc 69,776 100.0 3.0 100 10
36 35 38 34 37 Astellas Pharma 66,168 0.4 4.1 96 11

Astellas Pharma 66,168 100.0 4.1 100 11
206 78 55 42 38 Merck-Schering Group 64,936 0.4 42.8 132 ******

Merck-Schering Group 64,936 100.0 42.8 100 ******
39 38 37 36 39 Alcon Canada 63,497 0.4 12.4 104 13

Alcon Canada 63,497 100.0 12.4 100 13

4-yr Avg
Ethical Compound
43 41 36 37 40 Teva Neuroscience 61,972 0.3 10.7 103 16

Teva Neuroscience 61,972 100.0 10.7 100 16
47 46 47 47 41 Mayne Pharma (Canada) Inc 60,154 0.3 65.3 153 18

Mayne Pharma (Canada) Inc 60,154 100.0 65.3 100 18
50 45 45 43 42 Biogen Idec 49,920 0.3 13.3 105 20

Biogen Idec 49,920 100.0 13.3 100 20
37 36 39 40 43 Stiefel 48,368 0.3 -0.2 92 3

Stiefel 48,368 100.0 -0.2 100 3
51 47 46 44 44 Solvay Pharma 48,265 0.3 10.1 102 20

Solvay Pharma 48,265 100.0 10.1 100 20
41 42 43 45 45 Axcan Pharma 45,945 0.3 4.8 97 5

Axcan Pharma 45,945 100.0 4.8 100 5
45 44 44 49 46 Shire Canada Inc 42,478 0.2 21.1 112 7

Shire Canada Inc 42,478 100.0 21.1 100 7
38 39 42 46 47 Jamieson 41,091 0.2 0.8 93 0

Jamieson 41,091 100.0 0.8 100 0
46 48 49 50 48 Allergan 40,924 0.2 16.8 108 6

Allergan 40,924 100.0 16.8 100 6
49 49 51 48 49 Taro Pharmaceuticals 37,346 0.2 6.4 99 10

Taro Pharmaceuticals 28,588 76.5 6.0 100 8
Taropharma 8,758 23.5 7.7 101 19
42 40 40 41 50 Fournier 36,678 0.2 -23.8 71 1

Fournier 36,678 100.0 -23.8 100 1
Total Others 606,850 3.4 20.5 112 8

T2 Leading 50 Manufacturers by Share of Total Ethical Purchases,
Drug Stores vs. Hospitals
Drug Stores Hospitals
Ethical
Rank Rank Rank Rank Rank Purchases % Share of % Change Evolution % Share of % Change Evolution
2002 2003 2004 2005 2006 2006 ($000s) Purchases Over 2005 Index 2006 Purchases Over 2005 Index 2006
Total Ethical Market 17,816,652 88.3 7.4 100 11.7 11.8 100
1 1 1 1 1 Pfizer 2,138,864 95.0 6.6 99 5.0 -24.3 68

3 2 2 2 2 AstraZeneca 1,172,092 92.8 4.3 97 7.2 8.1 97
5 4 4 3 3 Apotex Inc 1,101,172 97.1 16.2 108 2.9 15.1 103
2 3 3 4 4 GlaxoSmithKline 959,117 90.9 3.5 96 9.1 4.6 94
6 5 5 5 5 Janssen-Ortho Inc 805,421 84.3 0.1 93 15.7 -2.5 87
7 7 6 6 6 sanofi-aventis Canada 648,749 84.2 7.1 100 15.8 10.1 98
8 8 7 7 7 Novartis Pharma 620,320 78.0 7.6 100 22.0 4.3 93
11 12 10 10 8 Roche 600,857 36.6 1.0 94 63.4 50.7 135
9 9 8 8 9 Lilly 582,992 82.6 9.8 102 17.4 -0.5 89
12 10 9 9 10 Wyeth Pharmaceuticals 554,184 80.4 9.9 102 19.6 25.1 112
Leading 10 Manufacturers 9,183,767 86.2 6.8 99 13.8 12.5 101
15 16 13 11 11 Novopharm 485,092 92.6 8.1 101 7.4 10.9 99

10 11 11 12 12 Schering Health Care 446,659 86.2 10.2 103 13.8 1.4 91
32 25 22 18 13 Amgen 373,366 74.8 28.7 120 25.2 11.4 100
19 15 14 15 14 Genpharm Pharma 365,097 98.1 9.5 102 1.9 6.4 95
20 19 16 13 15 ratiopharm Inc 347,380 98.8 0.6 94 1.2 -2.1 88
24 24 19 17 16 BMS-Sanofi 335,039 96.3 11.3 104 3.7 5.8 95
13 13 17 19 17 Bayer Pharma 328,842 84.1 15.3 107 15.9 5.2 94
14 17 18 16 18 Abbott PCD 326,417 98.8 8.0 101 1.2 -8.1 82
23 23 23 21 19 ALTANA Pharma Inc 305,761 94.9 14.8 107 5.1 1.2 91
21 20 21 20 20 Boehringer Ingelheim 298,852 93.1 11.9 104 6.9 -0.5 89
17 14 15 14 21 MS&D 274,445 84.9 -18.8 76 15.1 -21.3 70

22 22 20 22 22 Pharmascience 265,325 93.4 -0.3 93 6.6 -7.7 83
4 6 12 23 23 Frosst 240,334 97.4 -8.6 85 2.6 -2.4 87
25 27 26 25 24 Purdue Pharma 238,858 97.0 18.8 111 3.0 10.2 99
18 21 25 24 25 Pfizer Consumer Health Care 214,132 96.0 3.3 96 4.0 8.8 97
27 28 27 27 26 P&G Pharmaceuticals Canada Inc 186,274 98.4 12.5 105 1.6 -6.3 84
40 40 37 33 27 Sandoz Canada Inc 185,429 58.3 57.4 147 41.7 105.6 184
16 18 24 26 28 BMS Pharma 163,614 76.0 -7.6 86 24.0 -24.0 68
36 34 31 29 29 Lifescan 117,545 95.5 5.6 98 4.5 7.3 96
42 41 40 37 30 Novo Nordisk Canada 117,131 96.7 28.0 119 3.3 18.0 106

T2 Leading 50 Manufacturers by Share of Total Ethical Purchases,
Drug Stores vs. Hospitals
Drug Stores Hospitals
Ethical
Rank Rank Rank Rank Rank Purchases % Share of % Change Evolution % Share of % Change Evolution
2002 2003 2004 2005 2006 2006 ($000s) Purchases Over 2005 Index 2006 Purchases Over 2005 Index 2006
30 31 32 32 31 Berlex Canada 116,920 92.9 10.6 103 7.1 -1.4 88

29 32 33 30 32 McNeil Consumer 109,347 99.5 -0.1 93 0.5 2.6 92
33 30 29 31 33 Private Label 107,507 100.0 -0.1 93 0.0 1.7 91
37 35 30 34 34 Roche Diagnostics 105,146 93.5 -0.9 92 6.5 -2.9 87
31 38 38 39 35 Abbott SPD 103,392 62.4 6.7 99 37.6 41.0 126
38 37 39 35 36 Serono Canada Inc 100,871 93.7 8.8 101 6.3 19.4 107
34 33 34 36 37 Organon 93,964 75.8 2.0 95 24.2 2.8 92
35 36 36 38 38 Wyeth Consumer Health Care 92,365 99.6 1.0 94 0.4 4.9 94
28 29 28 28 39 Biovail Pharma 83,669 96.8 -34.0 61 3.2 -44.9 49
39 39 41 40 40 Abbott Nutrition 77,788 84.9 5.1 98 15.1 -4.6 85
95 82 50 47 41 Cobalt Pharma 77,403 99.8 48.0 138 0.2 556.3 587

51 46 43 43 42 Servier Laboratories 75,193 99.3 23.0 115 0.7 1.5 91
26 26 35 46 43 Lundbeck Canada Inc 74,621 95.8 35.4 126 4.2 21.2 108
45 42 42 41 44 Leo Pharma Inc 69,776 76.1 12.3 105 23.9 -18.5 73
46 44 46 42 45 Astellas Pharma 66,168 73.3 2.8 96 26.7 7.9 96
236 105 69 50 46 Merck-Schering Group 64,936 99.5 42.8 133 0.5 40.1 125
50 47 45 44 47 Alcon Canada 63,497 93.8 12.9 105 6.2 6.2 95
56 50 44 45 48 Teva Neuroscience 61,972 95.6 11.0 103 4.4 3.7 93
60 59 59 58 49 Mayne Pharma Canada 60,154 27.2 36.3 127 72.8 79.6 161
63 58 55 52 50 Biogen Idec 49,920 96.6 14.1 106 3.4 -5.1 85
Total Others 1,362,687 92.3 10.5 103 7.7 19.3 107

T3 Leading 50 Manufacturers by Ethical Drug Store Purchases
4-yr Avg
Drug Store Compound
2002 2003 2004 2005 2006 2006 ($000s) of Market over 2005 Index 2006 2002-06
Total Ethical Drug Store Purchases 15,736,712 100.0 7.4 100 8
1 1 1 1 1 Pfizer 2,030,970 12.9 6.6 99 8

3 2 2 2 2 AstraZeneca 1,087,186 6.9 4.3 97 8
5 4 4 3 3 Apotex Inc 1,068,940 6.8 16.2 108 15
7 6 5 5 5 Janssen-Ortho Inc 679,343 4.3 0.1 93 17
Leading 5 Manufacturers 5,737,837 36.5 6.5 99 9

8 8 7 7 7 Novartis Pharma 484,147 3.1 7.6 100 10
9 9 8 8 8 Lilly 481,517 3.1 9.8 102 11
14 13 12 9 9 Novopharm 449,271 2.9 8.1 101 18
10 10 9 10 10 Wyeth Pharmaceuticals 445,625 2.8 9.9 102 11
11 11 13 11 11 Schering Health Care 384,952 2.4 10.2 103 10

17 12 11 13 12 Genpharm Pharma 358,177 2.3 9.5 102 15
19 17 14 12 13 ratiopharm Inc 343,165 2.2 0.6 94 17
24 22 17 15 14 BMS-Sanofi 322,754 2.1 11.3 104 22
12 14 16 14 15 Abbott PCD 322,426 2.0 8.0 101 7

37 28 24 23 17 Amgen 279,212 1.8 28.7 120 45
13 15 18 21 19 Bayer Pharma 276,471 1.8 15.3 107 4
22 23 20 20 20 Pharmascience 247,933 1.6 -0.3 93 12
4 5 10 17 21 Frosst 234,193 1.5 -8.6 85 -23

16 16 15 16 22 MS&D 232,975 1.5 -18.8 76 1
25 26 25 25 23 Purdue Pharma 231,665 1.5 18.8 111 19
20 24 23 22 24 Roche 219,671 1.4 1.0 94 6
15 18 22 24 25 Pfizer Consumer Health Care 205,490 1.3 3.3 96 -2

T3 Leading 50 Manufacturers by Ethical Drug Store Purchases
4-yr Avg
Drug Store Compound
2002 2003 2004 2005 2006 2006 ($000s) of Market over 2005 Index 2006 2002-06

18 21 26 27 27 BMS Pharma 124,354 0.8 -7.6 86 -11
33 32 31 31 29 Lifescan 112,247 0.7 5.6 98 8
28 31 30 29 30 McNeil Consumer 108,754 0.7 -0.1 93 1
30 33 34 33 31 Berlex Canada 108,590 0.7 10.6 103 5

31 30 29 30 33 Private Label 107,454 0.7 -0.1 93 6
32 34 35 34 36 Wyeth Consumer Health Care 91,962 0.6 1.0 94 2

29 29 28 28 37 Biovail Pharma 80,955 0.5 -34.0 61 -6
92 79 49 45 38 Cobalt Pharma 77,278 0.5 48.0 138 90
36 37 37 37 41 Organon 71,184 0.5 2.0 95 3

38 39 41 39 42 Abbott Nutrition 66,067 0.4 5.1 98 3
232 102 67 50 43 Merck-Schering Group 64,582 0.4 42.8 133 ******
42 40 40 41 44 Abbott SPD 64,498 0.4 6.7 99 6
51 49 46 44 45 Alcon Canada 59,577 0.4 12.9 105 13
54 48 43 42 46 Teva Neuroscience 59,220 0.4 11.0 103 16

48 47 48 48 47 Leo Pharma Inc 53,123 0.3 12.3 105 10
59 60 58 49 48 Astellas Pharma 48,469 0.3 2.8 96 20
60 57 54 54 49 Biogen Idec 48,242 0.3 14.1 106 21
43 43 44 47 50 Stiefel 47,496 0.3 -0.7 92 3
Total Others 1,226,594 7.8 11.2 104 7

T4 Leading 50 Manufacturers by Ethical Hospital Purchases
4-yr Avg
Hospital Compound
Total Ethical Hospital Purchases 2,079,940 100.0 11.8 100 9
1 1 1 1 1 Roche 381,185 18.3 50.7 135 27

4 3 4 3 2 Novartis Pharma 136,173 6.5 4.3 93 6
2 2 2 4 3 Janssen-Ortho Inc 126,078 6.1 -2.5 87 -2
3 4 3 2 5 Pfizer 107,893 5.2 -24.3 68 -2
Leading 5 Manufacturers 859,889 41.3 15.9 104 13

6 5 5 5 7 Lilly 101,474 4.9 -0.5 89 7
16 11 9 8 8 Amgen 94,154 4.5 11.4 100 40
7 7 8 10 10 AstraZeneca 84,906 4.1 8.1 97 4

9 9 11 11 12 Schering Health Care 61,707 3.0 1.4 91 2
13 12 13 14 13 Bayer Pharma 52,371 2.5 5.2 94 6
19 17 17 19 14 Mayne Pharma Canada 43,803 2.1 79.6 161 17
14 14 14 12 15 MS&D 41,471 2.0 -21.3 70 12
11 10 12 13 16 BMS Pharma 39,260 1.9 -24.0 68 -8

12 15 16 18 17 Abbott SPD 38,894 1.9 41.0 126 -2
15 16 15 16 18 Novopharm 35,821 1.7 10.9 99 9
25 24 22 17 19 Apotex Inc 32,232 1.5 15.1 103 24
20 18 18 20 20 Organon 22,780 1.1 2.8 92 1
22 23 23 21 21 Boehringer Ingelheim 20,478 1.0 -0.5 89 5

21 20 24 24 22 Astellas Pharma 17,699 0.9 7.9 96 -4
23 22 21 23 23 Pharmascience 17,392 0.8 -7.7 83 3
27 21 20 22 24 Leo Pharma Inc 16,653 0.8 -18.5 73 10

T4 Leading 50 Manufacturers by Ethical Hospital Purchases
4-yr Avg
Hospital Compound
10 28 28 27 26 Hospira 12,358 0.6 3.3 92 -31

30 30 27 28 27 BMS-Sanofi 12,285 0.6 5.8 95 13
26 26 26 26 28 Abbott Nutrition 11,722 0.6 -4.6 85 -2
224 223 62 31 29 Gilead Sciences 10,276 0.5 31.5 118 ******
35 36 35 30 30 Pfizer Consumer Health Care 8,642 0.4 8.8 97 12
29 29 29 29 31 Berlex Canada 8,330 0.4 -1.4 88 -5

39 35 33 33 32 Purdue Pharma 7,193 0.3 10.2 99 11
40 47 49 42 33 Pharmaceutical Partners of Canada Inc 6,998 0.3 74.1 156 11
41 37 32 34 34 Genpharm Pharma 6,921 0.3 6.4 95 11

24 25 30 35 37 Frosst 6,142 0.3 -2.4 87 -20
45 42 41 37 38 Lifescan 5,298 0.3 7.3 96 13
36 41 40 41 39 Baxter Canada Inc 4,371 0.2 3.9 93 -5
43 40 38 40 40 ratiopharm Inc 4,215 0.2 -2.1 88 3
32 38 39 39 41 Abbott PCD 3,991 0.2 -8.1 82 -10

48 45 43 44 42 Alcon Canada 3,920 0.2 6.2 95 7
42 44 45 43 44 AMO Canada Company 3,674 0.2 -3.9 86 -2
66 59 50 48 45 Omega 3,289 0.2 14.4 102 33
50 48 46 46 46 Pendopharm 3,237 0.2 1.0 90 6

85 76 72 69 47 Genzyme Corp 3,181 0.2 142.0 216 71
225 224 224 229 49 TKT Canada Inc 3,096 0.1 ****** ****** ******
46 43 53 55 50 Abbott Diabetic Care 3,078 0.1 52.3 136 0
Total Others 63,478 3.1 4.1 93 1

T5 Leading 20 Manufacturers and Top Five Products by Ethical Purchases
Ethical
Launch Date Purchases % Share % Change
(MMYY) 2006 ($000s) of Market Over 2005
Total Ethical Market 17,816,652 100.0 7.9
1 Pfizer 2,138,864 12.0 4.4

Lipitor 0397 1,025,448 47.9 9.1
Norvasc 0992 379,555 17.7 11.1
Celebrex 0499 126,426 5.9 9.1
Aricept 0897 97,746 4.6 2.5
Viagra 0399 62,716 2.9 3.4
2 AstraZeneca 1,172,092 6.6 4.6

Crestor 0203 206,465 17.6 35.7
Losec 0689 179,620 15.3 -29.1
Nexium 0801 166,593 14.2 17.2
Seroquel 0198 139,756 11.9 17.4
Symbicort 0202 72,566 6.2 15.9
3 Apotex Inc 1,101,172 6.2 16.1

Apo-Omeprazole 0104 85,504 7.8 74.2
Apo-Simvastatin 0103 49,100 4.5 0.9
Apo-Sertraline 0999 41,591 3.8 -1.4
Apo-Paroxetine 1003 40,931 3.7 27.9
Apo-Lisinopril 1296 39,636 3.6 -22.8
4 GlaxoSmithKline 959,117 5.4 3.6

Flovent HFA 0202 138,591 14.4 -2.4
Avandia 0300 129,702 13.5 13.7
Advair 1099 129,410 13.5 6.9
Advair MDI 0102 64,873 6.8 20.0
Valtrex 0596 59,129 6.2 20.7
5 Janssen-Ortho Inc 805,421 4.5 -0.4

Eprex 0390 174,099 21.6 -1.1
Pariet 0702 146,309 18.2 29.1
Duragesic 0592 106,198 13.2 -3.3
Risperdal 0593 87,408 10.9 -23.7
Concerta 0803 55,675 6.9 20.3

Ethical
6 sanofi-aventis Canada 648,749 3.6 7.6

Altace 0194 379,920 58.6 7.7
Taxotere 0995 47,372 7.3 16.2
Lovenox 0293 29,984 4.6 10.6
Eligard 0404 20,121 3.1 67.4
Lantus 1104 19,134 2.9 116.7
7 Novartis Pharma 620,320 3.5 6.9

Diovan 1197 75,643 12.2 18.0
Gleevec 1001 71,838 11.6 18.1
Clozaril 0491 58,672 9.5 4.2
Diovan HCT 0500 49,795 8.0 25.3
Visudyne 0800 36,904 5.9 -6.6
8 Roche 600,857 3.4 27.7

Herceptin 0899 138,277 23.0 169.5
Rituxan 0400 107,618 17.9 16.0
Cellcept 1295 58,010 9.7 13.2
Rocephin 0787 30,231 5.0 5.0
TNKase 1001 27,215 4.5 5.2
9 Lilly 582,992 3.3 7.8

Zyprexa 1196 225,726 38.7 -0.6
Actos 0800 76,449 13.1 30.1
Zyprexa Zydis 0301 64,408 11.0 24.4
Humalog 1196 29,120 5.0 11.2
Gemzar 0297 24,310 4.2 10.5
10 Wyeth Pharmaceuticals 554,184 3.1 12.6

Effexor XR 0398 334,029 60.3 15.0
Prevnar 0601 69,912 12.6 30.6
Alesse 0198 53,744 9.7 10.6
Tazocin 0694 24,218 4.4 16.8
Premarin 0242 16,583 3.0 -3.0

Ethical
11 Novopharm 485,092 2.7 8.3

Novo-Gabapentin 0702 28,295 5.8 -11.0
Novo-Pravastatin 0103 24,270 5.0 -11.3
Novo-Alendronate 0503 22,647 4.7 69.1
Novo-Simvastatin 0304 18,466 3.8 6.6
Novo-Ranidine 0789 15,868 3.3 1.3
12 Schering Health Care 446,659 2.5 8.9

Remicade 0601 169,842 38.0 36.1
Nasonex 0898 47,254 10.6 10.1
Nitro-Dur 0291 34,137 7.6 -5.6
Temodal 1099 26,415 5.9 4.3
Pegetron Redipen 0904 25,005 5.6 22.6
13 Amgen 373,366 2.1 23.9

Enbrel 0301 159,692 42.8 28.7
Aranesp 0802 115,330 30.9 25.0
Neupogen 0392 79,304 21.2 10.2
Neulasta 0404 13,788 3.7 56.2
Kineret 0602 2,530 0.7 -9.0
14 Genpharm Pharma 365,097 2.0 9.4

Gen-Simvastatin 0203 50,228 13.8 1.6
Gen-Paroxetine 1003 28,324 7.8 -7.1
Gen-Metformin 0495 25,509 7.0 42.3
Gen-Citalopram 0204 18,219 5.0 -55.7
Gen-Ranitidine 0396 17,713 4.9 -5.4
15 ratiopharm Inc 347,380 1.9 0.6

ratio-Salbutamol HFA 0202 33,048 9.5 1.6
ratio-Citalopram 0704 24,625 7.1 130.5
ratio-Diltiazem CD 1296 23,027 6.6 -9.4
ratio-Oxycocet 0484 22,227 6.4 -10.2
ratio-Metformin 0601 19,520 5.6 4.7

Ethical
16 BMS-Sanofi 335,039 1.9 11.1

Plavix 1098 210,219 62.7 8.1
Avapro 0698 79,301 23.7 14.6
Avalide 0400 45,519 13.6 20.1
17 Bayer Pharma 328,842 1.8 13.6

Adalat XL 0492 139,989 42.6 8.8
Ascensia Microfill 1003 46,320 14.1 85.4
Avelox 1000 27,956 8.5 28.9
Ascensia Elite 1102 25,830 7.9 -24.3
Cipro I.V. 0292 25,172 7.7 8.7
18 Abbott PCD 326,417 1.8 7.7

Prevacid 0695 150,102 46.0 10.5
Biaxin BID 0792 45,151 13.8 -10.4
Biaxin XL 0802 33,203 10.2 28.6
Synthroid 0157 31,204 9.6 5.5
Biaxin Pediatric 0395 17,304 5.3 6.0
19 ALTANA Pharma Inc 305,761 1.7 14.0

Pantoloc 0397 290,402 95.0 14.3
Panto IV 0499 14,580 4.8 3.3
Alvesco 0906 477 0.2 ******
Resultz 0906 303 0.1 ******
20 Boehringer Ingelheim 298,852 1.7 10.9

Spiriva 0103 72,801 24.4 27.3
Flomax 0698 50,882 17.0 -9.4
Micardis 0999 40,254 13.5 19.9
Combivent 0196 29,117 9.7 -0.6
Mirapex 0298 26,887 9.0 13.1
Total Others 5,020,380 28.2 6.8

T6 Leading 50 Manufacturers by Total Ethical Prescriptions
4-yr Avg
Compound
Rank Rank Rank Rank Rank # of Rx % Share % Change Evolution Growth Rate
2002 2003 2004 2005 2006 2006 (000s) of Market over 2005 Index 2006 2002-06
Total Ethical Prescriptions 410,142 100.0 6.7 100 6
1 1 1 1 1 Apotex Inc 74,702 18.2 12.3 105 8

2 2 2 2 2 Pfizer 32,319 7.9 4.4 98 5
3 3 3 3 3 Novopharm 29,337 7.2 8.2 101 7
7 5 4 4 4 ratiopharm Inc 17,000 4.1 1.1 95 9
9 8 6 7 5 AstraZeneca 16,504 4.0 9.8 103 10
6 7 5 5 6 Janssen-Ortho Inc 16,160 3.9 -0.4 93 7
12 10 9 9 7 Genpharm Pharma 15,848 3.9 10.2 103 13
13 12 10 6 8 Pharmascience 15,612 3.8 1.6 95 15
8 9 11 10 10 Abbott PCD 14,975 3.7 7.0 100 7
4 4 8 11 11 GlaxoSmithKline 13,758 3.4 0.6 94 -3

15 15 13 13 13 Novartis Pharma 8,028 2.0 1.8 95 3
14 14 15 14 14 Schering Health Care 6,021 1.5 -1.3 93 -8
18 18 18 18 16 Bayer Pharma 5,199 1.3 13.0 106 6
27 23 21 19 17 BMS-Sanofi 5,156 1.3 13.7 107 22
21 20 20 20 19 Lilly 4,690 1.1 4.7 98 6
10 13 14 17 21 Frosst 4,428 1.1 -6.6 87 -20

19 19 16 16 22 MS&D 3,958 1.0 -22.2 73 1
50 43 32 27 24 Riva 3,855 0.9 23.7 116 51
20 21 22 24 25 Pro Doc 3,698 0.9 -2.8 91 0
16 17 19 22 26 Bristol-Myers Squibb Canada 3,579 0.9 -9.9 84 -9
33 28 29 26 27 Taro Pharmaceuticals 3,362 0.8 7.5 101 15
31 32 28 28 28 Purdue Pharma 3,155 0.8 13.1 106 12
30 27 27 30 29 Pendopharm 2,714 0.7 3.9 97 6
37 37 34 32 30 Alcon Canada 2,513 0.6 13.3 106 13

T6 Leading 50 Manufacturers by Total Ethical Prescriptions
4-yr Avg
Compound
2002 2003 2004 2005 2006 2006 (000s) of Market over 2005 Index 2006 2002-06
44 38 37 35 31 Europharm 2,469 0.6 28.9 121 22

32 31 30 33 32 Organon 2,165 0.5 5.4 99 3
36 36 36 34 33 Stiefel 2,048 0.5 2.3 96 5
22 29 31 31 35 Roche 2,000 0.5 -11.7 83 -5
101 82 56 46 36 Cobalt Pharma 1,977 0.5 79.6 168 132
39 40 43 43 38 Berlex Canada 1,910 0.5 36.4 128 6
23 24 26 29 39 Biovail Pharma 1,898 0.5 -29.5 66 -6
34 35 38 36 40 Virco Pharma Inc 1,710 0.4 0.2 94 -2
40 39 40 41 41 Leo Pharma Inc 1,690 0.4 7.2 100 5

29 34 39 38 42 Pfizer Consumer Health Care 1,688 0.4 3.4 97 -7
24 33 35 39 43 Valeant Pharma 1,626 0.4 0.0 94 -9
272 274 268 235 44 Ranbaxy Pharma Canada 1,551 0.4 ****** ****** ******
38 41 44 42 45 Nu-Pharm Inc 1,410 0.3 -4.4 90 -2
42 46 46 47 46 Allergan 1,224 0.3 13.2 106 0
90 59 48 45 47 Lifescan 1,172 0.3 5.8 99 85
45 45 47 49 50 Squire Pharma Inc 1,069 0.3 4.3 98 -1
Total Others 21,969 5.4 5.8 99 4

T7 Leading 20 Manufacturers and Top Five Products
by Total Ethical Prescriptions
Rank Launch Date # of Rx 2006 % Share % Change

2006 (MMYY) (000’s) of Market Over 2005
Total Ethical Prescriptions 410,142 100.0 6.7
1 Apotex Inc 74,702 18.2 12.3

Apo-Furosemide 0676 3,801 5.1 6.2
Apo-Hydro 1074 3,632 4.9 4.9
Apo-Amoxi 0884 3,267 4.4 49.0
Apo-Lorazepam 1185 2,653 3.6 4.6
Apo-Amitriptyline 0675 2,423 3.2 2.1
2 Pfizer 32,319 7.9 4.4

Lipitor 0397 12,702 39.3 13.1
Norvasc 0992 6,314 19.5 14.7
Celebrex 0499 2,237 6.9 10.4
Arthrotec 0493 1,264 3.9 -0.9
Xalatan 0797 1,168 3.6 -0.8
3 Novopharm 29,337 7.2 8.2

Novo-Hydrazide 0170 2,863 9.8 4.9
Novo-Metoprol 0386 1,463 5.0 6.2
Novamoxin 0179 1,316 4.5 -44.3
Novo-Glyburide 1191 1,144 3.9 18.9
Novo-Semide 0876 1,041 3.5 14.5
4 ratiopharm Inc 17,000 4.1 1.1

ratio-Salbutamol HFA 0202 3,794 22.3 1.5
ratio-Oxycocet 0484 1,166 6.9 -5.2
ratio-Metformin 0601 827 4.9 15.9
ratio-Lenoltec #3 1185 803 4.7 106.6
ratio-Atenolol 0396 723 4.3 -11.4
5 Pharmascience 16,858 4.1 1.6

PMS-Metformin 0297 1,649 9.8 -7.5
PMS-Clonazepam-R 0396 1,174 7.0 0.7
PMS-Atenolol 1198 812 4.8 4.7
PMS-Clonazepam 0194 757 4.5 7.8
PMS-Metoprolol-L 1097 684 4.1 7.6


6 AstraZeneca 16,504 4.0 9.8

Crestor 0203 3,270 19.8 35.1
Seroquel 0198 2,862 17.3 28.4
Nexium 0801 2,259 13.7 16.7
Losec 0689 1,625 9.8 -31.1
Atacand 1298 1,450 8.8 14.8

Tylenol with Codeine #3 0171 3,957 24.6 -11.5
Pariet 0702 3,128 19.4 34.9
Risperdal 0593 2,126 13.2 -12.0
Tri-Cyclen 0793 1,853 11.5 -9.4
Concerta 0803 580 3.6 21.0
8 Genpharm Pharma 15,848 3.9 10.2

Gen-Metformin 0495 2,017 12.7 44.0
Gen-Simvastatin 0203 966 6.1 11.7
Gen-Paroxetine 1003 837 5.3 -1.0
Gen-Citalopram 0204 799 5.0 -44.6
Gen-Ranitidine 0396 786 5.0 -2.5
9 Wyeth Pharmaceuticals 15,131 3.7 2.9

Effexor XR 0398 5,758 38.1 14.9
Alesse 0198 2,699 17.8 4.3
Ativan 0477 2,522 16.7 3.4
Premarin 0242 2,347 15.5 -3.8
Triphasil 0283 662 4.4 -32.4
10 Abbott PCD 14,975 3.7 7.0

Synthroid 0157 9,789 65.4 7.6
Prevacid 0695 1,927 12.9 9.9
Biaxin Bid 0792 963 6.4 -13.8
Biaxin XL 0802 712 4.8 30.8
Dilaudid 0370 436 2.9 4.3


11 GlaxoSmithKline 13,758 3.4 0.6

Flovent HFA 0202 2,490 18.1 -1.1
Eltroxin 0151 2,168 15.8 4.5
Flonase 0993 1,201 8.7 -1.8
Avandia 0300 1,195 8.7 15.2
Advair 1099 1,101 8.0 3.5
12 sanofi-aventis Canada 13,417 3.3 5.6

Altace 0194 8,958 66.8 9.6
Imovane 0890 635 4.7 5.9
Xatral 0302 365 2.7 46.2
Renedil 0292 357 2.7 -2.6
Nasacort AQ 0596 348 2.6 3.3

Diovan 1197 1,480 18.4 20.5
Diovan HCT 0500 1,026 12.8 22.3
Lopresor SR 1282 524 6.5 17.5
Lamisil 0593 468 5.8 -0.2
Slow-K 0670 358 4.5 5.7
14 Bayer Pharma 7,109 1.7 18.5

Adalat XL 0492 2,756 38.8 4.9
Yasmin 1204 622 8.7 192.8
Diane-35 0498 604 8.5 -1.5
Ascensia Microfill 1003 579 8.1 96.2
Avelox 1000 523 7.4 22.3
15 Schering Health Canada 6,021 1.5 -1.3

Nasonex 0898 1,706 28.3 9.5
Nitro-Dur 0291 1,217 20.2 -3.7
Elocom 0191 676 11.2 3.4
Prometrium 0695 500 8.3 3.1
K-Dur 20 0189 361 6.0 -9.1


16 Boehringer Ingelheim 5,871 1.4 10.2

Flomax 0698 1,295 22.1 -2.5
Combivent 0196 935 15.9 -1.8
Micardis 0999 806 13.7 17.8
Spiriva 0103 786 13.4 25.7
Micardis Plus 0901 429 7.3 26.8
17 BMS-Sanofi 5,156 1.3 13.7

Plavix 1098 2,435 47.2 13.0
Avapro 0698 1,696 32.9 13.6
Avalide 0400 1,026 19.9 15.4
18 Sandoz Canada Inc 4,953 1.2 17.2

Sandoz-Bisoprolol 0803 1,161 23.4 8.9
Vit B12 0157 368 7.4 1.0
Sandoz-Diltiazem T 0106 354 7.2 ******
Sandoz-Azithromycin 1205 221 4.5 ******
Supeudol 0968 217 4.4 26.2
19 Lilly 4,690 1.1 4.7

Zyprexa 1196 1,819 38.8 4.0
Actos 0800 555 11.8 23.1
Humulin N 0783 551 11.7 -7.4
Zyprexa Zydis 0301 348 7.4 39.4
Humalog 1196 331 7.1 4.1

Pantoloc 0397 4,496 99.9 15.9
Alvesco 0906 2 0.0 ******
Panto IV 0499 - 0.0 106.2
Resultz 0906 - 0.0 ******
Total Others 87,856 21.4 5.5

T8 Leading 20 Manufacturers and Top Five Products by Detailing Activity
Rank Launch Date # of Details % Share % Change

2006 (MMYY) 2006 (000s) of Market Over 2005
Total Number of Details 3,334 100.0 -8.9
1 Pfizer 388 11.6 -6.4

Lipitor 0397 69 17.7 -7.4
Norvasc 0992 47 12.1 -13.0
Celebrex 0499 39 10.1 -26.7
Caduet 0206 37 9.6 ******
Lyrica 0605 36 9.2 169.1
2 GlaxoSmithKline 306 9.2 -4.9

Advair 1099 58 19.0 -0.6
Avandia 0300 50 16.3 1.7
Flonase 0993 39 12.6 -7.2
Valtrex 0596 38 12.3 -3.0
Paxil CR 1203 32 10.5 54.0
3 AstraZeneca 261 7.8 0.8

Nexium 0801 70 26.9 2.9
Crestor 0203 67 25.6 -2.4
Symbicort 0202 46 17.6 -4.9
Atacand 1298 32 12.4 10.9
Atacand Plus 0601 10 3.8 -12.9
4 Janssen-Ortho Inc 177 5.3 -22.2

Pariet 0702 47 26.4 -23.2
Tramacet 0705 38 21.6 131.2
Tri-Cyclen Lo 0205 14 8.2 10.7
Duragesic 0592 13 7.5 23.2
Evra 0104 11 6.4 -35.1
5 Novartis Pharma 171 5.1 -6.2

Diovan 1197 49 29.0 -7.0
Famvir 0895 30 17.3 58.6
Diovan HCT 0500 18 10.8 -13.4
Elidel 0303 18 10.3 -43.5
Lopresor SR 1282 15 8.9 ******


6 sanofi-aventis Canada 168 5.0 -19.1

Altace 0194 46 27.3 -15.2
Plavix 1098 20 12.2 -3.6
Actonel 1199 18 10.4 -19.7
Avapro 0698 15 8.7 -14.1
Xatral 0302 14 8.2 -7.0
7 Abbott PCD 142 4.3 -8.6

Biaxin XL 0802 43 30.3 -11.7
Prevacid 0695 43 30.0 -17.7
Mavik 0198 16 11.1 -0.7
Meridia 0301 13 9.3 1.4
Biaxin Pediatric 0395 12 8.4 -20.2
8 MS&D 140 4.2 8.3

Singulair 0898 21 15.2 28.0
Fosavance 0306 20 14.1 ******
Ezetrol 0603 19 13.4 -17.2
Cozaar 1095 18 13.0 43.8
Hyzaar 1196 10 7.4 23.0
9 Lilly 130 3.9 -14.5

Cialis 1103 36 27.7 -8.3
Actos 0800 31 23.6 -21.1
Zyprexa 1196 23 17.5 -42.4
Strattera 0205 19 14.2 24.5
Evista 0199 7 5.3 -15.3
10 Bayer Pharma 126 3.8 -8.8

Adalat XL 0492 32 25.2 27.0
Avelox 1000 31 24.5 -16.3
Cipro XL 0803 30 23.8 -22.4
Levitra 0304 29 22.6 -12.8
General Discussion - 2 1.8 12.8


11 Boehringer Ingelheim 121 3.6 -12.9

Micardis 0999 41 33.7 -10.4
Spiriva 0103 30 24.5 -22.6
Micardis Plus 0901 19 15.6 -2.4
Flomax 0698 16 13.4 -38.1
Flomax CR 0506 11 8.8 ******
12 Schering Health Care 113 3.4 -6.0

Nasonex 0898 42 36.8 1.9
Aerius 0102 34 30.3 -6.3
Ezetrol 0603 30 26.4 -3.5
General Discussion - 2 1.8 -18.4
Remicade 0601 2 1.5 1.5
13 Solvay Pharma 95 2.8 16.2

General Discussion - 24 25.7 ******
Teveten 1200 16 16.7 -12.6
Dicetel 0579 16 16.5 21.3
Pennsaid 0303 11 11.3 -49.4
Lipidil EZ 0805 8 8.1 ******
14 Wyeth Pharmaceuticals 90 2.7 -19.1

Effexor XR 0398 51 56.6 -15.5
Alesse 0198 31 33.9 -22.3
Premarin 0242 3 3.6 -45.0
General Discussion - 2 2.3 39.4
Premplus 1100 1 1.0 -20.5
15 Servier Laboratories 86 2.6 9.1

Coversyl 1194 42 48.1 21.9
Diamicron MR 0401 27 31.4 24.6
Coversyl Plus 0103 14 15.7 17.6
Starnoc 0600 1 1.4 -84.9


16 ALTANA Pharma Inc 64 1.9 -30.9

Pantoloc 0397 48 75.5 -22.0
Alvesco 0906 12 18.7 ******
General Discussion 1297 3 5.1 108.2
Panto IV 0499 - 0.3 -30.2
Zithromax 0994 - 0.3 -99.0
17 BMS Pharma 62 1.8 -24.0

Avapro 0698 19 31.5 -18.5
Plavix 1098 18 29.9 -12.8
Avalide 0400 13 20.5 -8.6
Cefzil 1095 6 10.4 -29.0
18 Wyeth Consumer Health Care 52 1.6 0.4

Robax Platinum 0603 5 9.6 -6.9
Dimetapp 0361 4 8.5 -12.8
Centrum Select 0291 4 8.0 27.7
Materna 0179 4 7.6 25.3
Centrum Forte 0683 4 7.2 15.8
19 P&G Pharmaceuticals Canada Inc 46 1.4 -30.1

Actonel 1199 23 51.0 -15.3
Zomig 0998 11 23.9 -28.9
Zomig Rapidmelt 0201 5 10.8 -29.2
Actonel Plus Calcium 0606 3 7.4 ******
Macrobid 0194 1 2.7 -91.1
20 Organon 44 1.3 3.3

Marvelon 0793 11 25.2 -19.1
Nuvaring 0105 11 24.4 -33.1
Remeron RD 0204 9 19.4 2.4
Linessa 0606 8 18.1 ******
Andriol 1092 3 7.8 107.3
Total Others 551 16.5 -8.8

by Journal Ad Expenditures
Journal Ad
Rank Launch Date Expenditures % Share % Change
2006 (MMYY) 2006 ($000s) of Market Over 2005
Total Journal Ad Expenditures 63,968 100.0 -0.8
1 Pfizer 9,379 14.7 9.9

Lipitor 0397 2,011 21.4 -20.2
Caduet 0206 1,606 17.1 ******
Lyrica 0605 1,570 16.7 108.1
Celebrex 0499 1,403 15.0 132.9
Arthrotec 0493 657 7.0 522.5
2 AstraZeneca 6,936 10.8 -14.1

Crestor 0203 2,386 34.4 -7.4
Symbicort 0202 1,486 21.4 4.3
Atacand 1298 1,211 17.5 -7.8
Nexium 0801 1,117 16.1 -37.9
Seroquel 0198 437 6.3 -21.9
3 Wyeth Pharmaceuticals 2,993 4.7 -6.8

Effexor XR 0398 1,936 64.7 23.9
Alesse 0198 664 22.2 -25.1
Prevnar 0601 384 12.8 3.3
Institutional - 10 0.3 ******
Effexor 1094 - 0.0 -100.0
4 sanofi-aventis Canada 2,856 4.5 -5.7

Altace 0194 1,348 47.2 -22.6
Lantus 1104 1,061 37.1 42.0
Xatral 0302 252 8.8 -10.1
Taxotere 0995 89 3.1 114.0
Institutional - 85 3.0 307.6
5 GlaxoSmithKline 2,799 4.4 -32.2

Avandamet 0303 1,034 36.9 20.5
Advair 1099 650 23.2 -37.0
Advair MDI 0102 649 23.2 -31.4
Avandia 0300 370 13.2 -55.0
Avodart 1103 66 2.3 ******

Journal Ad
6 BMS-Sanofi 2,688 4.2 -5.3

Plavix 1098 1,213 45.1 10.1
Avalide 0400 758 28.2 33.0
Avapro 0698 718 26.7 -38.5

Pariet 0702 796 35.0 200.1
Tramacet 0705 365 16.1 31.9
Tri-Cyclen Lo 0205 271 11.9 12.8
Concerta 0803 201 8.8 17.0
Reminyl 0701 185 8.1 -67.4
8 Abbott PCD 2,189 3.4 -15.1

Meridia 0301 541 24.7 489.8
Prevacid 0695 417 19.0 -50.1
Biaxin XL 0802 365 16.7 50.6
Biaxin Pediatric 0395 273 12.5 -29.9
Prevacid Fastab 0205 177 8.1 ******
9 Organon 1,831 2.9 27.5

Nuvaring 0105 470 25.7 -3.9
Remeron RD 0204 439 24.0 20.6
Linessa 0606 387 21.1 ******
Andriol 1092 318 17.4 -4.6
Marvelon 0793 81 4.4 -59.6

Diovan HCT 0500 618 33.9 46.0
Diovan 1197 617 33.8 46.5
Femara 0997 176 9.7 -14.0
Multiproducts - 137 7.5 ******
Visudyne 0800 109 6.0 53.6

Journal Ad
11 Bayer Pharma 1,769 2.8 -18.4

Adalat XL 0492 1,140 64.4 26.8
Avelox 1000 242 13.7 -46.8
Avelox I.V. 0603 238 13.5 -43.9
Trasylol 0177 72 4.1 ******
Cipro Xl 0803 53 3.0 -85.3

Pantoloc 0397 950 53.7 13.2
Alvesco 0906 507 28.7 ******
Institutional - 108 6.1 ******
Resultz 0906 106 6.0 ******
Panto IV 0499 97 5.5 -48.8
13 Purdue Pharma 1,714 2.7 -2.8

Hydromorph Contin 0695 435 25.4 -24.5
Uromax 0606 354 20.7 ******
Biphentin 0806 347 20.2 ******
Codeine Contin 1095 284 16.6 3.1
Oxycontin 0896 110 6.4 -64.1
14 Boehringer Ingelheim 1,574 2.5 -12.3

Spiriva 0103 1,133 72.0 4.0
Micardis 0999 342 21.7 -50.5
Flomax CR 0506 95 6.0 ******
Aggrenox 0400 3 0.2 -67.6
Mirapex 0298 - 0.0 -100.0
15 Schering Health Care 1,530 2.4 196.0

Remicade 0601 1,022 66.8 405.3
Nasonex 0898 289 18.9 49.8
Aerius 0102 108 7.0 86.2
Institutional - 33 2.2 101.5
Earigate 0106 30 2.0 ******

Journal Ad
16 MS&D 1,364 2.1 -30.2

Singulair 0898 763 56.0 -24.8
Fosavance 0306 416 30.5 ******
Rotateq 0906 111 8.2 ******
Proscar 1192 68 5.0 -78.4
Maxalt 0899 4 0.3 -94.5
17 Lundbeck Canada Inc 1,273 2.0 -47.8

Cipralex 0205 1,021 80.2 -27.6
Ebixa 1204 251 19.8 -67.7
Celexa 0399 - 0.0 -100.0
Keppra 0703 - 0.0 -100.0
Institutional - - 0.0 -100.0
18 Astellas Pharma 1,146 1.8 121.0

Protopic 0901 425 37.1 22.6
Vesicare 0706 357 31.2 ******
Institutional 0292 197 17.2 ******
Amevive 1004 167 14.6 -3.1
19 Fournier 1,118 1.7 143.9

Lipidil EZ 0805 1,118 100.0 143.9
20 Biovail Pharma 1,057 1.7 87.4

Wellbutrin XL 0306 606 57.3 ******
Glumetza 1105 451 42.7 -16.4
Tiazac XC 1204 - 0.0 -100.0
Wellbutrin SR 0598 - 0.0 -100.0
Total Others 13,887 21.7 4.6

Products
andMolecules
T 10 Top 50 Products by Total Ethical Purchases
4-yr Avg
Launch Ethical Compound
Rank Rank Rank Rank Rank Date Purchases % Share % Change Evolution Growth Rate
2002 2003 2004 2005 2006 (MMYY) MFR 2006 ($000s) of Market Over 2005 Index 2006 2002-06
1 1 1 1 1 Lipitor 0397 PFZ 1,025,448 5.8 9.1 101 14

5 3 3 2 2 Altace 0194 S.A 379,920 2.1 7.7 100 13
4 4 4 3 3 Norvasc 0992 PFZ 379,555 2.1 11.1 103 12
11 7 5 4 4 Effexor XR 0398 WYE 334,029 1.9 15.0 107 22
10 8 7 5 5 Pantoloc 0397 AAA 290,402 1.6 14.3 106 16
Leading 5 Products 2,409,353 13.5 10.6 102 15
7 5 6 7 6 Zyprexa 1196 LLY 225,726 1.3 -0.6 92 4

18 15 10 8 7 Plavix 1098 BSA 210,219 1.2 8.1 100 22
- 88 16 10 8 Crestor 0203 AZN 206,465 1.2 35.7 126 ******
2 2 2 6 9 Losec 0689 AZN 179,620 1.0 -29.1 66 -19
9 9 9 9 10 Eprex 0390 JNO 174,099 1.0 -1.1 92 -1
31 25 21 15 11 Remicade 0601 SHC 169,842 1.0 36.1 126 32

38 22 17 11 12 Nexium 0801 AZN 166,593 0.9 17.2 109 36
75 35 26 16 13 Enbrel 0301 AAI 159,692 0.9 28.7 119 51
17 17 12 13 14 Prevacid 0695 ABD 150,102 0.8 10.5 102 9
494 70 29 25 15 Pariet 0702 JNO 146,309 0.8 29.1 120 146
40 28 23 23 16 Oxycontin 0896 PUF 142,236 0.8 24.9 116 32

16 18 15 14 17 Adalat XL 0492 BAY 139,989 0.8 8.8 101 7
43 32 24 19 18 Seroquel 0198 AZN 139,756 0.8 17.4 109 32
163 13 11 12 19 Flovent HFA 0202 GSK 138,591 0.8 -2.4 90 73
117 122 110 58 20 Herceptin 0899 ROC 138,277 0.8 169.5 250 60
28 27 22 22 21 Avandia 0300 GSK 129,702 0.7 13.7 105 20

19 20 18 18 22 Advair 1099 GSK 129,410 0.7 6.9 99 8
8 10 8 20 23 Celebrex 0499 PFZ 126,426 0.7 9.1 101 -8
47 38 30 27 24 Actonel 1199 PRG 119,990 0.7 20.5 112 29
627 64 35 30 25 Aranesp 0802 AAI 115,330 0.6 25.0 116 152
48 Products and Molecules

T 10 Top 50 Products by Total Ethical Purchases
4-yr Avg
13 14 13 17 26 Vasotec 0887 FRO 115,107 0.6 -6.5 87 -6

84 81 39 29 27 Rituxan 0400 ROC 107,618 0.6 16.0 107 40
44 31 25 26 28 Duragesic 0592 JNO 106,198 0.6 -3.3 90 24
59 41 36 31 29 One Touch Ultra 0301 LFS 102,169 0.6 20.9 112 28
27 24 27 28 30 Aricept 0897 PFZ 97,746 0.5 2.5 95 11
20 21 19 21 31 Risperdal 0593 JNO 87,408 0.5 -23.7 71 -1

26 30 32 32 32 Rebif 0398 SER 85,667 0.5 5.3 98 7
- - 222 63 33 Apo-Omeprazole 0104 ATX 85,504 0.5 74.2 161 ******
34 37 37 33 34 Neupogen 0392 AAI 79,304 0.4 10.2 102 11
48 46 41 35 35 Avapro 0698 BSA 79,301 0.4 14.6 106 17
104 82 60 43 36 Actos 0800 LLY 76,449 0.4 30.1 121 34

53 48 45 37 37 Diovan 1197 NVR 75,643 0.4 18.0 109 17
- 219 77 45 38 Spiriva 0103 B.I 72,801 0.4 27.3 118 ******
186 78 56 38 39 Symbicort 0202 AZN 72,566 0.4 15.9 107 54
130 67 61 41 40 Gleevec 1001 NVR 71,838 0.4 18.1 109 38
61 53 47 40 41 Atacand 1298 AZN 71,555 0.4 15.6 107 18

207 101 68 54 42 Prevnar 0601 WYE 69,912 0.4 30.6 121 57
- 554 137 70 43 Ezetrol 0603 MU& 64,936 0.4 42.8 132 ******
246 89 72 53 44 Advair MDI 0102 GSK 64,873 0.4 20.0 111 63
160 100 75 56 45 Zyprexa Zydis 0301 LLY 64,408 0.4 24.4 115 42
33 40 42 39 46 Cozaar 1095 FRO 63,439 0.4 1.7 94 5

56 56 51 44 47 Singulair 0898 MSD 63,370 0.4 10.3 102 13
25 23 34 42 48 Viagra 0399 PFZ 62,716 0.4 3.4 96 -3
62 59 54 48 49 Copaxone 0997 TVN 61,679 0.3 10.2 102 16
115 91 76 64 50 Valtrex 0596 GSK 59,129 0.3 20.7 112 28
Total Others 10,337,588 58.0 5.0 97 4
Products and Molecules 49

T 11 Top 50 Products by Ethical Drug Store Purchases
4-yr Avg
Launch Drug Store Compound
1 1 1 1 1 Lipitor 0397 PFZ 1,010,922 6.4 9.1 102 14

5 3 3 2 2 Altace 0194 S.A 373,892 2.4 7.8 100 13
4 4 4 3 3 Norvasc 0992 PFZ 370,687 2.4 11.1 103 12
10 7 5 4 4 Effexor XR 0398 WYE 326,962 2.1 15.3 107 22
9 8 6 5 5 Pantoloc 0397 AAA 289,432 1.8 14.5 107 17
8 6 7 7 6 Zyprexa 1196 LLY 206,648 1.3 -0.1 93 4

- 78 15 9 7 Crestor 0203 AZN 205,229 1.3 35.6 126 ******
18 15 9 8 8 Plavix 1098 BSA 199,341 1.3 8.3 101 23
2 2 2 6 9 Losec 0689 AZN 178,335 1.1 -29.0 66 -19
33 21 16 10 10 Nexium 0801 AZN 166,202 1.1 17.3 109 36
71 32 22 14 11 Enbrel 0301 AAI 158,308 1.0 28.8 120 52

16 16 11 12 12 Prevacid 0695 ABD 149,645 1.0 10.6 103 9
435 63 27 21 13 Pariet 0702 JNO 145,782 0.9 30.8 122 146
80 39 34 25 14 Remicade 0601 SHC 142,959 0.9 44.3 134 52
35 25 21 19 15 Oxycontin 0896 PUF 140,193 0.9 25.0 116 32
15 17 14 13 16 Adalat XL 0492 BAY 137,818 0.9 8.9 101 7

141 13 10 11 17 Flovent HFA 0202 GSK 132,633 0.8 -2.3 91 73
27 24 20 18 18 Avandia 0300 GSK 127,799 0.8 13.8 106 20
17 19 17 16 19 Advair 1099 GSK 127,197 0.8 6.5 99 8
49 34 26 22 20 Seroquel 0198 AZN 124,616 0.8 18.6 110 34
7 9 8 17 21 Celebrex 0499 PFZ 124,294 0.8 9.0 101 -8

38 35 29 26 22 Actonel 1199 PRG 118,364 0.8 20.9 113 29
12 12 12 15 23 Vasotec 0887 FRO 112,819 0.7 -6.6 87 -6
52 37 35 29 24 One Touch Ultra 0301 LFS 101,839 0.6 20.8 112 28
42 31 23 23 25 Duragesic 0592 JNO 100,438 0.6 -3.5 90 25

T 11 Top 50 Products by Ethical Drug Store Purchases
4-yr Avg
Launch Drug Store Compound
28 26 25 27 26 Aricept 0897 PFZ 88,711 0.6 1.8 95 10

22 22 28 28 27 Eprex 0390 JNO 87,749 0.6 0.8 94 4
- - 200 51 28 Apo-Omeprazole 0104 ATX 84,952 0.5 74.2 162 ******
26 27 30 30 29 Rebif 0398 SER 82,084 0.5 4.6 97 6
20 20 19 24 30 Risperdal 0593 JNO 80,320 0.5 -22.3 72 1
40 42 37 31 31 Avapro 0698 BSA 77,954 0.5 14.6 107 17

93 74 53 39 32 Actos 0800 LLY 75,633 0.5 29.9 121 34
46 44 41 33 33 Diovan 1197 NVR 74,613 0.5 18.0 110 17
163 72 49 35 34 Symbicort 0202 AZN 71,623 0.5 15.6 108 54
56 48 43 36 35 Atacand 1298 AZN 70,555 0.4 15.5 108 18
- 194 67 41 36 Spiriva 0103 B.I 70,189 0.4 26.8 118 ******

- 497 121 58 37 Ezetrol 0603 MU& 64,582 0.4 42.8 133 ******
48 50 44 40 38 Singulair 0898 MSD 62,807 0.4 10.3 103 13
23 23 31 38 39 Viagra 0399 PFZ 62,138 0.4 3.0 96 -3
32 38 39 37 40 Cozaar 1095 FRO 61,833 0.4 1.6 95 5
221 81 64 46 41 Advair MDI 0102 GSK 60,115 0.4 17.9 110 61

59 55 47 45 42 Copaxone 0997 TVN 58,934 0.4 10.5 103 16
105 82 66 52 43 Valtrex 0596 GSK 58,242 0.4 20.5 112 29
- 125 82 68 44 Aranesp 0802 AAI 56,695 0.4 37.1 128 202
- 282 93 56 45 Concerta 0803 JNO 55,495 0.4 20.3 112 ******
67 61 57 53 46 Alesse 0198 WYE 53,198 0.3 10.8 103 15

68 73 75 42 47 Arthrotec 0493 PFZ 52,996 0.3 -2.4 91 15
92 89 81 72 49 Coversyl 1194 SVR 50,436 0.3 27.6 119 20
63 68 63 60 50 Neupogen 0392 AAI 50,065 0.3 16.4 108 12
Total Others 8,801,113 55.9 4.7 97 4

T 12 Top 50 Products by Ethical Hospital Purchases
4-yr Avg
Launch Hospital Compound
11 11 8 5 1 Herceptin 0899 ROC 138,274 6.6 169.5 241 60

5 4 2 1 2 Rituxan 0400 ROC 106,884 5.1 15.4 103 39
1 1 1 2 3 Eprex 0390 JNO 86,351 4.2 -3.0 87 -5
101 20 7 3 4 Prevnar 0601 WYE 69,687 3.4 34.5 120 119
125 16 4 6 5 Aranesp 0802 AAI 58,635 2.8 15.2 103 128
Leading 5 Products 459,831 22.1 37.0 123 30
9 8 5 7 6 Taxotere 0995 S.A 47,372 2.3 16.2 104 21

6 3 6 10 7 Clozaril 0491 NVR 30,741 1.5 11.1 99 2
13 10 12 8 8 Neupogen 0392 AAI 29,239 1.4 1.1 90 9
14 15 14 11 9 Rocephin 0787 ROC 27,411 1.3 4.6 94 10
8 9 9 12 10 TNKase 1001 ROC 27,176 1.3 5.2 94 3
17 13 13 9 11 Visudyne 0800 NVR 27,104 1.3 -4.9 85 13

3 7 11 13 12 Remicade 0601 SHC 26,883 1.3 4.4 93 -2
16 17 17 14 13 Cipro I.V. 0292 BAY 24,997 1.2 8.7 97 10
22 18 18 18 14 Gemzar 0297 LLY 24,287 1.2 11.0 99 16
40 22 21 15 15 Gleevec 1001 NVR 23,759 1.1 5.1 94 33
15 14 15 17 16 Lovenox 0293 S.A 23,189 1.1 4.6 94 5

55 31 24 20 17 Tazocin 0694 WYE 22,241 1.1 15.6 103 41
10 12 16 19 18 Zyprexa 1196 LLY 19,078 0.9 -5.8 84 -3
24 24 22 23 19 Cellcept 1295 ROC 17,609 0.8 8.7 97 9
- - - - 20 Irinotecan HCL 0206 M3Y 17,511 0.8 ****** ****** ******
25 29 29 37 21 Merrem 1096 AZN 17,170 0.8 56.7 140 10

4 6 19 22 22 Neoral 0395 NVR 15,601 0.8 -7.6 83 -14
19 19 20 21 23 Pharmorubicin 0785 PFZ 15,155 0.7 -17.9 73 -1
41 39 28 27 24 Seroquel 0198 AZN 15,140 0.7 8.2 97 19
18 21 23 24 25 Reopro 0996 LLY 14,919 0.7 -1.5 88 -2

T 12 Top 50 Products by Ethical Hospital Purchases
4-yr Avg
Launch Hospital Compound
26 26 26 25 26 Zemuron 0295 ORG 14,895 0.7 4.9 94 6

- - - 444 27 Avastin 1105 ROC 14,881 0.7 ****** ****** ******
2 2 3 4 28 Camptosar 0997 PFZ 14,636 0.7 -71.5 25 -18
48 45 38 30 29 Lipitor 0397 PFZ 14,526 0.7 15.0 103 22
37 32 27 26 30 Panto IV 0499 AAA 14,508 0.7 3.3 92 15
20 81 73 74 31 Sevorane 1295 AHP 13,679 0.7 159.8 232 -3

34 36 36 32 32 Fragmin 0395 PFZ 13,094 0.6 13.2 101 9
27 33 34 33 34 Prograf 0496 AES 12,660 0.6 10.9 99 3
38 34 32 36 35 Kaletra 0301 AHP 11,758 0.6 5.3 94 10
- - 53 44 36 Eligard 0404 S.A 11,738 0.6 25.3 112 ******

- - 100 57 37 Reyataz 0104 BMS 11,377 0.5 57.3 141 ******
134 60 52 45 38 Cancidas 0901 MSD 11,122 0.5 20.2 108 55
71 51 41 39 39 Temodal 1099 SHC 11,039 0.5 3.3 92 26
7 5 10 16 40 Taxol 0293 BMS 10,879 0.5 -51.2 44 -19
45 42 37 40 41 Plavix 1098 BSA 10,878 0.5 4.5 93 12

- 46 35 34 42 Xigris 0303 LLY 10,463 0.5 -7.2 83 ******
- - - 76 43 Velcade 0205 JNO 9,972 0.5 100.9 180 ******
50 44 42 38 44 Trasylol 0177 BAY 9,611 0.5 -11.0 80 11
21 23 40 43 45 Zoladex LA 0896 AZN 9,603 0.5 0.1 90 -9
29 30 44 46 46 Lupron Depot 0290 AHP 9,087 0.4 3.0 92 -5

66 55 47 49 47 Aricept 0897 PFZ 9,035 0.4 9.3 98 18
33 35 31 31 48 Zofran 0591 GSK 8,921 0.4 -28.1 64 -1
53 53 50 50 49 Norvasc 0992 PFZ 8,868 0.4 9.4 98 10
64 58 51 47 50 Caelyx 0898 SHC 8,806 0.4 2.5 92 14
Total Others 864,408 41.6 7.6 96 2

T 13 Top 25 Molecules in Top 15 Therapeutic Classes
by Total Ethical Purchases
4-yr Avg
Total Ethical Market

14,313,392 100.0 8.3 100 9
for Top 15 Classes
1 1 1 1 1 Atorvastatin 1,028,900 7.2 9.5 101 14
Lipitor 0397 PFZ 1,025,448 99.7 9.1 100 14
Caduet 0206 PFZ 3,452 0.3 ****** ****** ******
5 5 4 3 2 Amlodipine 383,007 2.7 12.1 103 12

Norvasc 0992 PFZ 379,555 99.1 11.1 99 12
Caduet 0206 PFZ 3,452 0.9 ****** ****** ******
6 4 3 2 3 Ramipril 380,443 2.7 7.8 100 13

Altace 0194 S.A 379,920 99.9 7.7 100 13
ratio-Ramipril 1206 RAT 349 0.1 ****** ****** ******
Altace HCT 1106 S.A 174 0.0 ****** ****** ******
12 9 7 6 4 Venlafaxine 342,013 2.4 17.8 109 20

Effexor XR 0398 WYE 334,029 97.7 15.0 98 22
Novo-Venlafaxine XR 1206 NVP 7,984 2.3 ****** ****** ******
Effexor 1094 WYE 1 0.0 -92.7 6 -92
4 3 5 4 5 Fluticasone 341,139 2.4 4.9 97 8

Flovent HFA 0202 GSK 138,591 40.6 -2.4 93 73
Advair 1099 GSK 129,410 37.9 6.9 102 8
Advair MDI 0102 GSK 64,873 19.0 20.0 114 63
Flovent Diskus 0598 GSK 8,078 2.4 2.0 97 0
Cutivate 1104 GKC 188 0.1 62.4 155 ******
11 10 8 8 6 Pantoprazole 304,982 2.1 13.7 105 16

Pantoloc 0397 AAA 290,402 95.2 14.3 101 16
Panto IV 0499 AAA 14,580 4.8 3.3 91 15
8 6 6 7 7 Olanzapine 290,410 2.0 4.1 96 8

Zyprexa 1196 LLY 225,726 77.7 -0.6 96 4
Zyprexa Zydis 0301 LLY 64,408 22.2 24.4 120 42
Zyprexa Intramuscular 0104 LLY 276 0.1 13.2 109 ******

4-yr Avg
2 2 2 5 8 Omeprazole 266,421 1.9 -12.6 81 -11

Losec 0689 AZN 179,620 67.4 -29.1 81 -19
Apo-Omeprazole 0104 ATX 85,504 32.1 74.2 199 ******
Losec Mups 0301 AZN 1,279 0.5 -44.8 63 -12
ratio-Omeprazole 1206 RAT 18 0.0 ****** ****** ******
25 20 14 11 9 Hydrochlorothiazide 225,071 1.6 16.0 107 25

Diovan HCT 0500 NVR 49,795 22.1 25.3 108 41
Avalide 0400 BSA 45,519 20.2 20.1 104 30
Atacand Plus 0601 AZN 22,314 9.9 22.5 106 53
Micardis Plus 0901 B.I 19,851 8.8 30.9 113 60
Hyzaar DS 0200 MSD 19,046 8.5 9.2 94 26
15 13 12 9 10 Salmeterol 213,831 1.5 7.9 100 13

Advair 1099 GSK 129,410 60.5 6.9 99 8
Advair MDI 0102 GSK 64,873 30.3 20.0 111 63
Serevent Diskus 0598 GSK 10,329 4.8 389.4 453 56
Serevent 1294 GSK 9,219 4.3 -55.9 41 -21
23 19 13 10 11 Clopidogrel 210,219 1.5 8.1 100 22

Plavix 1098 BSA 210,219 100.0 8.1 100 22
741 99 23 16 12 Rosuvastatin 206,465 1.4 35.7 125 ******

Crestor 0203 AZN 206,465 100.0 35.7 100 ******
39 29 24 15 13 Oxycodone 188,123 1.3 19.2 110 31

Oxycontin 0896 PUF 142,236 75.6 24.9 105 32
ratio-Oxycocet 0484 RAT 22,227 11.8 -10.2 75 29
Endocet 0987 LSN 9,349 5.0 55.6 131 53
Supeudol 0968 SDZ 5,630 3.0 24.4 104 19
Oxy.IR 0300 PUF 4,252 2.3 18.2 99 41

4-yr Avg
3 7 9 12 14 Simvastatin 181,965 1.3 -5.3 87 -10

Gen-Simvastatin 0203 GN3 50,228 27.6 1.6 107 ******
Apo-Simvastatin 0103 ATX 49,100 27.0 0.9 107 ******
Co Simvastatin 1103 CBT 22,588 12.4 6.1 112 ******
Novo-Simvastatin 0304 NVP 18,466 10.1 6.6 113 ******
Zocor 0890 FRO 17,180 9.4 -50.4 52 -50
10 11 11 13 15 Erythropoietin Alpha 174,099 1.2 -1.1 91 -1

Eprex 0390 JNO 174,099 100.0 -1.1 100 -1
16 18 18 14 16 Acetaminophen 173,032 1.2 5.4 97 9

Tylenol Extra Strength 1075 MCC 35,867 20.7 5.3 100 -4
ratio-Oxycocet 0484 RAT 22,227 12.8 -10.2 85 29
Tylenol with Codeine #3 0171 JNO 18,158 10.5 -3.5 92 3
Tylenol Arthritis 1099 MCC 15,093 8.7 6.1 101 18
Endocet 0987 LSN 9,349 5.4 55.6 148 53
49 39 30 26 17 Infliximab 169,842 1.2 36.1 126 32

Remicade 0601 SHC 169,842 100.0 36.1 100 32
64 31 25 18 18 Esomeprazole 166,593 1.2 17.2 108 36

Nexium 0801 AZN 166,593 100.0 17.2 100 36
88 53 35 27 19 Etanercept 159,692 1.1 28.7 119 51

Enbrel 0301 AAI 159,692 100.0 28.7 100 51
18 21 19 19 20 Lansoprazole 157,874 1.1 11.1 103 9

Prevacid 0695 ABD 150,102 95.1 10.5 99 9
HP-Pac 0898 ABD 6,917 4.4 11.2 100 1
Prevacid Fastab 0205 ABD 854 0.5 ****** ****** ******
298 86 45 31 21 Rabeprazole Sodium 146,309 1.0 29.1 119 146

Pariet 0702 JNO 146,309 100.0 29.1 100 146

4-yr Avg
41 35 28 24 22 Rosiglitazone 146,088 1.0 14.0 105 24

Avandia 0300 GSK 129,702 88.8 13.7 100 20
Avandamet 0303 GSK 16,282 11.1 16.5 102 ******
Avandaryl 0506 GSK 104 0.1 ****** ****** ******
20 22 22 21 23 Nifedipine 141,107 1.0 8.5 100 6

Adalat XL 0492 BAY 139,989 99.2 8.8 100 7
Apo-Nifed PA 0995 ATX 945 0.7 -18.7 75 -14
Apo-Nifed 1287 ATX 173 0.1 -15.5 78 3
Adalat PA10 0589 BAY - 0.0 ****** ****** -100
Nifedipine PA 1296 PDO - 0.0 ****** ****** -100
67 48 31 29 24 Quetiapine 139,756 1.0 17.4 108 32

Seroquel 0198 AZN 139,756 100.0 17.4 100 32
120 128 116 83 25 Trastuzumab 138,277 1.0 169.5 249 60

Herceptin 0899 ROC 138,277 100.0 169.5 100 60
Total Others 9,324,687 65.1 6.2 98 7

T 14 Brand-Name Products Launched by Total Purchases
Average
Total Monthly
Launch Date Purchases Purchases
(MMYY) MFR 2006 ($000s) ($000s)
02000 Analgesics
Zytram XL 1206 PUF 11 11
09000 Antiarthritics
Prexige 1106 NVR 521 261
20000 Neurological Disorders, Miscellaneous

Azilect 0906 TVN 293 73
Aricept RDT 0106 PFZ 40 3
23000 Antispasmodic/Antisecretory
Vesicare 0706 AES 312 52
Uromax 0606 PUF 152 22
Enablex 0306 NVR 145 15
Trosec 0806 ORY 34 7
27000 Biologicals
Gardasil 0706 FRO 1,950 325
Menactra 1006 SF2 128 43
Rotateq 0906 MSD 58 15
28000 Bronchial Therapy

Alvesco 0906 AAA 477 119
30000 Oncology
Sutent 0606 PFZ 1,768 253
Faslodex 0206 AZN 647 59
Bexxar 0406 GSK 44 5
Trelstar LA 0706 PDN 7 1
31000 Cardiovasculars
Flomax CR 0506 B.I 8,504 1,063
Caduet 0206 PFZ 3,452 314
Revatio 0606 PFZ 199 28
Altace HCT 1106 S.A 174 87

T 14 Brand-Name Products Launched by Total Purchases
Average
Total Monthly
Launch Date Purchases Purchases
(MMYY) MFR 2006 ($000s) ($000s)
32000 Antihyperlipidemic Agents

Advicor 0106 ORY 109 9
33000 Contraceptives
Linessa 0606 ORG 415 59
39000 Diabetes Therapy

Levemir 0106 N-N 12,360 1,030
Avandaryl 0506 GSK 104 13
Hypurin NPH 0406 N&U 83 9
Hypurin R 0406 N&U 74 8
52000 Hormones
Fosavance 0306 MSD 1,228 123
Somavert 0206 PFZ 214 19
Actonel Plus Calcium 0606 PRG 128 18
DDAVP Melt 1106 FER 83 42
61000 Ophthalmic Preparations

Duotrav 0406 ALC 182 20
64000 Psychotherapeutics
Wellbutrin XL 0306 B5L 6,267 627
Biphentin 0806 PUF 708 142
78000 Miscellaneous Ethical, Others

Exjade 1106 NVR 157 79
81000 Anti-Virals
Truvada 0406 GS- 4,372 486
Hepsera 0606 GS- 759 108
Prezista 0806 JNO 109 18
Baraclude 0806 BMS 56 9
Denavir 0806 NV- 47 8
86000 Immunologic Agents

Rebif Initiation Pack 0506 SER 281 35

T 15 Top 50 Products by Total Prescriptions
4-yr Avg
Launch # of Rx Evolution Compound
Rank Rank Rank Rank Rank Date 2006 % Change Index Growth Rate
2002 2003 2004 2005 2006 (MMYY) MFR (000s) Over 2005 2006 (Rx) 2002-06
Total Ethical Prescriptions 410,142 6.7 100 6
2 1 1 1 1 Lipitor 0397 PFZ 12,702 13.1 106 16

1 2 2 2 2 Synthroid 0157 ABD 9,789 7.6 101 9
3 3 3 3 3 Altace 0194 S.A 8,958 9.6 103 14
7 5 4 4 4 Norvasc 0992 PFZ 6,314 14.7 108 13
15 7 6 5 5 Effexor XR 0398 WYE 5,758 14.9 108 20
Leading 5 Products 43,522 11.5 105 14
23 16 10 7 6 Pantoloc 0397 AAA 4,496 15.9 109 19

5 4 5 6 7 Tylenol with Codeine #3 0171 JNO 3,957 -11.5 83 -3
11 10 9 9 8 Apo-Furosemide 0676 ATX 3,801 6.2 100 5
406 12 8 8 9 ratio-Salbutamol HFA 0202 RAT 3,794 1.5 95 119
13 14 11 10 10 Apo-Hydro 1074 ATX 3,632 4.9 98 6
- 173 31 18 11 Crestor 0203 AZN 3,270 35.1 127 ******

14 26 30 26 12 Apo-Amoxi 0884 ATX 3,267 49.0 140 4
718 96 37 23 13 Pariet 0702 JNO 3,128 34.9 126 161
33 21 14 11 14 Novo-Hydrazide 0170 NVP 2,863 4.9 98 17
92 50 35 25 15 Seroquel 0198 AZN 2,862 28.4 120 40
21 18 15 12 16 Adalat XL 0492 BAY 2,756 4.9 98 5

27 25 16 13 17 Alesse 0198 WYE 2,699 4.3 98 10
18 19 17 14 18 Apo-Lorazepam 1185 ATX 2,653 4.6 98 2
17 17 19 17 19 Ativan 0477 WYE 2,522 3.4 97 1
492 22 22 15 20 Flovent HFA 0202 GSK 2,490 -1.1 93 110
60 41 32 27 21 Plavix 1098 BSA 2,435 13.0 106 24

22 20 21 20 22 Apo-Amitriptyline 0675 ATX 2,423 2.1 96 2
6 11 13 16 23 Premarin 0242 WYE 2,347 -3.8 90 -14
98 48 36 32 24 Nexium 0801 AZN 2,259 16.7 109 33
10 15 12 30 25 Celebrex 0499 PFZ 2,237 10.4 103 -8

T 15 Top 50 Products by Total Prescriptions
4-yr Avg
Launch # of Rx Evolution Compound
Rank Rank Rank Rank Rank Date 2006 % Change Index Growth Rate
2002 2003 2004 2005 2006 (MMYY) MFR (000s) Over 2005 2006 (Rx) 2002-06
118 73 44 34 26 Actonel 1199 PRG 2,224 21.9 114 38

25 28 28 28 27 Eltroxin 0151 GSK 2,168 4.5 98 3
30 30 23 19 28 Risperdal 0593 JNO 2,126 -12.0 82 7
- - 277 49 29 Apo-Omeprazole 0104 ATX 2,018 49.1 140 ******
44 34 45 47 30 Gen-Metformin 0495 GN3 2,017 44.0 135 11
28 29 29 33 31 Apo-Oxazepam 0979 ATX 1,947 1.6 95 2

38 36 38 36 32 Prevacid 0695 ABD 1,927 9.9 103 8
24 23 24 29 33 Tri-Cyclen 0793 JNO 1,853 -9.4 85 -3
19 24 26 31 34 Vasotec 0887 FRO 1,832 -5.9 88 -6
46 38 34 37 35 Zyprexa 1196 LLY 1,819 4.0 97 9
26 32 33 38 36 Lanoxin 0136 VP3 1,710 0.2 94 -2

57 47 48 40 37 Nasonex 0898 SHC 1,706 9.5 103 13
71 55 51 43 38 Avapro 0698 BSA 1,696 13.6 107 16
229 135 52 35 39 PMS-Metformin 0297 P8I 1,649 -7.5 87 52
45 39 39 39 40 Apo-Prednisone 0382 ATX 1,641 4.1 98 5
4 6 7 22 41 Losec 0689 AZN 1,625 -31.1 65 -22

76 61 56 46 42 Apo-Naproxen 0882 ATX 1,556 10.5 104 15
97 78 53 52 43 Apo-Warfarin 1200 ATX 1,552 18.0 111 21
41 40 40 42 44 Marvelon 0793 ORG 1,501 0.2 94 2
69 54 55 50 45 Apo-Allopurinol 0681 ATX 1,487 10.5 104 12
88 75 65 58 46 Diovan 1197 NVR 1,480 20.5 113 17

74 62 49 48 47 Novo-Metoprol 0386 NVP 1,463 6.2 100 13
87 79 63 55 48 Atacand 1298 AZN 1,450 14.8 108 16
37 43 46 45 49 Coumadin 0556 BMS 1,429 0.1 94 0
36 31 25 21 50 Novamoxin 0179 NVP 1,316 -44.3 52 -3
Total Others 263,538 6.0 99 4

T 16 Top 15 Products by Total Ethical Purchases, Canada vs. United States
Ethical
Launch Date Purchases % Change # of Rx % Change
(MMYY) MFR 2006 ($000s) Over 2005 2006 (000s) Over 2005
Canada
Total Ethical Market 17,816,652 7.9 410,142 6.7
Lipitor 0397 PFZ 1,025,448 9.1 12,702 13.1

Altace 0194 S.A 379,920 7.7 8,958 9.6
Norvasc 0992 PFZ 379,555 11.1 6,314 14.7
Effexor XR 0398 WYE 334,029 15.0 5,758 14.9
Pantoloc 0397 AAA 290,402 14.3 4,496 15.9
Zyprexa 1196 LLY 225,726 -0.6 1,819 4.0
Plavix 1098 BSA 210,219 8.1 2,435 13.0
Crestor 0203 AZN 206,465 35.7 3,270 35.1
Losec 0689 AZN 179,620 -29.1 1,625 -31.1
Eprex 0390 JNO 174,099 -1.1 92 5.9
Remicade 0601 SHC 169,842 36.1 42 19.8
Nexium 0801 AZN 166,593 17.2 2,259 16.7
Enbrel 0301 AAI 159,692 28.7 111 11.4
Prevacid 0695 ABD 150,102 10.5 1,927 9.9
Pariet 0702 JNO 146,309 29.1 3,128 34.9
United States*
Total Market 285,872,516 8.0 3,852,956 5.0
Lipitor 0197 PFZ 8,661,575 3.0 74,020 -2.0

Nexium 0301 AZN 5,147,839 18.0 30,437 15.0
Advair Diskus 0301 GSK 3,954,176 10.0 20,626 1.0
Aranesp 1001 AAI 3,941,352 42.0 457 31.0
Prevacid 0595 TP/ 3,589,504 -6.0 21,507 -11.0
Epogen 0689 AAI 3,241,262 9.0 90 -22.0
Zocor 0192 MSD 3,184,886 -29.0 18,687 -32.0
Enbrel 1198 AAI 3,085,515 12.0 1,793 19.0
Seroquel 1097 AZN 3,025,647 16.0 14,198 12.0
Singulair 0298 MSD 3,003,530 19.0 28,079 14.0
Plavix 0298 BSA 2,948,924 -16.0 18,627 -19.0
Neulasta 0302 AAI 2,923,178 28.0 52 17.0
Procrit (Eprex in Canada) 0291 OBD 2,891,005 -3.0 1,249 15.0
Norvasc 0992 PFZ 2,702,565 3.0 40,075 3.0
Effexor XR 1097 WYE 2,640,454 2.0 18,743 1.0
* US numbers are derived from retail and mail order channels, Data source: National Sales Perspectives, Note - US numbers and growth rates may not correlate
long-term care facilities, clinics, HMO’s, non-federal National Prescription Audit Plus with previous years due to corrections to the
hospitals and other federal facilities. market made after publication.

T 17 Top 50 Molecules by Total Prescriptions
4-yr Avg
Compound
2002 2003 2004 2005 2006 2006 (000s) of Market Over 2005 Index 2006 2002-06
Total Ethical Prescriptions 410,142 100.0 6.7 100 6
5 3 1 1 1 Hydrochlorothiazide 13,715 3.3 7.4 101 12

6 6 5 3 2 Atorvastatin 12,712 3.1 13.1 106 16
4 4 4 4 3 Levothyroxine 11,998 2.9 7.4 101 8
2 2 3 2 4 Acetaminophen 11,747 2.9 2.9 96 2
1 1 2 5 5 Ethinylestradiol 11,198 2.7 2.3 96 0
Leading 5 Molecules 61,370 15.0 6.7 100 7
12 8 7 7 6 Ramipril 8,958 2.2 9.6 103 14

3 5 6 6 7 Codeine 8,437 2.1 -3.5 90 -2
14 12 11 8 8 Metformin 7,699 1.9 13.2 106 14
17 14 12 12 9 Calcium 6,781 1.7 11.9 105 13
10 10 9 10 10 Lorazepam 6,395 1.6 3.3 97 3
19 17 15 14 11 Amlodipine 6,324 1.5 14.9 108 13

7 7 8 9 12 Caffeine 6,249 1.5 -3.3 91 -2
8 9 10 11 13 Salbutamol 6,146 1.5 -0.5 93 1
11 11 13 13 14 Amoxicillin 5,801 1.4 0.3 94 0
31 22 19 17 15 Venlafaxine 5,789 1.4 15.1 108 19
21 20 18 16 16 Metoprolol 5,546 1.4 10.3 103 11

13 13 14 15 17 Fluticasone 5,479 1.3 0.9 95 3
18 16 16 18 18 Furosemide 5,384 1.3 8.5 102 8
41 32 22 21 19 Citalopram 4,519 1.1 10.9 104 18
45 34 29 22 20 Pantoprazole 4,496 1.1 15.9 109 19
16 15 17 19 21 Levonorgestrel 4,420 1.1 -1.8 92 1

20 21 20 20 22 Atenolol 4,245 1.0 -0.2 94 3
43 30 24 24 23 Ergocalciferol 4,223 1.0 10.4 104 17
32 28 23 23 24 Warfarin 4,213 1.0 8.7 102 10
29 27 26 26 25 Clonazepam 3,901 1.0 7.8 101 6

T 17 Top 50 Molecules by Total Prescriptions
4-yr Avg
Compound
47 37 34 30 26 Oxycodone 3,755 0.9 12.9 106 16

15 18 21 25 27 Omeprazole 3,645 0.9 -1.9 92 -5
376 63 35 29 28 Glucose, Blood Tests 3,586 0.9 6.0 99 143
30 24 25 27 29 Simvastatin 3,572 0.9 0.4 94 5
25 25 27 28 30 Glyburide 3,466 0.8 1.2 95 1
- 202 58 45 31 Rosuvastatin 3,270 0.8 35.1 127 ******

425 132 75 48 32 Rabeprazole Sodium 3,128 0.8 34.9 126 161
28 31 31 32 33 Hydrocortisone 3,087 0.8 -0.2 94 0
73 49 40 36 34 Alendronate 3,065 0.7 8.3 102 22
22 23 30 31 35 Paroxetine 3,043 0.7 -3.2 91 -3
52 47 43 41 36 Zopiclone 3,024 0.7 13.8 107 11

42 45 45 37 37 Naproxen 3,004 0.7 6.3 100 7
53 48 42 43 38 Docusate 2,981 0.7 18.1 111 11
58 60 55 34 39 Diclofenac 2,925 0.7 -1.1 93 13
129 94 73 52 40 Quetiapine 2,862 0.7 28.4 120 40
26 29 33 35 41 Ranitidine 2,844 0.7 -1.5 92 -4

37 40 38 38 42 Diltiazem 2,829 0.7 3.5 97 5
9 19 28 33 43 Estrogenic Substances, Conjugated 2,820 0.7 -5.0 89 -17
35 38 36 39 44 Amitriptyline 2,797 0.7 3.4 97 3
39 39 39 40 45 Nifedipine 2,794 0.7 4.5 98 5
77 64 53 46 46 Irbesartan 2,721 0.7 14.3 107 20

61 55 47 44 47 Risperidone 2,712 0.7 9.6 103 14
34 35 37 42 48 Norgestimate 2,579 0.6 1.4 95 0
98 76 68 57 49 Valsartan 2,506 0.6 21.2 114 24
59 56 52 50 50 Mometasone 2,451 0.6 8.0 101 9
Total Others 232,448 56.7 6.4 100 4

T 18 Top 50 Ethical Products by Total Promotional Dollars
Promotional # of Details # of Detail

Launch Date Expenditures # of # of Details with Samples % of Details # of Samples Minutes
(MMYY) MFR 2006 ($000s) Ad Pages (000s) (000s) with Samples (000s) (000s)
Total Ethical Market 245,505 18,272 3,334 2,306 69.2 26,855 12,649
Crestor 0203 AZN 5,947 578 67 53 79.8 1,044 258

Lipitor 0397 PFZ 5,841 627 69 52 74.9 1,113 267
Effexor XR 0398 WYE 5,726 596 51 42 81.7 1,010 230
Nexium 0801 AZN 4,775 265 70 60 85.0 1,020 235
Pantoloc 0397 AAA 4,752 273 50 44 88.6 752 174
Leading 5 Products 27,041 2,339 307 251 81.6 4,938 1,162
Altace 0194 S.A 4,401 400 46 36 78.5 833 177

Ezetrol 0603 MU& 4,058 261 50 33 66.1 374 224
Cipralex 0205 LUN 3,877 297 34 28 83.2 474 184
Symbicort 0202 AZN 3,784 336 46 36 79.1 361 150
Pariet 0702 JNO 3,748 201 47 37 79.4 496 163
Caduet 0206 PFZ 3,723 497 37 23 61.8 376 174

Plavix 1098 BSA 3,566 376 39 26 66.5 179 163
Advair 1099 GSK 3,440 188 58 43 74.0 235 210
Lyrica 0605 PFZ 3,424 532 36 26 73.1 216 147
Celebrex 0499 PFZ 3,416 479 39 31 78.7 661 141
Diovan 1197 NVR 3,281 167 49 33 66.8 351 179

Coversyl 1194 SVR 3,044 54 42 30 73.3 259 181
Actonel 1199 PRG 3,003 103 41 30 73.8 279 177
Avandia 0300 GSK 2,836 106 50 36 72.0 270 190
Prevacid 0695 ABD 2,765 80 43 35 81.6 441 156
Tramacet 0705 JNO 2,758 113 38 29 76.5 306 157

Adalat XL 0492 BAY 2,653 305 32 23 73.0 252 101
Biaxin XL 0802 ABD 2,639 89 43 32 74.8 279 151
Atacand 1298 AZN 2,623 296 32 23 72.5 432 112
Spiriva 0103 B.I 2,589 408 30 20 69.0 139 108
Leading 25 Products 92,669 7,626 1,137 862 75.8 12,150 4,406

T 18 Top 50 Ethical Products by Total Promotional Dollars
Promotional # of Details # of Detail

Launch Date Expenditures # of # of Details with Samples % of Details # of Samples Minutes
(MMYY) MFR 2006 ($000s) Ad Pages (000s) (000s) with Samples (000s) (000s)
Avapro 0698 BSA 2,510 198 34 24 69.2 255 126

Singulair 0898 MSD 2,440 202 21 16 73.0 335 89
Micardis 0999 B.I 2,425 110 41 28 67.9 244 158
Nasonex 0898 SHC 2,393 83 42 34 82.4 348 133
Alesse 0198 WYE 2,302 190 31 23 76.6 287 92
Leading 30 Products 104,740 8,410 1,306 987 75.6 13,619 5,004
Norvasc 0992 PFZ 2,210 71 47 36 75.9 440 122

Lipidil EZ 0805 FOU 2,147 301 16 12 76.8 98 57
Cialis 1103 L&I 1,887 - 36 29 80.3 190 110
Viagra 0399 PFZ 1,834 - 34 27 80.1 194 105
Aricept 0897 PFZ 1,833 165 19 10 51.6 59 96
Leading 35 Products 114,651 8,946 1,458 1,101 75.5 14,601 5,494
Fosavance 0306 MSD 1,771 111 20 14 69.7 122 79

Avandamet 0303 GSK 1,732 302 17 11 65.0 83 63
Avelox 1000 BAY 1,691 57 31 23 73.5 156 102
Lantus 1104 S.A 1,690 312 8 1 7.1 7 56
Valtrex 0596 GSK 1,678 - 38 29 76.1 214 117
Wellbutrin XL 0306 B5L 1,668 155 15 10 64.4 233 90

Actos 0800 LLY 1,664 - 31 21 67.0 235 115
Paxil CR 1203 GSK 1,631 - 32 25 77.9 254 128
Zyprexa 1196 LLY 1,624 - 23 13 57.6 160 168
Aerius 0102 SHC 1,508 26 34 28 82.3 348 86
Advair MDI 0102 GSK 1,499 188 23 23 99.2 113 52

Yasmin 1204 BXL 1,474 91 16 14 86.6 229 57
Strattera 0205 LLY 1,452 - 19 11 59.8 201 133
Flonase 0993 GSK 1,452 - 39 33 85.1 273 81
Detrol LA 0302 PFZ 1,382 125 19 15 75.7 132 66
Total Others 106,941 7,958 1,512 936 61.9 9,496 5,760

Therapeutic
Classes
T 19 Top 15 Therapeutic Classes and Leading Manufacturers
4-yr Avg
Ethical Compound
1 1 1 1 1 31000 Cardiovasculars 2,470,714 13.9 6.2 98 7

Pfizer 440,868 17.8 10.3 104 9
Frosst 192,347 7.8 -2.6 92 -3
Apotex Inc 184,206 7.5 0.3 94 3
AstraZeneca 153,639 6.2 12.5 106 9
2 2 2 2 2 64000 Psychotherapeutics 1,743,818 9.8 9.0 101 8

Lilly 316,197 18.1 6.9 98 10
Apotex Inc 211,237 12.1 12.4 103 18
AstraZeneca 139,756 8.0 17.4 108 32
3 3 3 3 3 32000 Antihyperlipidemic Agents 1,671,515 9.4 8.7 101 11

Pfizer 1,026,795 61.4 9.1 100 14
AstraZeneca 206,465 12.4 35.7 125 ******
Apotex Inc 100,746 6.0 2.8 95 8
Genpharm Pharma 66,733 4.0 5.9 97 40
Merck-Schering GP 64,936 3.9 42.8 131 ******
4 4 4 4 4 23000 Antispasmodic/Antisecretory 1,318,400 7.4 7.3 99 8

AstraZeneca 347,492 26.4 -12.6 81 -7
Janssen-Ortho Inc 165,792 12.6 26.7 118 81
Abbott PCD 157,874 12.0 11.1 104 9
Apotex Inc 140,995 10.7 34.1 125 31
10 10 10 6 5 30000 Oncology 876,288 4.9 19.5 111 17

Roche 291,305 33.2 79.3 150 49
AstraZeneca 115,689 13.2 -5.5 79 5
Novartis Pharma 93,457 10.7 18.8 99 39
Abbott SPD 48,285 5.5 3.4 87 1
Leading 5 Classes 8,080,734 45.4 8.8 101 9
68 Therapeutic Classes
4-yr Avg
Ethical Compound
9 9 9 8 6 02000 Analgesics 783,746 4.4 8.9 101 12

Purdue Pharma 220,316 28.1 19.8 110 20
McNeil Consumer 69,998 8.9 1.9 94 5
ratiopharm Inc 50,436 6.4 4.5 96 22
GlaxoSmithKline 46,947 6.0 -24.9 69 -7
8 8 8 7 7 28000 Bronchial Therapy 758,307 4.3 5.0 97 9

AstraZeneca 123,887 16.3 5.3 100 10
BoehrIngelheimer Ingelheim 119,055 15.7 11.9 107 18
MS&D 63,370 8.4 10.3 105 13
ratiopharm Inc 40,394 5.3 -4.7 91 24
5 5 5 5 8 15000 Anti-infectives, Systemic 757,125 4.2 0.7 93 3

Apotex Inc 103,428 13.7 15.0 114 12
Abbott PCD 97,036 12.8 3.2 102 4
Bayer Healthcare 70,341 9.3 20.8 120 -9
Novopharm 58,878 7.8 -8.6 91 10
Pfizer 47,652 6.3 -47.3 52 -12
6 7 7 9 9 52000 Hormones 690,529 3.9 -1.2 92 3

Schering Health Canada 52,932 7.7 -0.3 101 -5
Lilly 47,085 6.8 8.4 110 4
MS&D 45,008 6.5 -60.3 40 -15
Apotex Inc 40,789 5.9 74.1 176 73
7 6 6 10 10 09000 Antiarthritics 683,151 3.8 15.7 107 4

Pfizer 180,141 26.4 1.5 88 -4
Schering Health Canada 169,842 24.9 36.1 118 32
Amgen 162,222 23.7 27.8 111 50
Apotex Inc 67,850 9.9 25.3 108 26
Novopharm 28,189 4.1 35.4 117 33
Leading 10 Classes 11,753,591 66.0 7.7 100 8
Therapeutic Classes 69
4-yr Avg
Ethical Compound
11 11 11 11 11 20000 Neurological Disorders, Miscellaneous 651,905 3.7 10.8 103 13

Pfizer 152,734 23.4 27.8 115 14
Apotex Inc 82,979 12.7 31.4 119 29
Novartis Pharma 53,125 8.1 9.1 98 17
12 12 12 12 12 39000 Diabetes Therapy 578,274 3.2 16.8 108 17

Lilly 152,114 26.3 13.3 97 14
Genpharm Pharma 32,818 5.7 34.3 115 1
13 13 13 13 13 11000 Hemostatic Modifiers 470,518 2.6 6.0 98 11

BMS-Sanofi 210,219 44.7 8.1 102 22
Roche 43,611 9.3 8.8 103 -1
Pfizer 38,981 8.3 19.2 112 13
Lilly 25,385 5.4 -3.9 91 12
18 18 14 14 14 81000 Anti-Virals 442,992 2.5 11.0 103 16

BMS Pharma 64,246 14.5 16.8 105 13
Roche 53,950 12.2 13.1 102 47
Abbott SPD 36,868 8.3 11.4 100 13
Gilead Sciences 28,289 6.4 76.6 159 ******
17 15 15 15 15 48000 Hematinics 416,112 2.3 10.0 102 13

Amgen 209,008 50.2 20.5 109 39
GSK Consumer 5,731 1.4 -3.4 88 9
Jamieson 4,108 1.0 13.3 103 11
Leading 15 Classes 14,313,392 80.3 8.3 100 9
by Ethical Drug Store Purchases
4-yr Avg
Drug Store Compound
Total Ethical Drug Store Purchases 15,736,712 100.0 7.4 100 8

Pfizer 430,757 17.9 10.2 104 9
Frosst 187,477 7.8 -2.6 92 -3
Apotex Inc 179,386 7.4 0.3 95 2
AstraZeneca 151,272 6.3 12.6 106 9

Pfizer 1,012,258 61.3 9.0 100 14
AstraZeneca 205,229 12.4 35.6 125 ******
Apotex Inc 99,465 6.0 3.1 95 8
Genpharm Pharma 66,419 4.0 5.8 97 40

Lilly 283,574 17.5 8.1 99 11
Apotex Inc 207,093 12.8 12.5 103 18
AstraZeneca 124,616 7.7 18.6 108 34

AstraZeneca 344,691 27.0 -12.3 82 -7
Abbott PCD 157,341 12.3 11.2 104 9
Apotex Inc 139,352 10.9 34.2 125 31
9 9 7 5 5 02000 Analgesics 746,240 4.7 7.8 100 12

Purdue Pharma 214,669 28.8 19.9 111 21
McNeil Consumer 69,841 9.4 1.9 95 5
ratiopharm Inc 49,698 6.7 4.3 97 22
Leading 5 Classes 7,706,262 49.0 7.7 100 9
4-yr Avg
Drug Store Compound

AstraZeneca 120,015 16.7 5.2 100 10
MS&D 62,807 8.8 10.3 105 13
ratiopharm Inc 39,708 5.5 -4.1 91 24
6 5 5 9 7 09000 Antiarthritics 649,468 4.1 16.2 108 5

Pfizer 177,481 27.3 1.4 87 -4
Amgen 160,781 24.8 28.0 110 51
Apotex Inc 66,781 10.3 25.5 108 26
Novopharm 27,878 4.3 35.9 117 33
5 6 8 7 8 52000 Hormones 634,434 4.0 -1.3 92 4

MS&D 44,775 7.1 -59.9 41 -15
Lilly 40,113 6.3 12.3 114 6
Apotex Inc 39,245 6.2 76.4 179 74

Pfizer 142,191 23.0 28.6 116 14
Apotex Inc 80,079 13.0 31.7 119 30
Novartis Pharma 48,931 7.9 9.0 98 16

Lilly 148,859 26.3 13.5 97 14
Genpharm Pharma 32,603 5.8 35.6 116 1
Leading 10 Classes 10,892,285 69.2 8.0 101 9
4-yr Avg
Drug Store Compound
7 8 9 8 11 15000 Anti-infectives, Systemic 565,288 3.6 -1.4 92 2

Apotex Inc 99,500 17.6 15.1 117 13
Abbott PCD 94,614 16.7 3.2 105 5
Novopharm 47,150 8.3 -10.8 90 11
Bayer Pharma 36,367 6.4 27.8 130 -17
Pfizer 35,301 6.2 -54.0 47 -15
13 13 13 12 12 40000 Diagnostic Aids 366,205 2.3 6.9 100 9

Lifescan 112,247 30.7 5.6 99 8
Roche Diagnostics 98,274 26.8 -0.9 93 6
Bayer Pharma 89,006 24.3 19.8 112 15
Abbott Diabetic Care 42,819 11.7 0.2 94 4
Becton Dickinson 7,188 2.0 25.5 117 111
19 15 14 14 13 81000 Anti-virals 351,081 2.2 10.7 103 18

Roche 46,361 13.2 13.1 102 59
BMS Pharma 42,762 12.2 16.4 105 13
Schering Health Canada 25,650 7.3 -26.9 66 226
Abbott SPD 23,617 6.7 13.6 103 16
12 12 12 13 14 37000 Dermatologicals 327,720 2.1 -0.3 93 2

Leo Pharma Inc 33,197 10.1 7.2 108 7
Stiefel 26,077 8.0 0.1 100 7
Pfizer Consumer Health Care 22,710 6.9 5.1 105 3
J&J 21,376 6.5 12.1 113 8
Roche 20,960 6.4 -31.7 68 -9
16 17 15 15 15 30000 Oncology 319,035 2.0 12.2 104 14

AstraZeneca 97,208 30.5 -5.7 84 6
Novartis Pharma 65,498 20.5 23.3 110 41
Abbott SPD 39,196 12.3 3.5 92 2
Roche 20,206 6.3 80.0 161 34
Leading 15 Classes 12,821,613 81.5 7.5 100 9
Total Others 2,915,099 18.5 7.2 100 7
by Ethical Hospital Purchases
4-yr Avg
Hospital Compound
Total Ethical Hospital Purchases 2,079,940 100.0 11.8 100 9
1 1 1 1 1 30000 Oncology 557,253 26.8 24.1 111 20

Roche 271,099 48.6 79.2 144 50
Pfizer 33,069 5.9 -54.7 36 -11
Lilly 28,214 5.1 10.7 89 20

Bayer Pharma 33,973 17.7 14.0 106 7
Roche 27,411 14.3 4.6 97 10
MS&D 19,406 10.1 10.6 103 25
AstraZeneca 17,170 9.0 56.7 146 10
4 4 3 3 3 48000 Hematinics 185,040 8.9 5.0 94 9

Amgen 92,281 49.9 11.1 106 41
Janssen-Ortho Inc 87,388 47.2 -2.0 93 -4
Luitpold Pharma 2,131 1.2 13.1 108 71
Odan Lab 139 0.1 -0.4 95 46

Roche 43,475 26.4 9.8 110 -1
Lilly 25,382 15.4 -3.9 96 12
Leo Pharma Inc 15,253 9.3 -20.4 80 10
Pfizer 13,723 8.3 13.3 113 0
5 5 5 5 5 64000 Psychotherapeutics 120,344 5.8 4.4 93 3

Lilly 32,623 27.1 -2.0 94 3
Novartis Pharma 30,770 25.6 11.0 106 2
AstraZeneca 15,140 12.6 8.2 104 19
Leading 5 Classes 1,218,866 58.6 12.5 101 11
4-yr Avg
Hospital Compound
19 11 8 6 6 27000 Biologicals 101,182 4.9 13.8 102 55

MS&D 18,652 18.4 -37.5 55 17
Solvay Pharma 163 0.2 26.1 111 ******
Sanofi-Pasteur 146 0.1 47.2 129 7
8 7 6 7 7 81000 Anti-virals 91,911 4.4 12.3 100 11

BMS Pharma 21,484 23.4 17.5 105 14
Abbott SPD 13,251 14.4 7.8 96 9
Gilead Sciences 10,276 11.2 31.5 117 ******
Roche 7,589 8.3 12.7 100 15
6 6 7 8 8 86000 Immunologic Agents 72,534 3.5 6.9 96 0

Novartis Pharma 19,482 26.9 -0.3 93 -11
Roche 19,475 26.8 9.0 102 8
Astellas Pharma 12,706 17.5 11.1 104 3
9 9 10 10 9 31000 Cardiovasculars 61,866 3.0 12.0 100 1

Pfizer 10,112 16.3 11.9 100 7
sanofi-aventis Canada 6,512 10.5 3.7 93 -8
Frosst 4,870 7.9 -0.5 89 -5
Apotex Inc 4,820 7.8 3.6 92 16
7 8 9 9 10 52000 Hormones 56,095 2.7 0.1 90 -3

Novartis Pharma 7,791 13.9 -7.8 92 1
Mayne Pharma (Canada) Inc 7,686 13.7 -4.0 96 -12
Lilly 6,972 12.4 -9.5 90 -5
Roche 5,654 10.1 10.4 110 -1
Pfizer 4,059 7.2 5.6 105 -6
Leading 10 Classes 1,602,454 77.0 11.8 100 10
4-yr Avg
Hospital Compound
10 15 15 13 11 04000 Anesthetics 52,398 2.5 30.6 117 2

AstraZeneca 23,136 44.2 10.5 85 20
Abbott SPD 14,925 28.5 161.3 200 -4
Novopharm 2,718 5.2 ****** ****** 416
Hospira 2,548 4.9 -17.7 63 -37
Odan Lab 2,025 3.9 6.9 82 25
14 12 12 11 12 61000 Ophthalmic Preparations 43,524 2.1 -1.3 88 10

Novartis Pharma 28,063 64.5 -4.9 96 13
AMO Canada Company 3,674 8.4 -3.9 97 -2
Alcon Canada 3,002 6.9 4.9 106 6
Bausch & Lomb 2,107 4.8 11.0 113 6
Pharmascience 1,936 4.4 2.1 103 26
11 10 11 12 13 23000 Antispasmodic/Antisecretory 43,284 2.1 6.6 95 1

Novartis Pharma 11,380 26.3 27.0 119 9
AstraZeneca 2,801 6.5 -40.2 56 -25
Apotex Inc 1,643 3.8 22.8 115 30

Boehringer Ingelheim 11,503 28.3 -1.2 94 6
AstraZeneca 3,872 9.5 7.1 102 8
Roche 2,254 5.6 0.2 95 5
Genpharm Pharma 1,311 3.2 42.0 135 7
16 17 17 17 15 02000 Analgesics 37,507 1.8 38.9 124 12

Purdue Pharma 5,647 15.1 15.3 83 14
Church & Dwight Ltd 1,684 4.5 9.2 79 10
Pharmascience 1,124 3.0 27.1 91 17
Leading 15 Classes 1,819,766 87.5 12.1 100 10
Total Others 260,173 12.5 10.0 98 3
T 22 Top 15 Therapeutic Classes and Leading Brand-Name Manufacturers
4-yr Avg
Ethical Compound
Total Ethical Purchases 17,816,652 100.0 7.9 100 8

Brand Manufacturers 2,012,389 81.4 6.0 100 8
Pfizer 440,868 21.9 10.3 104 9
Frosst 192,347 9.6 -2.6 92 -3
AstraZeneca 153,639 7.6 12.5 106 9
Bayer Pharma 141,677 7.0 8.8 103 7

Lilly 316,197 26.5 6.9 99 10
AstraZeneca 139,756 11.7 17.4 109 32
Novartis Pharma 65,846 5.5 0.8 94 -1

Pfizer 1,026,795 74.4 9.1 99 14
AstraZeneca 206,465 15.0 35.7 123 ******
Fournier 36,678 2.7 -23.8 69 1
Frosst 17,180 1.2 -50.4 45 -50

AstraZeneca 347,492 31.8 -12.6 83 -7
Abbott PCD 157,874 14.4 11.1 106 9
Novartis Pharma 46,325 4.2 21.5 116 18
4-yr Avg
Ethical Compound
10 10 10 6 5 30000 Oncology 876,288 4.9 19.5 111 17

Brand Manufacturers 789,130 90.1 15.8 97 17
Roche 291,305 36.9 79.3 155 49
AstraZeneca 115,689 14.7 -5.5 82 5
Novartis Pharma 93,457 11.8 18.8 103 39
Abbott SPD 48,285 6.1 3.4 89 1
9 9 9 8 6 02000 Analgesics 783,746 4.4 8.9 101 12

Purdue Pharma 220,316 35.3 19.8 113 20
McNeil Consumer 69,998 11.2 1.9 96 5
AstraZeneca 30,676 4.9 5.0 99 4

AstraZeneca 123,887 17.8 5.3 100 10
MS&D 63,370 9.1 10.3 104 13
Roche 8,431 1.2 7.0 101 12

Brand Manufacturers 486,359 64.2 -5.9 93 -2
Abbott PCD 97,036 20.0 3.2 110 4
Bayer Pharma 70,341 14.5 20.8 128 -9
Pfizer 47,652 9.8 -47.3 56 -12
BMS Pharma 31,690 6.5 -19.6 85 2
4-yr Avg
Ethical Compound
6 7 7 9 9 52000 Hormones 690,529 3.9 -1.2 92 3

Brand Manufacturers 540,372 78.3 -8.0 93 0
Lilly 47,085 8.7 8.4 118 4
MS&D 45,008 8.3 -60.3 43 -15
Novartis Pharma 32,802 6.1 -10.4 97 -9
7 6 6 10 10 09000 Antiarthritics 683,151 3.8 15.7 107 4

Pfizer 180,141 32.7 1.5 87 -4
Amgen 162,222 29.5 27.8 110 50
Squire Pharma Inc 10,937 2.0 23.1 106 137
sanofi-aventis Canada 9,044 1.6 -26.0 64 -26

Pfizer 152,734 36.4 27.8 122 14
Novartis Pharma 53,121 12.7 9.1 104 17

Lilly 152,114 33.5 13.3 95 14
Servier Laboratories 13,010 2.9 21.2 102 16
4-yr Avg
Ethical Compound

BMS-Sanofi 210,219 49.4 8.1 103 22
Roche 43,611 10.2 8.8 104 -1
Pfizer 38,981 9.2 19.2 114 13
Lilly 25,385 6.0 -3.9 92 12
18 18 14 14 14 81000 Anti-virals 442,992 2.5 11.0 103 16

BMS Pharma 64,246 14.9 16.8 105 13
Roche 53,950 12.5 13.1 102 47
Abbott SPD 36,868 8.5 11.4 100 13
Gilead Sciences 28,289 6.6 76.6 159 ******
17 15 15 15 15 48000 Hematinics 416,112 2.3 10.0 102 13

Amgen 209,008 52.0 20.5 109 39
GSK Consumer 5,731 1.4 -3.4 88 9
Jamieson 4,108 1.0 13.3 103 11
Luitpold Pharma 2,653 0.7 12.7 102 33
Total Others 3,503,260 19.7 6.3 98 6
T 23 Top 15 Therapeutic Classes and Leading Generic Manufacturers
4-yr Avg
Ethical Compound
Total Ethical Market 100.0 7.9 100 8

17,816,652
Generic Manufacturers 458,325 18.6 7.2 101 7
Apotex Inc 184,206 40.2 0.3 94 3
Novopharm 93,779 20.5 12.4 105 15
ratiopharm Inc 49,015 10.7 -2.0 91 3
Genpharm Pharma 43,490 9.5 19.1 111 1

Apotex Inc 211,237 38.5 12.4 100 18
Genpharm Pharma 85,604 15.6 -14.2 77 36
Novopharm 68,046 12.4 29.8 116 18
ratiopharm Inc 64,039 11.7 9.2 97 50
Pharmascience 51,093 9.3 4.4 93 13

Apotex Inc 100,746 34.5 2.8 100 8
Genpharm Pharma 66,733 22.8 5.9 103 40
Novopharm 47,958 16.4 -4.0 94 105
ratiopharm Inc 23,962 8.2 2.4 100 157
Cobalt Pharma 23,330 8.0 1.5 99 ******

Apotex Inc 140,995 62.8 34.1 110 31
Novopharm 24,664 11.0 -11.8 72 0
Genpharm Pharma 23,680 10.5 5.5 86 -6
Pharmascience 9,223 4.1 15.9 95 1
4-yr Avg
Ethical Compound
10 10 10 6 5 30000 Oncology 876,288 4.9 19.5 111 17

Novopharm 19,593 22.5 22.7 73 14
Apotex Inc 10,351 11.9 26.8 76 27
ratiopharm Inc 3,756 4.3 20.4 72 20
Genpharm Pharma 3,161 3.6 -11.4 53 0
9 9 9 8 6 02000 Analgesics 783,746 4.4 8.9 101 12

ratiopharm Inc 50,436 31.7 4.5 85 22
Apotex Inc 17,449 11.0 22.6 100 16
Private Label 16,175 10.2 -2.5 79 1
Pharmascience 15,498 9.7 15.4 94 36

Generic Manufacturers 62,638 8.3 -0.8 94 9
ratiopharm Inc 40,394 64.5 -4.7 96 24
Apotex Inc 10,486 16.7 0.1 101 0
Genpharm Pharma 6,082 9.7 42.1 143 -4
Pharmascience 3,314 5.3 -17.5 83 10

Apotex Inc 103,428 38.2 15.0 100 12
Novopharm 58,878 21.7 -8.6 79 10
Genpharm Pharma 29,500 10.9 44.6 126 40
ratiopharm Inc 17,922 6.6 -32.1 59 -2
4-yr Avg
Ethical Compound
6 7 7 9 9 52000 Hormones 690,529 3.9 -1.2 92 3

Apotex Inc 40,789 27.2 74.1 129 73
Novopharm 26,269 17.5 57.2 117 60
ratiopharm Inc 21,523 14.3 4.8 78 12
Taro Pharmaceuticals 16,441 10.9 11.0 82 22
Mayne Pharma (Canada) Inc 10,755 7.2 6.9 79 -6
7 6 6 10 10 09000 Antiarthritics 683,151 3.8 15.7 107 4

Apotex Inc 67,850 51.1 25.3 112 26
Novopharm 28,189 21.2 35.4 121 33
Private Label 9,926 7.5 -2.8 87 16
Pharmascience 8,569 6.5 -46.4 48 90
ratiopharm Inc 6,326 4.8 -9.5 81 34

Apotex Inc 82,979 35.6 31.4 106 29
Novopharm 49,731 21.4 -6.3 76 28
Pharmascience 47,700 20.5 12.3 91 0
Genpharm Pharma 27,567 11.8 55.4 126 51
ratiopharm Inc 13,409 5.8 116.2 175 6

Genpharm Pharma 32,818 26.3 34.3 123 1
ratiopharm Inc 21,249 17.0 5.4 97 34
Apotex Inc 20,911 16.8 44.8 133 12
Pharmascience 19,795 15.9 -20.9 73 38
Novopharm 18,972 15.2 -10.2 82 -1
4-yr Avg
Ethical Compound

Apotex Inc 22,050 49.2 13.1 97 12
Taro Pharmaceuticals 9,538 21.3 -10.5 76 -4
Genpharm Pharma 4,021 9.0 14.3 98 36
Pharmaceutical Partners of Canada Inc 1,928 4.3 267.4 314 ******
18 18 14 14 14 81000 Anti-virals 442,992 2.5 11.0 103 16

Apotex Inc 3,824 34.0 4.0 94 -5
Genpharm Pharma 3,203 28.5 153.0 228 41
ratiopharm Inc 2,557 22.7 -43.7 51 -12
Sandoz Canada Inc 745 6.6 394.1 446 77
Pharmaceutical Partners of Canada Inc 479 4.3 70.5 154 34
17 15 15 15 15 48000 Hematinics 416,112 2.3 10.0 102 13

Apotex Inc 2,830 20.1 6.5 97 14
Private Label 1,576 11.2 6.2 96 1
Pharmascience 485 3.4 -16.6 76 -4
Cytex 327 2.3 55.8 141 5
Total Others 3,503,260 19.7 6.3 98 6
by Total Prescriptions
4-yr Avg
Compound
Total Ethical Market 410,142 100.0 6.7 100 7

Pfizer 7,733 17.3 11.9 105 12
AstraZeneca 3,768 8.5 9.6 103 10
Frosst 3,390 7.6 -1.6 93 -2
Novartis Pharma 3,238 7.3 18.1 111 18

AstraZeneca 2,862 13.7 28.4 121 28
Lilly 2,353 11.3 11.3 105 11
Lundbeck Canada Inc 967 4.6 14.7 108 15
3 3 3 3 3 52000 Hormones 24,879 6.1 2.7 96 3

Wyeth Pharmaceuticals 2,464 16.6 -3.7 103 -4
MS&D 1,053 7.1 -54.0 49 -54
Stiefel 986 6.6 1.9 109 2
8 7 6 5 4 32000 Antihyperlipidemic Agents 24,392 5.9 11.6 105 12

Pfizer 12,725 69.3 13.0 100 13
AstraZeneca 3,270 17.8 35.1 119 35
Merck-Schering 824 4.5 47.8 131 48
Fournier 817 4.4 -14.2 76 -14
Frosst 237 1.3 -53.2 41 -53
4-yr Avg
Compound
4 4 4 4 5 15000 Anti-infectives Systemic 24,221 5.9 0.3 94 0

Abbott PCD 2,123 31.5 0.6 121 1
Bayer Healthcare 1,014 15.1 27.9 154 28
Pfizer 933 13.9 -58.1 51 -58
P&G Pharmaceuticals Canada Inc 780 11.6 9.3 132 9
BMS Pharma 760 11.3 -16.3 101 -16

AstraZeneca 3,886 25.9 -9.6 83 -10
Abbott PCD 2,016 13.5 10.5 101 10
Pfizer 595 4.0 15.7 106 16
5 5 7 7 7 02000 Analgesics 20,353 5.0 4.5 98 4

Purdue Pharma 2,082 18.3 16.3 118 16
sanofi-aventis Canada 529 4.7 -7.5 94 -8
Abbott PCD 442 3.9 4.0 105 4
GlaxoSmithKline 402 3.5 -24 77 -24

Lilly 1,880 31.1 -0.2 90 0
sanofi-aventis Canada 545 9.0 22.3 110 22
Servier Laboratories 390 6.5 27.4 115 27
4-yr Avg
Compound
10 10 9 9 9 41000 Diuretics 16,521 4.0 5.4 99 5

Brand Manufacturers 585 3.5 -9.5 86 -10
Pfizer 307 52.4 -10.5 99 -10
sanofi-aventis Canada 182 31.0 1.6 112 2
Servier Laboratories 89 15.2 -15.4 93 -15
MS&D 5 0.8 -71.4 32 -71
Leo Pharma Inc 2 0.4 6.9 118 7

AstraZeneca 1,850 18.3 1.7 100 2
MS&D 782 7.7 10.0 108 10
Purdue Pharma 175 1.7 -5.9 92 -6

Pfizer 2,314 48.9 22.4 115 22
Novartis Pharma 774 16.4 4.8 98 5
Janssen-Ortho Inc 551 11.7 -29.8 66 -30
Boehringer Ingelheim 217 4.6 21.3 114 21
Roche 162 3.4 -0.9 93 -1
7 8 8 12 12 09000 Antiarthritics 13,507 3.3 3.4 97 3

Pfizer 3,506 75.8 1.8 103 2
Novartis Pharma 270 5.8 -18.9 82 -19
Squire Pharma Inc 248 5.4 16.7 118 17
Roche 191 4.1 -7.9 93 -8
sanofi-aventis Canada 129 2.8 -23.8 77 -24
4-yr Avg
Compound
14 14 14 13 13 72000 Thyroid Therapy 12,224 3.0 7.3 101 7

Abbott PCD 9,789 80.3 7.6 101 8
Lilly 108 0.9 4.2 97 4
Squire Pharma Inc 49 0.4 -5.4 88 -5
Theramed Ltd 38 0.3 13.3 106 13
12 13 13 14 14 33000 Contraceptives 11,358 2.8 2.1 96 2

Wyeth Pharmaceuticals 3,739 32.9 -5.9 92 -6
Organon 1,634 14.4 6.5 104 6
Bayer Pharma 1,191 10.5 79.3 176 79
Pfizer 758 6.7 -20.3 78 -20
20 19 18 18 15 60000 Nutrients & Supplements 7,323 1.8 13.1 106 13

Europharm 1,223 44.7 27.4 113 27
Novartis Pharma 364 13.3 5.8 94 6
Schering Health Canada 361 13.2 -9.1 81 -9
Wyeth Pharmaceuticals 285 10.4 2.9 91 3
Wyeth Consumer Health Care 145 5.3 17.4 104 17
Total Others 67,676 16.5 7.1 100 7
4-yr Avg
Compound
Total Ethical Market 410,142 100.0 6.7 100 7

Apotex Inc 8,500 41.1 9.5 99 9
Novopharm 4,485 21.7 17.3 106 17
Genpharm Pharma 2,083 10.1 22.5 111 22
Pharmascience 2,012 9.7 0.3 91 0

Apotex Inc 15,569 52.4 7.3 100 7
Novopharm 3,938 13.3 19.3 111 19
Genpharm Pharma 3,258 11.0 -6.1 88 -6
Pharmascience 2,845 9.6 3.6 97 4
ratiopharm Inc 1,523 5.1 17.2 109 17
3 3 3 3 3 52000 Hormones 24,879 6.1 2.7 96 3

Apotex Inc 2,889 30.2 36.4 112 36
ratiopharm Inc 1,809 18.9 2.1 84 2
Taro Pharma 1,561 16.3 11.7 92 12
Novopharm 1,213 12.7 103.4 167 103
Sandoz Canada Inc 656 6.9 -4.4 79 -4
8 7 6 5 4 32000 Antihyperlipidemic Agents 24,392 5.9 11.6 105 12

Apotex Inc 2,305 38.3 4.9 98 5
Genpharm Pharma 1,305 21.7 17.1 109 17
Novopharm 873 14.5 3.8 97 4
Pharmascience 400 6.6 17.1 109 17
ratiopharm Inc 329 5.5 17.8 110 18
4-yr Avg
Compound
4 4 4 4 5 15000 Anti-infectives Systemic 24,221 5.9 0.3 94 0

Apotex Inc 9,554 55.5 19.5 112 20
Novopharm 3,523 20.5 -21.2 74 -21
Genpharm Pharma 1,248 7.2 38.1 129 38
ratiopharm Inc 724 4.2 -33.9 62 -34
Cobalt Pharma 490 2.8 152.5 236 152

Apotex Inc 4,717 58.6 18.7 109 19
Genpharm Pharma 1,038 12.9 -0.6 92 -1
Novopharm 917 11.4 -5.5 87 -5
Pharmascience 549 6.8 5.1 97 5
ratiopharm Inc 316 3.9 -25.1 69 -25
5 5 7 7 7 02000 Analgesics 20,353 5.0 4.5 98 4

ratiopharm Inc 3,370 37.5 13.7 101 14
Apotex Inc 1,409 15.7 11.1 99 11
Novopharm 1,031 11.5 0.4 89 0
Linson Pharma Inc 1,017 11.3 35.9 121 36
Pharmascience 670 7.5 12.1 100 12

Genpharm Pharma 2,765 24.8 24.2 114 24
Apotex Inc 2,273 20.4 23.4 113 23
Novopharm 2,129 19.1 3.0 94 3
Pharmascience 1,864 16.8 -8.5 84 -9
ratiopharm Inc 1,053 9.5 11.9 102 12
4-yr Avg
Compound
10 10 9 9 9 41000 Diuretics 16,521 4.0 5.4 99 5

Apotex Inc 8,755 54.9 5.0 99 5
Novopharm 5,327 33.4 8.3 102 8
Pharmascience 551 3.5 18.2 111 18
Pro Doc 466 2.9 2.1 96 2
Nu-Pharm Inc 384 2.4 1.2 95 1

ratiopharm Inc 3,930 75.9 0.8 101 1
Apotex Inc 1,031 19.9 -1.1 99 -1
Genpharm Pharma 97 1.9 28.1 128 28
Pharmascience 69 1.3 -32.7 67 -33
Novopharm 34 0.6 5.5 105 5

Pharmascience 3,483 32.2 4.9 93 5
Apotex Inc 3,460 32.0 25.5 111 26
Novopharm 1,614 14.9 0.2 89 0
Genpharm Pharma 1,120 10.4 25.6 111 26
ratiopharm Inc 344 3.2 30.7 116 31
7 8 8 12 12 09000 Antiarthritics 13,507 3.3 3.4 97 3

Apotex Inc 5,606 61.6 7.1 102 7
Novopharm 1,684 18.5 23.1 117 23
Pharmascience 475 5.2 -35.3 62 -35
Odan Lab 238 2.6 11.2 106 11
Novartis Pharma 225 2.5 -20.9 75 -21
4-yr Avg
Compound
14 14 14 13 13 72000 Thyroid Therapy 12,224 3.0 7.3 101 7

Generic Manufacturers 41 0.3 ****** ****** ******
Genpharm Pharma 41 99.7 ****** 118 ******
Apotex Inc - 0.3 -30.4 2 -30
Pharmaceutical Partners of Canada Inc - 0.0 ****** ****** ******
Pharmascience - 0.0 -100.0 0 -100
ratiopharm Inc - 0.0 ****** ****** ******
12 13 13 14 14 33000 Contraceptives 11,358 2.8 2.1 96 2
20 19 18 18 15 60000 Nutrients & Supplements 7,323 1.8 13.1 106 13

Riva 1,412 30.8 54.4 136 54
Apotex Inc 1,095 23.9 9.8 97 10
Pro Doc 878 19.1 -3.9 85 -4
Trianon 612 13.3 -7.1 82 -7
Novopharm 336 7.3 44.9 128 45
Total Others 67,676 16.5 7.1 100 7
T 26 15 Fastest and Slowest Growing Therapeutic Classes
(larger than $10 million) by Total Ethical Purchases
4-yr Avg
Ethical Compound
Fastest Growing
135 130 128 127 107 09300 Gout-Specific Preparations 13,905 0.1 149.3 231 39
176 174 134 133 111 30600 EGFR Agents 11,674 0.1 130.1 213 ******
177 176 175 106 93 64900 Psychotherapeutic, Others 21,419 0.1 81.3 168 ******
73 103 95 93 84 04200 Anesthetics, General 29,778 0.2 56.5 145 -2
36 28 23 17 12 30900 Antineoplastics, Miscellaneous 390,328 2.2 56.4 145 43
127 119 120 119 114 48200 Hematinics, Parenteral 10,511 0.1 34.7 125 21
130 123 117 109 106 33100 Intra-uterine Contraceptives 14,241 0.1 29.1 120 37
106 77 65 61 54 27200 Vaccines, Respiratory 71,461 0.4 28.8 119 55
72 68 61 57 47 78800 Miscellaneous Ethical, Other 79,954 0.4 27.4 118 24
105 102 105 104 98 60700 Nutrients & Supplements, Other 17,830 0.1 23.3 114 9
28 27 29 26 25 39100 Diabetes Therapy, Insulin 192,299 1.1 19.9 111 13
69 69 69 66 65 31600 Cardiovascular Agents, Other 52,013 0.3 18.6 110 10
22 20 20 20 18 81100 Narrow Spectrum 269,941 1.5 17.8 109 12
53 49 47 49 46 23700 Antispasmodics, Other G.I. Tract Agents 83,017 0.5 15.7 107 12
120 116 115 111 112 56500 Laxative Saline 11,249 0.1 15.7 107 15
Slowest Growing
35 36 33 32 41 30300 Antimitotic Agent/Plant Derivatives 106,776 0.6 -17.2 77 3
37 41 44 45 51 37100 Acne Therapy 75,663 0.4 -10.5 83 -3
74 72 74 76 82 34400 Cough Only Preparations 31,064 0.2 -9.9 83 -1
67 71 72 74 79 34100 Cold Preparations, Oral 31,908 0.2 -9.2 84 -3
75 76 75 75 81 30400 Cytostatic Antibiotics 31,642 0.2 -9.2 84 2
83 88 92 98 105 05100 Antacids without Antispasmodics 14,978 0.1 -6.8 86 -9
58 61 64 71 73 76300 Vitamins, Other Ethical 35,613 0.2 -4.5 88 -7
12 12 12 12 16 52900 Bone Metabolism Regulators 339,968 1.9 -3.8 89 8
79 78 79 77 80 34300 Cough/Cold Preparations 31,817 0.2 -3.6 89 4
24 24 25 30 31 15800 Quinolones 133,192 0.7 -3.5 89 -3
29 29 35 37 40 23600 H-2 Receptor Antagonists 106,933 0.6 -3.1 90 -2
46 48 49 53 60 31200 Vasodilators 63,702 0.4 -2.7 90 -1
68 67 62 62 63 61700 Ophthalmic Preparations, Other 53,190 0.3 -2.4 90 11
18 25 27 29 30 52100 Sex Hormones 143,608 0.8 -1.7 91 -6
60 66 71 70 72 18000 Anti-Obesity Preparations 38,351 0.2 -1.7 91 -5
T 27 Top 15 Therapeutic Classes and Leading Corporations
Journal Ad
Expenditures % Share % Change % Share of Total
2006 ($000s) of Market Over 2005 Promotional Dollars
Total Journal Ad Expenditures 63,968 100.0 -0.8 26.1
31000 Cardiovasculars 10,243 16.0 -6.7 23.1

Pfizer 1,977 19.3 11.8 29.2
sanofi-aventis Canada 1,621 15.8 -19.8 23.2
Bristol-Myers Squibb 1,475 14.4 -15.1 46.6
Novartis 1,318 12.9 56.1 23.0
AstraZeneca 1,226 12.0 -14.8 38.3
32000 Antihyperlipidemic Agents 6,556 10.2 -0.6 34.3

AstraZeneca 2,386 36.4 -7.4 40.1
Pfizer 2,011 30.7 -20.2 34.4
Fournier 1,118 17.1 143.9 52.0
Merck-Schering 938 14.3 -9.6 91.3
Oryx Pharma Inc 79 1.2 ****** 15.9
64000 Psychotherapeutics 5,326 8.3 -13.0 24.4

Wyeth Pharmaceuticals 1,936 36.3 -0.5 33.6
Lundbeck Canada Inc 1,021 19.2 -32.1 26.0
Biovail Corporation International 606 11.4 ****** 33.5
Akzo 498 9.4 36.5 46.5
AstraZeneca 437 8.2 -21.9 35.2
28000 Bronchial Therapy 5,192 8.1 -5.7 29.1

AstraZeneca 1,486 28.6 4.3 36.2
GlaxoSmithKline 1,299 25.0 -34.3 24.2
Boehringer Ingelheim 1,133 21.8 4.0 43.6
Merck Frosst 763 14.7 -24.8 31.3
ALTANA Pharma Inc 507 9.8 ****** 37.6
23000 Antispasmodic/Antisecretory 4,723 7.4 -4.0 22.6

AstraZeneca 1,117 23.6 -37.9 23.4
ALTANA Pharma Inc 1,047 22.2 1.8 21.9
J&J 796 16.9 192.9 19.9
Abbott 594 12.6 -28.8 17.9
Pfizer 454 9.6 -18.4 31.0
Journal Ad
09000 Antiarthritics 4,684 7.3 84.5 55.0

Pfizer 2,060 44.0 88.1 43.4
Schering-Plough 1,022 21.8 405.3 86.9
Amgen 645 13.8 63.3 85.5
Abbott 510 10.9 46.2 90.0
Pharmascience 333 7.1 -31.6 72.5
39000 Diabetes Therapy 3,320 5.2 1.0 28.4

GlaxoSmithKline 1,404 42.3 -16.4 29.4
sanofi-aventis Canada 1,061 32.0 42.0 60.5
Biovail Corporation International 451 13.6 -16.4 53.3
Novo Nordisk Canada 404 12.2 71.8 37.0
Lilly - 0.0 ****** 0.0
20000 Neurological Disorder, Miscellaneous 2,895 4.5 -18.3 35.9

Pfizer 2,262 78.1 51.4 42.0
J&J 370 12.8 -56.7 33.2
Lundbeck Canada Inc 251 8.7 -69.2 34.6
GlaxoSmithKline 8 0.3 -44.6 28.7
Genpharm Pharma 4 0.1 -85.6 100.0
78000 Miscellaneous, Ethical Other 2,827 4.4 86.0 22.7

Merck Frosst 596 21.1 55.3 37.7
Pfizer 363 12.9 37.8 37.1
ratiopharm Inc 269 9.5 123.0 100.0
ALTANA Pharma Inc 214 7.6 ****** 52.4
Astellas Pharma 197 7.0 ****** 96.5
33000 Contraceptives 2,369 3.7 -15.2 28.1

Akzo 939 39.6 35.9 38.2
Wyeth Pharmaceuticals 664 28.0 -25.9 28.7
J&J 394 16.6 -24.3 19.3
Bayer Inc 373 15.7 -45.8 23.1
Pfizer - 0.0 ****** 0.0
Journal Ad
37000 Dermatologicals 2,340 3.7 15.8 31.3

Stiefel 798 34.1 90.9 54.5
sanofi-aventis Canada 701 30.0 22.9 63.1
Astellas Pharma 425 18.2 22.6 72.9
Bayer Inc 145 6.2 ****** 28.2
J&J 129 5.5 -13.0 54.1
52000 Hormones 2,310 3.6 -2.2 21.7

Solvay Pharma 863 37.4 161.0 84.5
P&G Pharmaceuticals Canada Inc 499 21.6 -21.5 22.2
Merck Frosst 416 18.0 -20.7 17.5
Akzo 318 13.8 -4.6 67.1
Novo Nordisk Canada 130 5.6 -39.3 66.8
-
27000 Biologicals 1,878 2.9 287.8 65.6
Merck Frosst 858 45.7 ****** 57.5
sanofi-aventis Canada 637 33.9 464.4 80.4
Wyeth Pharmaceuticals 384 20.4 3.3 88.9
GlaxoSmithKline - 0.0 ****** 0.0
02000 Analgesics 1,713 2.7 -44.8 17.3

Purdue Pharma 896 52.3 -29.9 48.2
J&J 598 34.9 -23.6 14.0
AstraZeneca 162 9.4 -15.5 32.9
Pfizer 47 2.7 -93.2 4.3
Merck Frosst 5 0.3 -94.3 0.7
15000 Anti-infectives, Systemic 1,569 2.5 -47.4 17.6

Abbott 751 47.9 2.8 21.3
Bayer Inc 533 34.0 -57.0 16.1
Ferring 106 6.8 -2.2 61.1
Axcan Pharma 74 4.7 -40.0 55.6
P&G Pharmaceuticals Canada Inc 52 3.3 -71.9 30.3
Total Others 6,022 9.4 4.8 18.5
by Detailing and Sampling Activity
# of Details
Rank # of Details % Share % Change with Samples # of Samples % Change
2006 2006 (000s) of Market Over 2005 (000s) (000s) Over 2005
Total Number of Details 3,334 100.0 -8.9 2,306 26,855 1.6
1 31000 Cardiovasculars 671 20.1 0.5 486 5,646 22.3

Pfizer 103 15.4 12.3 72 976 45.7
sanofi-aventis Canada 93 13.8 -6.8 70 1,176 25.8
Novartis 91 13.6 21.6 65 640 49.3
Boehringer Ingelheim 87 12.9 -5.8 64 498 21.2
Servier Laboratories 55 8.2 20.8 42 326 44.2
2 23000 Antispasmodic/Antisecretory 273 8.2 -13.0 222 3,077 5.1

AstraZeneca 70 25.8 2.8 60 1,020 32.7
J&J 51 18.9 -28.3 40 528 -11.6
Abbott 50 18.3 -3.9 41 476 6.1
ALTANA Pharma Inc 48 17.7 -22.0 43 732 -6.7
Pfizer 21 7.6 -4.7 15 140 4.4
3 28000 Bronchial Therapy 240 7.2 -1.2 182 1,395 9.1

GlaxoSmithKline 93 38.6 -3.1 73 388 6.2
AstraZeneca 55 23.0 -9.1 44 399 -2.8
Boehringer Ingelheim 30 12.4 -23.0 20 139 28.4
Merck Frosst 21 8.9 28.0 16 335 30.5
Pfizer 17 7.1 -17.8 11 42 -44.8
4 64000 Psychotherapeutics 228 6.9 -6.1 155 2,723 28.7

Wyeth Pharmaceuticals 52 22.6 -15.2 42 1,014 6.1
Lilly 48 21.1 -18.2 29 416 33.3
Lundbeck Canada Inc 35 15.1 8.3 28 474 22.7
GlaxoSmithKline 33 14.5 44.3 25 257 108.0
J&J 19 8.4 -46.1 6 69 -11.4
5 32000 Antihyperlipidemic Agents 218 6.5 -0.9 161 2,727 9.0

Pfizer 69 31.6 -7.3 52 1,113 -7.7
AstraZeneca 67 30.6 -2.4 53 1,044 36.8
Schering-Plough 30 13.7 -3.5 20 201 -11.3
Merck Frosst 20 9.0 -16.0 12 161 -12.8
Fournier 16 7.2 -10.4 12 100 46.6
# of Details
6 39000 Diabetes Therapy 158 4.8 -7.8 98 822 -19.7

GlaxoSmithKline 71 45.0 -5.9 49 368 -17.4
Lilly 33 20.7 -16.6 21 235 -15.2
Servier Laboratories 28 17.6 21.0 19 128 56.4
sanofi-aventis Canada 10 6.2 -33.1 2 15 -79.1
Novo Nordisk Canada 8 5.3 -15.1 2 19 -76.1
7 02000 Analgesics 155 4.7 -3.6 101 896 1.2

J&J 66 42.5 29.8 42 568 11.5
Pfizer 22 13.9 42.3 17 87 44.0
Purdue Pharma 17 11.3 -11.7 - - ******
P&G Pharmaceuticals Canada Inc 16 10.2 -29.0 13 60 -40.2
8 52000 Hormones 150 4.5 -14.5 103 1,054 -11.7

Merck Frosst 28 18.7 31.9 19 199 -13.5
sanofi-aventis Canada 26 17.4 -5.5 20 238 17.8
Stiefel 12 7.7 7.6 10 109 7.2
Lilly 9 6.2 -16.6 4 30 -32.1
9 15000 Anti-infectives, Systemic 142 4.3 -46.7 104 828 -49.6

Bayer Inc 61 43.1 -20.7 46 362 -20.1
Abbott 56 39.0 -14.9 42 313 -7.7
Bristol-Myers Squibb 7 5.1 -57.8 6 54 -54.3
10 78000 Miscellaneous, Ethical Others 137 4.1 26.5 6 88 91.4

Solvay Pharma 24 17.8 ****** - - ******
Merck Frosst 12 9.0 -18.8 4 59 70.4
GlaxoSmithKline 9 6.5 65.2 2 28 161.9
Pfizer 9 6.4 -13.7 - - ******
J&J 8 6.0 54.4 - - ******
# of Details
11 34000 Cough/Cold Ethical 116 3.5 -10.9 95 994 -4.7

Schering-Plough 42 36.2 2.2 35 350 19.8
Wyeth Pharmaceuticals 16 13.8 -14.9 12 237 -7.0
Purdue Pharma 5 4.3 -37.6 4 34 -23.5
12 37000 Dermatologicals 115 3.4 -14.7 84 1,069 -12.5

Stiefel 21 18.3 34.0 18 233 39.8
Leo Pharma Inc 19 16.5 -7.7 14 91 -6.3
Novartis 18 15.4 -43.5 12 110 -38.3
sanofi-aventis Canada 12 10.3 0.9 7 103 26.6
3M Canada 11 9.7 20.4 7 51 15.0
13 33000 Contraceptives 111 3.3 -19.5 87 1,024 -9.2

J&J 31 28.0 -29.6 25 258 -28.4
Wyeth Pharmaceuticals 31 27.6 -22.1 24 287 -19.1
Akzo 30 26.8 0.1 23 249 5.4
Bayer Inc 19 17.4 -21.2 14 230 30.6
Pfizer - 0.1 ****** - - ******
14 82000 Sexual Function Disorders 99 3.0 -24.5 79 558 -20.4

Lilly 36 36.6 -8.3 29 190 -22.1
Pfizer 34 34.4 -40.5 27 194 -39.0
Bayer Inc 29 28.9 -12.8 23 173 29.2
GlaxoSmithKline - 0.2 -90.4 - 1 -85.2
15 20000 Neurological Disorders, Miscellaneous 85 2.6 0.9 53 388 26.5

Pfizer 56 65.3 56.6 37 277 90.9
J&J 11 13.4 -50.6 7 34 -6.1
Lundbeck Canada Inc 9 10.2 -35.1 6 45 -40.0
Novartis 8 9.0 6.1 3 22 27.0
Teva Neuroscience 1 0.9 -7.5 - 8 ******
Total Others 435 13.1 -7.1 290 3,566 -5.8
Diagnoses
andTherapies
T 29 Profile of Leading Diagnoses
Acute Upper
Essential Diabetes Respiratory Normal Other Ill-defined
Hypertention Mellitus (Without Health Depressive Infections Pregnancy and Unknown Causes of Otitis Media
Profile Element All Diagnosis (Unspecified) Complications) Check-Up* Disorders (NEC) Anxiety States (Unspecified Sites) Hyperlipidemia Supervision Morbidity and Mortality Unspecified
Patient Visits (000s) 319,137 20,560 9,141 8,654 8,417 5,790 5,295 4,882 4,578 3,819 3,478
Patient Visits 59 81 67 1 79 59 43 79 15 97 78
With Drugs (%)
Most Often ****** Altace Metformin D-Vi-Sol Effexor XR Ativan Amoxil Lipitor Materna Pantoloc Amoxil
Recommended Therapy HCL
Patient Gender Profile 41/59 47/53 53/47 45/55 35/65 32/68 43/57 59/41 100 40/60 51/49
Male/Female (%)
Age Group (%)
Under 10 <1 <1 39 <1 <1 34 <1 - 2 63
10-19 years <1 <1 6 3 4 15 <1 6 2 13
20-39 years 4 7 16 29 28 24 7 91 8 10
40-59 years 36 37 24 49 42 17 41 3 34 10
60-64 years 13 13 4 7 7 2 14 - 10 2
65 + 46 43 10 11 19 8 37 - 44 2
Most Productive GP GP Internal Pediatrician Psych/Neuro Psych/Neuro GP Internal OB/Gyn GP ENT/Opth
Specialty Medicine Medicine
First Visit/ 43/57 13/87 14/86 63/37 13/87 27/73 71/29 19/81 20/80 65/35 66/34
Subsequent Visits (%)
Most Desired Action ****** Lower Blood Control Vitamin Anti-Depressant Reduce Combat Reduce Lipid Prenatal Pain Relief Antibiotic
of Therapy Pressure Diabetes Mineral Anxiety Infection Level Vitamin
Supplement
* Health check-up is comprised of Diagnoses: V20.2 Routine Child Health Check-up and V70.0 Routine General Medical Exam and Health Check-up
Diagnoses and Therapies

102
T 30 Profile of Leading Recommended Drug Therapies
Drug Mentions
per Physician
Drug Mentions % Change per Year in Most New/Cont’d First/Subsequent
Drug Manufacturer 2006 (000s) Over 2005 % Used Alone Most Productive Specialty Productive Specialty Therapy % Visits %
Total 245,344 -2.1
Lipitor Pfizer 4,708 3.2 61 Internal Medicine 256 13/87 17/83

Amoxil Wyeth Pharmaceuticals 4,207 -7.8 83 GP 198 95/5 69/31
Altace sanofi-aventis Canada 4,062 -11.5 36 Internal Medicine 176 14/86 16/84
Effexor XR Wyeth Pharmaceuticals 3,629 19.0 67 Psych/Neuro 371 23/77 15/85
Metformin HCL Manufacturer Not Stated 3,430 17.5 46 Internal Medicine & GP 147 13/87 13/87
ASA Manufacturer Not Stated 3,053 12.3 14 Internal Medicine 258 20/80 30/70
Synthroid Abbott PPD 2,976 8.9 98 Internal Medicine 145 13/87 21/79
Hydrochlorothiazide Manufacturer Not Stated 2,966 -14.7 29 GP 139 17/83 18/82
Tylenol with Codeine #3 Janssen-Ortho Inc 2,943 -7.3 66 GP 130 51/49 32/68
Norvasc Pfizer 2,776 -4.5 28 GP 122 18/82 12/88
Ventolin HFA GlaxoSmithKline 2,505 -6.7 24 Pediatrician 223 27/73 41/59
Celexa Lundbeck Canada Inc 2,034 -18.9 68 Psych/Neuro 227 28/72 17/83
Crestor AstraZeneca 1,956 14.3 69 GP 84 23/77 16/84
Flovent HFA GlaxoSmithKline 1,862 -11.4 20 Pediatrician 260 36/64 40/60
Celebrex Pfizer 1,851 16.0 75 GP 86 54/46 39/61
Metroprolol Manufacturer Not Stated 1,807 1.5 23 Internal Medicine 121 12/88 20/80
Ativan Wyeth Pharmaceuticals 1,793 6.5 61 Psych/Neuro 123 35/65 30/70
Nasonex Schering Health Care 1,780 4.9 55 ENT/Opth 193 67/33 59/41
Zithromax Pfizer 1,747 -9.6 71 GP 88 99/1 72/28
Naprosyn Roche 1,699 11.8 68 GP 81 70/30 52/48
Diagnoses and Therapies

103
Generic
Manufacturers
T 31 Leading 10 Generic Manufacturers and Top Five Products
by Ethical Purchases
Ethical
Rank Rank Rank Rank Rank Launch Date Puchases % Share % Change
2002 2003 2004 2005 2006 (MMYY) 2006 ($000s) of Market Over 2005
Total Ethical Generic Market 17,816,652 18.0 14.0
Apotex Inc 1,101,172 34.2 16.1

- - 13 2 1 Apo-Omeprazole 0104 85,504 7.8 74.2
- 3 2 3 2 Apo-Simvastatin 0103 49,100 4.5 0.9
4 4 3 4 3 Apo-Sertraline 0999 41,591 3.8 -1.4
- 155 7 6 4 Apo-Paroxeine 1003 40,931 3.7 27.9
1 1 1 1 5 Apo-Lisinopril 1296 39,636 3.6 -22.8
Novopharm 485,092 15.1 8.3

54 5 2 1 1 Novo-Gabapentin 0702 28,295 5.8 -11.0
- 8 1 2 2 Novo-Pravastatin 0103 24,270 5.0 -11.3
- 25 16 8 3 Novo-Alendronate 0503 22,647 4.7 69.1
- - 20 3 4 Novo-Simvastatin 0304 18,466 3.8 6.6
3 1 7 4 5 Novo-Ranidine 0789 15,868 3.3 1.3
Genpharm Pharma 365,097 11.4 9.4

- 1 1 1 1 Gen-Simvastatin 0203 50,228 13.8 1.6
- 15 3 3 2 Gen-Paroxetine 1003 28,324 7.8 -7.1
2 3 5 5 3 Gen-Metformin 0495 25,509 7.0 42.3
- - 2 2 4 Gen-Citalopram 0204 18,219 5.0 -55.7
1 2 4 4 5 Gen-Ranitidine 0396 17,713 4.9 -5.4
ratiopharm Inc 347,380 10.8 0.6

35 2 3 1 1 ratio-Salbutamol HFA 0202 33,048 9.5 1.6
- - 49 9 2 ratio-Citalopram 0704 24,625 7.1 130.5
1 1 1 2 3 ratio-Diltiazem CD 1296 23,027 6.6 -9.4
3 5 7 3 4 ratio-Oxycocet 0484 22,227 6.4 -10.2
11 4 4 4 5 ratio-Metformin 0601 19,520 5.6 4.7
Pharmascience 263,910 8.2 -0.8

1 1 1 2 1 PMS-Gabapentin 0201 22,440 8.5 1.0
9 2 2 1 2 PMS-Metformin 0297 18,882 7.2 -20.2
- - 13 6 3 PMS-Citalopram 0104 10,629 4.0 18.4
5 3 4 4 4 PMS-Atenolol 1198 9,609 3.6 -1.2
156 69 3 3 5 PMS-Meloxicam 1103 8,105 3.1 -47.7
106 Generic Manufacturers

T 31 Leading 10 Generic Manufacturers and Top Five Products
by Ethical Purchases
Ethical
Rank Rank Rank Rank Rank Launch Date Puchases % Share % Change
2002 2003 2004 2005 2006 (MMYY) 2006 ($000s) of Market Over 2005
Sandoz Canada Inc 185,429 5.8 74.5

- - - - 1 Sandoz-Diltiazem T 0106 17,419 9.4 ******
- 9 1 1 2 Sandoz-Bisoprolol 0803 9,341 5.0 10.7
- - - 104 3 Sandoz-Azithromycin 1205 5,968 3.2 ******
2 1 2 2 4 Infufer 0197 5,932 3.2 15.7
3 3 3 3 5 Supeudol 0968 5,630 3.0 24.4
Private Label 107,507 3.3 -0.1

15 1 3 1 1 Nicotine 1202 11,142 10.4 5.1
3 3 1 2 2 Ibuprofen 0195 9,926 9.2 -2.8
1 2 2 3 3 Acetaminophen with Codeine 0195 8,206 7.6 -5.1
4 4 4 4 4 Allergy Relief 0790 7,123 6.6 3.2
5 6 6 5 5 Acetaminophen 0482 5,576 5.2 -1.2
Cobalt Pharma 77,403 2.4 48.2

- 2 1 1 1 Co Simvastatin 1103 22,588 29.2 6.1
10 12 3 2 2 Co Citalopram 0204 13,852 17.9 23.5
1 1 2 3 3 Co Fluoxetine 0500 7,353 9.5 -8.7
3 5 14 6 4 Co Alendronate 0605 5,428 7.0 418.4
- - 4 4 5 Co Ciprofloxacin 0204 5,093 6.6 2.6
Mayne Pharma (Canada) Inc 60,154 1.9 65.3

- - - - 1 Irinotecan HCL 0206 17,946 29.8 ******
1 1 1 1 2 Pamidronate Disodium 1001 10,754 17.9 7.0
2 2 2 2 3 Apo-Methotrexate 1202 7,684 12.8 21.7
3 3 3 3 4 Methotrexate 0286 5,751 9.6 50.9
- - 32 6 5 Vinorelbine 1104 2,392 4.0 50.8
Taro Pharmaceuticals 37,346 1.2 6.4

1 1 1 1 1 Taro-Warfarin 1000 9,538 25.5 -10.5
8 4 5 2 2 Betaderm 0879 5,070 13.6 18.1
2 2 2 3 3 Clotrimaderm 0689 4,182 11.2 3.3
16 7 3 4 4 Ketoderm 0602 2,785 7.5 4.0
- 3 4 5 5 Lyderm 1083 2,479 6.6 13.0
Generic Manufacturers 107

T 32 Leading 10 Brand and Generic Drug Manufacturers
and Top Five Provinces by Total Ethical Prescriptions
# of Rx 2006 % Share
(000s) of Market
Total Ethical Prescriptions 410,142 100.0
Brand Manufacturers 228,186 55.6
Pfizer 32,319 14.2

Quebec 13,599 42.1
Ontario 10,781 33.4
British Columbia 2,394 7.4
Alberta 2,038 6.3
Manitoba 868 2.7
AstraZeneca 16,504 7.2

Quebec 6,882 41.7
Ontario 5,215 31.6
Alberta 1,141 6.9
Nova Scotia 504 3.1
Janssen-Ortho Inc 16,110 7.1

Ontario 6,285 39.0
Quebec 3,581 22.2
Alberta 1,604 10.0
Manitoba 637 4.0
Wyeth Pharmaceuticals 15,131 6.6

Quebec 7,234 47.8
Ontario 3,356 22.2
Alberta 1,354 9.0
Manitoba 460 3.0
Abbott PPD 14,975 6.6

Quebec 7,479 49.9
Ontario 3,416 22.8
Alberta 1,245 8.3
Nova Scotia 432 2.9

(000s) of Market
GlaxoSmithKline 13,758 6.0

Ontario 5,863 42.6
Quebec 3,638 26.4
Alberta 1,196 8.7
Manitoba 502 3.6
sanofi-aventis Canada 13,417 5.9

Ontario 5,094 38.0
Quebec 4,285 31.9
Alberta 757 5.6
Saskatchewan 374 2.8
Novartis Pharma 8,028 3.5

Quebec 3,560 44.3
Ontario 2,152 26.8
British Columbia 644 8.0
Alberta 635 7.9
Bayer Pharma 7,109 3.1

Quebec 3,173 44.6
Ontario 1,980 27.8
Alberta 418 5.9
Manitoba 239 3.4
Schering Health Care 6,021 2.6

Quebec 2,371 39.4
Ontario 1,872 31.1
Alberta 432 7.2

(000s) of Market
Generic Manufacturers 181,955 44.4
Apotex Inc 74,702 41.1

Ontario 32,068 42.9
Quebec 16,075 21.5
Alberta 7,020 9.4
Manitoba 3,024 4.0
Novopharm 29,337 16.1

Quebec 12,761 43.5
Ontario 8,825 30.1
Alberta 1,527 5.2
Manitoba 859 2.9
ratiopharm Inc 17,000 9.3

Ontario 6,637 39.0
Quebec 5,094 30.0
Alberta 1,485 8.7
Manitoba 567 3.3
Pharmascience 16,819 9.2

Quebec 7,529 44.8
Ontario 4,567 27.2
Alberta 1,204 7.2
Manitoba 402 2.4
Genpharm Pharma 15,848 8.7

Quebec 4,305 27.2
Ontario 4,011 25.3
Alberta 1,593 10.1
Manitoba 913 5.8

(000s) of Market
Sandoz Canada Inc 4,953 2.7

Quebec 2,111 42.6
Ontario 1,322 26.7
Alberta 399 8.1
Manitoba 159 3.2
Taro Pharmaceuticals 3,978 2.2

Ontario 1,724 43.3
Quebec 860 21.6
Alberta 384 9.6
Manitoba 161 4.0
Riva 3,855 2.1

Quebec 3,806 98.7
Alberta 14 0.4
Ontario 5 0.1
Manitoba 4 0.1
Pro Doc 3,698 2.0

Quebec 3,695 99.9
Alberta 2 0.1
Ontario - 0.0
New Brunswick - 0.0
Saskatchewan - 0.0
Cobalt Pharma 1,977 1.1

Ontario 522 26.4
Alberta 354 17.9
Manitoba 220 11.2
Nova Scotia 85 4.3

T 33 Share of Prescription Market by Province, Brand vs. Generic Manufacturers
Average Rx
# of Rx 2006 % Share Size (# of Average
(000s) of Market Extended Units) Rx Price ($)
Total Prescriptions 410,142 100.0 56.3 47.32
Quebec 150,466 36.7 39.0 34.79

Brand Manufacturers 91,419 60.8 36.3 45.97
Generic Manufacturers 59,047 39.2 43.1 17.50
Ontario 135,234 33.0 66.4 56.48

British Columbia 40,422 9.9 64.1 49.63

Alberta 31,670 7.7 68.9 56.55

Manitoba 12,853 3.1 63.2 52.20

Saskatchewan 11,366 2.8 54.7 41.80

Nova Scotia 10,730 2.6 74.8 59.81

New Brunswick 9,289 2.3 73.6 59.74

Prince Edward Island and Newfoundland 8,111 2.0 65.6 48.51


T 34 Total Ethical Purchases for the Five Leading Generic
and Brand Manufacturers by Province
Ethical
Purchases % Share of % Share of % Share of % Share of % Share of
2006 ($000s) Market 2006 Market 2005 Market 2004 Market 2003 Market 2002
Total Ethical Market 17,816,652 100.0 100.0 100.0 100.0 100.0
Brand Manufacturers 14,601,035 82.0 82.9 84.0 85.2 85.6
Ontario 5,853,551 40.1 39.9 39.7 39.3 39.5

Pfizer 893,648 15.3 15.7 16.2 15.5 15.5
AstraZeneca 477,516 8.2 8.5 8.7 8.1 7.7
GlaxoSmithKline 388,614 6.6 6.7 7.0 8.2 8.3
Janssen-Ortho Inc 353,320 6.0 6.6 6.3 5.6 4.7
sanofi-aventis Canada 274,050 4.7 4.7 4.7 4.8 4.6
Quebec 3,905,258 26.7 26.7 27.2 27.4 27.3

Pfizer 607,496 15.6 15.4 14.9 14.8 14.6
AstraZeneca 331,048 8.5 8.3 9.2 8.5 8.3
Novartis Pharma 163,782 4.2 4.3 4.3 4.3 4.1
British Columbia 1,587,009 10.9 11.0 10.7 10.7 10.8

Pfizer 199,180 12.6 13.0 13.7 12.9 12.6
AstraZeneca 108,858 6.9 6.5 6.6 7.0 7.4
Alberta 1,396,735 9.6 9.7 9.5 9.4 9.3

Pfizer 186,963 13.4 13.8 14.1 13.0 12.9
AstraZeneca 100,399 7.2 8.3 8.5 8.2 7.8
Wyeth Pharmaceuticals 72,296 5.2 4.8 4.8 4.5 3.6
Novartis Pharma 61,263 4.4 4.6 4.5 4.5 4.4
Nova Scotia 455,286 3.1 3.1 3.1 3.2 3.2

Pfizer 64,156 14.1 14.4 14.8 14.2 13.9
AstraZeneca 46,479 10.2 10.8 10.8 9.6 8.6
Novartis Pharma 20,347 4.5 4.4 4.4 4.1 4.0

Ethical
Manitoba 426,697 2.9 3.0 3.1 3.3 3.2

Pfizer 60,412 14.2 14.8 14.4 13.2 12.7
Roche 25,542 6.0 4.4 3.8 3.5 3.7
AstraZeneca 23,428 5.5 5.5 7.1 8.6 8.2
Saskatchewan 355,845 2.4 2.5 2.4 2.5 2.5

Pfizer 44,984 12.6 13.2 13.4 13.0 13.0
AstraZeneca 24,914 7.0 6.8 7.4 7.2 6.7
Novartis Pharma 17,006 4.8 4.6 4.9 5.1 5.1
New Brunswick 356,420 2.4 2.5 2.4 2.4 2.5

Pfizer 47,699 13.4 14.2 14.8 14.1 14.0
AstraZeneca 31,529 8.8 8.7 8.6 7.7 7.1
Prince Edward Island and Newfoundland 264,233 1.8 1.8 1.8 1.9 1.9
Pfizer 34,327 13.0 13.9 14.0 12.9 12.3
AstraZeneca 27,920 10.6 10.0 9.9 8.7 8.2
Generic Manufacturers 3,215,617 18.0 17.1 16.0 14.8 14.4
Ontario 1,279,482 39.8 39.9 39.7 39.6 39.9

Apotex Inc 545,062 42.6 42.0 40.3 41.5 44.3
Novopharm 175,214 13.7 14.6 13.0 12.5 11.7
ratiopharm Inc 168,740 13.2 14.4 13.6 11.6 10.1
Genpharm Pharma 109,904 8.6 9.7 13.4 13.1 9.3
Pharmascience 85,509 6.7 8.4 8.6 8.3 7.5

Ethical
Quebec 680,320 21.2 21.3 20.1 20.6 20.8

Apotex Inc 160,972 23.7 23.9 22.2 22.8 21.9
Novopharm 124,948 18.4 19.6 18.7 16.7 16.5
Pharmascience 79,415 11.7 12.4 12.6 12.6 12.1
Genpharm Pharma 71,629 10.5 8.8 8.1 6.9 5.9
ratiopharm Inc 66,539 9.8 10.6 11.4 10.9 10.3
British Columbia 426,418 13.3 13.3 13.9 13.7 13.6

Apotex Inc 127,026 29.8 29.0 26.3 27.8 29.5
Genpharm Pharma 63,262 14.8 15.6 17.2 18.6 16.3
Novopharm 55,482 13.0 13.7 13.5 12.5 12.6
Pharmascience 42,143 9.9 11.6 12.5 12.2 11.2
ratiopharm Inc 39,998 9.4 11.5 12.1 12.1 10.6
Alberta 312,935 9.7 9.5 9.9 9.6 9.6

Apotex Inc 108,141 34.6 32.1 30.4 30.6 29.1
Genpharm Pharma 43,166 13.8 15.5 20.3 18.1 18.9
Novopharm 37,389 11.9 14.3 14.0 12.4 12.5
ratiopharm Inc 30,011 9.6 11.9 12.1 13.7 11.4
Pharmascience 25,332 8.1 8.2 8.1 8.6 9.3
Nova Scotia 125,410 3.9 3.9 4.2 4.3 4.1

Apotex Inc 41,415 33.0 29.0 28.0 28.7 29.5
Novopharm 25,387 20.2 20.5 17.0 18.0 20.8
Genpharm Pharma 19,533 15.6 18.7 23.1 20.0 13.8
ratiopharm Inc 9,312 7.4 9.3 8.5 8.3 7.7
Pharmascience 8,118 6.5 7.9 7.6 7.4 7.1
Manitoba 120,447 3.7 3.7 3.6 3.3 3.4

Apotex Inc 43,838 36.4 37.7 35.2 27.7 31.0
Novopharm 21,982 18.3 17.1 17.4 16.8 19.0
Genpharm Pharma 17,992 14.9 16.2 18.9 22.2 18.3
ratiopharm Inc 9,426 7.8 9.6 9.6 10.8 7.8
Sandoz Canada Inc 6,713 5.6 3.1 2.3 2.1 1.5

Ethical
New Brunswick 98,844 3.1 3.1 3.2 3.3 3.2

Apotex Inc 29,189 29.5 31.4 28.7 30.7 32.5
Novopharm 18,324 18.5 15.5 12.7 12.2 11.8
Genpharm Pharma 15,995 16.2 18.2 23.8 22.4 16.4
ratiopharm Inc 11,142 11.3 12.8 11.7 10.1 9.7
Pharmascience 7,296 7.4 9.2 9.9 9.7 8.1
Saskatchewan 89,489 2.8 2.7 2.8 3.0 2.9

Apotex Inc 21,421 23.9 23.0 20.3 20.1 20.2
Nu-Pharm Inc 14,458 16.2 20.7 22.5 24.6 21.8
Dominion Pharmacal 11,002 12.3 14.2 13.7 12.7 9.0
Novopharm 8,916 10.0 8.1 7.0 7.0 8.9
Genpharm Pharma 7,667 8.6 5.7 6.4 5.1 3.3
Prince Edward Island and Newfoundland 82,271 2.6 2.6 2.7 2.7 2.5
Apotex Inc 24,107 29.3 29.4 28.4 30.9 33.0
Novopharm 17,449 21.2 21.4 20.5 20.6 19.8
Genpharm Pharma 15,949 19.4 17.8 20.2 18.7 15.4
ratiopharm Inc 7,732 9.4 11.4 11.3 8.5 7.6
Pharmascience 5,281 6.4 7.3 6.7 6.4 7.1

T 35 Top 25 Generic Molecules and Top Five Products
Ethical
Rank Launch Date Purchases % Share % Change
2006 (MMYY) MFR 2006 ($000s) of Market Over 2005
Total Ethical Market 17,816,652 100.0 7.9
Generic Manufacturers 3,217,032 18.1 14.0
1 Simvastatin 164,785 5.1 4.6

Gen-Simvastatin 0203 GN3 50,228 30.5 1.6
Apo-Simvastatin 0103 ATX 49,100 29.8 0.9
Co Simvastatin 1103 CBT 22,588 13.7 6.1
Novo-Simvastatin 0304 NVP 18,466 11.2 6.6
ratio-Simvastatin 0304 RAT 12,210 7.4 12.7
2 Citalopram 113,816 3.5 10.4

Apo-Citalopram 0104 ATX 29,145 25.6 16.4
ratio-Citalopram 0704 RAT 24,625 21.6 130.5
Gen-Citalopram 0204 GN3 18,219 16.0 -55.7
Co Citalopram 0204 CBT 13,852 12.2 23.5
PMS-Citalopram 0104 P8I 10,629 9.3 18.4
3 Paroxetine 97,352 3.0 -0.3

Apo-Paroxetine 1003 ATX 40,931 42.0 27.9
Gen-Paroxetine 1003 GN3 28,324 29.1 -7.1
Novo-Paroxetine 0104 NVP 9,171 9.4 -0.9
ratio-Paroxetine 1003 RAT 7,963 8.2 -51.7
PMS-Paroxetine 1103 P8I 6,178 6.3 2.4
4 Metformin 95,013 3.0 10.8

Gen-Metformin 0495 GN3 25,509 26.8 42.3
ratio-Metformin 0601 RAT 19,520 20.5 4.7
PMS-Metformin 0297 P8I 18,882 19.9 -20.2
Apo-Metformin 0995 ATX 12,692 13.4 84.3
Novo-Metformin 0494 NVP 8,697 9.2 -18.0
5 Diltiazem 94,450 2.9 37.7

Apo-Diltiaz CD 1196 ATX 30,651 32.5 5.7
ratio-Diltiazem CD 1296 RAT 23,027 24.4 -9.4
Sandoz-Diltiazem T 0106 SDZ 17,419 18.4 ******
Novo-Diltiazem ER 0106 NVP 8,610 9.1 ******
Novo-Diltazem CD 1000 NVP 6,849 7.3 -7.2

Ethical
6 Omeprazole 85,521 2.7 74.3

Apo-Omeprazole 0104 ATX 85,504 100.0 74.2
ratio-Omeprazole 1206 RAT 18 0.0 ******
7 Gabapentin 79,615 2.5 13.5

Novo-Gabapentin 0702 NVP 28,295 35.5 -11.0
PMS-Gabapentin 0201 P8I 22,440 28.2 1.0
Apo-Gabapentin 1101 ATX 19,832 24.9 180.4
Gen-Gabapentin 0404 GN3 4,070 5.1 -36.0
Dom-Gabapentin 0402 DMI 2,092 2.6 20.9
8 Ranitidine 79,013 2.5 -0.1

Apo-Ranitidine 0387 ATX 32,646 41.3 -1.1
Gen-Ranitidine 0396 GN3 17,713 22.4 -5.4
Novo-Ranidine 0789 NVP 15,868 20.1 1.3
PMS-Ranitidine 1000 P8I 3,465 4.4 49.2
Nu-Ranit 1290 NU- 2,936 3.7 -7.5
9 Acetaminophen 70,465 2.2 3.7

ratio-Oxycocet 0484 RAT 22,227 31.5 -10.2
Endocet 0987 LSN 9,349 13.3 55.6
Acetaminophen with Codeine 0195 PRL 8,206 11.6 -5.1
Acetaminophen 0482 PRL 5,576 7.9 -1.2
Muscle & Back Pain Relief 0198 PRL 3,746 5.3 6.3
10 Sertraline 69,418 2.2 -0.9

Apo-Sertraline 0999 ATX 41,591 59.9 -1.4
Gen-Sertraline 1100 GN3 8,911 12.8 -3.9
ratio-Sertraline 1002 RAT 6,273 9.0 6.9
Novo-Sertraline 0899 NVP 5,613 8.1 -14.7
PMS-Sertraline 0802 P8I 4,773 6.9 23.5

Ethical
11 Pravastatin 67,672 2.1 -6.8

Apo-Pravastatin 0301 ATX 27,592 40.8 -8.5
Novo-Pravastatin 0103 NVP 24,270 35.9 -11.3
ratio-Pravastatin 0203 RAT 5,728 8.5 -10.5
PMS-Pravastatin 0803 P8I 3,648 5.4 30.9
Gen-Pravastatin 1105 GN3 3,373 5.0 ******
12 Atenolol 66,425 2.1 -2.3

Novo-Atenol 0291 NVP 15,487 23.3 -0.4
ratio-Atenolol 0396 RAT 14,455 21.8 -6.7
Apo-Atenol 0888 ATX 13,287 20.0 -11.2
PMS-Atenolol 1198 P8I 9,609 14.5 -1.2
Gen-Atenolol 0795 GN3 7,544 11.4 6.4
13 Alendronate 60,029 1.9 122.4

Apo-Alendronate 0604 ATX 28,897 48.1 130.2
Novo-Alendronate 0503 NVP 22,647 37.7 69.1
Co Alendronate 0605 CBT 5,428 9.0 418.4
PMS-Alendronate 1205 P8I 1,434 2.4 ******
Riva-Alendronate 0905 RVA 993 1.7 ******
14 Fluoxetine 58,190 1.8 5.7

ratio-Fluoxetine 0300 RAT 18,835 32.4 2.0
Apo-Fluoxetine 0496 ATX 15,027 25.8 7.5
Co Fluoxetine 0500 CBT 7,353 12.6 -8.7
PMS-Fluoxetine 1295 P8I 5,803 10.0 23.9
Gen-Fluoxetine 0898 GN3 5,512 9.5 36.4
15 Salbutamol 52,714 1.6 -0.2

ratio-Salbutamol HFA 0202 RAT 33,048 62.7 1.6
Apo-Salvent CFC Free 1102 ATX 5,025 9.5 6.9
ratio-Ipra Sal UDV 1102 RAT 4,292 8.1 -27.3
Apo-Salvent 0789 ATX 3,092 5.9 4.4
Gen-Salbutamol PF 0393 GN3 2,974 5.6 30.7

Ethical
16 Metoprolol 40,661 1.3 5.8

Novo-Metoprol 0386 NVP 13,242 32.6 -4.5
Apo-Metoprolol-L 0587 ATX 10,180 25.0 5.7
Apo-Metoprolol 1084 ATX 6,987 17.2 17.6
PMS-Metoprolol-L 1097 P8I 4,723 11.6 -4.6
Gen-Metoprolol-L 0796 GN3 4,293 10.6 40.7
17 Lisinopril 39,636 1.2 -22.8

Apo-Lisinopril 1296 ATX 39,636 100.0 -22.8
18 Amoxicillin 38,365 1.2 7.8

Apo-Amoxi 0884 ATX 14,846 38.7 72.0
Apo-Amoxi Clav 0601 ATX 10,809 28.2 3.4
Novamoxin 0179 NVP 7,191 18.7 -34.0
ratio-Aclavulanate 0601 RAT 2,732 7.1 -6.3
Gen-Amoxicillin 0898 GN3 1,227 3.2 -3.1
19 Oxycodone 38,171 1.2 5.1

ratio-Oxycocet 0484 RAT 22,227 58.2 -10.2
Endocet 0987 LSN 9,349 24.5 55.6
Supeudol 0968 SDZ 5,630 14.7 24.4
ratio-Oxycodan 0484 RAT 395 1.0 -23.6
PMS-Oxycodone-Acet 1002 P8I 314 0.8 9.1
20 Ciprofloxacin 36,611 1.1 -7.8

Apo-Ciproflox 0204 ATX 7,106 19.4 -38.1
Ran-Ciprofloxacin 1005 RBY 7,053 19.3 ******
Gen-Ciprofloxacin 0204 GN3 6,036 16.5 -6.8
Co Ciprofloxacin 0204 CBT 5,093 13.9 2.6
ratio-Ciprofloxaci 0304 RAT 4,443 12.1 -46.4
21 Zopiclone 35,987 1.1 14.7

Gen-Zopiclone 0898 GN3 10,906 30.3 -17.6
Apo-Zopiclone 1196 ATX 7,989 22.2 11.6
Ran-Zopiclone 1005 RBY 5,476 15.2 ******
PMS-Zopiclone 0999 P8I 4,231 11.8 -3.0
ratio-Zopiclone 0601 RAT 3,547 9.9 8.0

Ethical
22 Codeine 33,337 1.0 2.9

Acetaminophen with Codeine 0195 PRL 8,206 24.6 -5.1
ratio-Lenoltec #3 1185 RAT 3,325 10.0 97.1
ratio-Lenoltec #1 0686 RAT 3,095 9.3 -15.3
ratio-Emtec 0484 RAT 2,884 8.7 0.2
ratio-Tecnal C 0784 RAT 2,599 7.8 16.0
23 Warfarin 32,900 1.0 9.1

Apo-Warfarin 1200 ATX 19,414 59.0 17.7
Taro-Warfarin 1000 TAR 9,538 29.0 -10.5
Gen-Warfarin 0802 GN3 3,056 9.3 5.7
Novo-Warfarin 0805 NVP 892 2.7 622.7
24 Fenofibrate 29,421 0.9 28.8

Gen-Fenofibrate Micro 0699 GN3 9,041 30.7 4.0
Apo-Feno-Super 0406 ATX 7,587 25.8 ******
Apo-Feno-Micro 0499 ATX 6,802 23.1 -9.1
Novo-Fenofibrate Micro 0501 NVP 2,109 7.2 -16.0
ratio-Fenofibrate 0704 RAT 1,662 5.6 35.0
25 Topiramate 28,585 0.9 449.7

Gen-Topiramate 0905 GN3 9,664 33.8 369.3
ratio-Topiramate 0905 RAT 7,735 27.1 392.1
PMS-Topiramate 0905 P8I 5,668 19.8 594.1
Sandoz-Topiramate 0905 SDZ 2,989 10.5 928.0
Novo-Topiramate 0905 NVP 2,322 8.1 403.0
Novo-Topirmate 0905 NVP 2,322 8.1 403.0

T 36 10 Fastest Growing Brand and Generic Manufacturers
(larger than $10 million) by Total Ethical Purchases
4-yr Avg
Ethical Compound
Purchases % Share % Change Growth Rate
2006 ($000s) of Market Over 2005 2002-06
Brand Manufacturers 14,601,035 82.0 6.7 7

Gilead Sciences 28,289 0.2 76.6 ******
Merck-Schering GP 64,936 0.4 42.8 ******
Valeant Pharma 26,705 0.2 37.1 29
Lundbeck Canada Inc 74,621 0.5 34.8 -11
Roche 600,857 4.1 27.7 17
Novo Nordisk Canada 117,131 0.8 27.7 19
Genzyme Corporation 20,851 0.1 26.4 29
Lilly Icos 37,966 0.3 25.1 ******
Amgen 373,366 2.6 23.9 44
Paladin 25,570 0.2 23.7 11
Generic Manufacturers 3,215,617 18.0 14.0 15

Ranbaxy Pharma Canada 34,232 1.1 ****** ******
Sandoz Canada Inc 185,429 5.8 74.5 32
Mayne Pharma (Canada) Inc 60,154 1.9 65.3 18
Cobalt Pharma 77,403 2.4 48.2 90
Riva 28,197 0.9 25.1 71
Apotex Inc 1,101,172 34.2 16.1 15
Genpharm Pharma 365,097 11.4 9.4 15
Novopharm 485,092 15.1 8.3 18
Taro Pharmaceuticals 37,346 1.2 6.4 10
Hospira 14,486 0.5 4.1 -30

Appendix
IMS Health Information Services
The data used to compile Canadian Pharmaceutical Industry Review were drawn from four IMS information services:
Canadian Drug Store and Hospital Purchases Audit (CDH)

The Canadian Drug Store and Hospital Purchases Audit (CDH) measures the dollar value and unit volume
of pharmaceutical and diagnostic products purchased by Canadian retail pharmacy outlets and hospitals.
Data for CDH are collected from a representative sample of 2,000 drug stores and 550 hospitals and long-term
care facilities. The sample data is then projected to the universe of drug stores and hospitals, to reflect all purchases
across Canada.
The drug store sample and universe are stratified by size (small, medium, large) and region (B.C., Alberta,
Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland/P.E.I.). The hospital
sample and universe are stratified by region and type (general, long term care, pediatric, psychiatric, cancer centres,
government, redistribution centers and all other specialties). General hospitals and long-term care centres are
further stratified by size (small vs. large). A stratum labeled “take-all” is used to represent highly skewed populations.
A take-all stratum corresponds to outlets whose purchasing habits (based on their therapeutic class) are atypical
or abnormal.
Canadian CompuScript
The CompuScript audit measures the number of prescriptions dispensed by Canadian retail pharmacies. Product
information is presented according to therapeutic class and for each product the following data elements are
collected: manufacturer, form, strength, new vs. refill prescriptions, prescription size and price, transaction location,
transaction date, MD number (if available), third-party payer (if available) and authorized repeats.
The CompuScript sample is drawn from IMS’s panel of over 4,500 pharmacies, which represents nearly two-thirds
of all retail pharmacies in Canada; over 2,600 stores are used for the CompuScript audit, each stratified by province,
type (chain or independent) and size (large or small). Records are collected monthly from each of these pharmacies
– via diskette for stores with independent computer systems, or via an external software supplier for stores that
are part of a data network system. Sample data collected are then projected to the universe in each province and
provincial totals are added together to provide a national estimate.
124 Appendix
Canadian Disease and Therapeutic Index (CDTI)
The Canadian Disease and Therapeutic Index collects treatment data from a sample of Canadian office-based
physicians and identifies usage and treatment patterns by drug and by physician specialty.
Data for CDTI are collected from a sample of 652 office-based physicians stratified by geographic region and
representing all major specialties. For each of four consecutive quarters, each physician submits a case record book,
detailing information for all patients (excluding patient identity) seen during a 48-hour reporting period during
the quarter. The data are then validated, coded and processed.
Canadian Promotion Audit (CPA)

The Canadian Promotion Audit (CPA) measures the promotional efforts of pharmaceutical manufacturers by
reporting on sales calls made by company representatives to a sample of Canadian physicians and by tracking journal
advertising placements and expenditures.
Information on the product detailing efforts of pharmaceutical representatives is collected each month from
642 office-based physicians, stratified by region and specialty, who record representative calls on a secure website.
The information is coded and processed and then projected to provide a national estimate. To collect advertising
spending information IMS conducts a monthly audit of ads placed in over 88 journals. The journals represent
virtually all medical publications in Canada, including general, specialty, pharmacy, nursing, hospital and dental
journals. Canadian Advertising Rates Data serve as the basis for estimating ad placement expenditures.
Appendix 125
Manufacturer Abbreviations
A9N Actelion Pharma Canada MSD Merck Frosst Can

AAA ALTANA Pharma Inc MU& Merck-Schering GP
AAI Amgen N-N Novo Nordisk CDA
ABD Abbott PPD N&U Nucro-Technics
AES Astellas Pharma NU– Nu-Pharm Inc
AHP Abbott HPD NV- Novartis Consumer Health
ALC Alcon Canada NVP Novopharm
ALL Allergan NVR Novartis Pharma
ATX Apotex Inc OBD Ortho-Biotech Products
AZN AstraZeneca ORG Organon
B.I Boehringer Ingelheim ORY Oryx Pharma Inc
B5L Biovail Pharma P8I Pharmascience
BAY Bayer Pharma PDN Paladin
BGE Biogen Idec PDO Pro Doc
BIH Bioenhance PFZ Pfizer
BMS B BMS Pharma PMQ Pharmascience Consumer Product Division
BSQ Bristol-Myers Squibb Canada PRG P&G Pharma
BSA BMS-Sanofi PRL Private Label
BXL Berlex Canada PUF Purdue Pharma
CBT Cobalt Pharma RAT ratiopharm Inc
DER Dermik RBY Ranbaxy Pharma Canada
DMI Dominion Pharmacal R-D Roche Diagnostics
FER Ferring ROC Roche
FOU Fournier RVA Riva
FRO Frosst S.A sanofi-aventis Canada
GLD Galderma S/C Shire Canada
GN3 Genpharm Pharma SDZ Sandoz Canada
GS- Gilead Sciences SER Serono Canada
GSK GlaxoSmithKline SF2 Sanofi-Pasteur
JNO Janssen-Ortho Inc SHC Schering
LEO Leo Pharma Inc SVR Servier Lab
LFS Lifescan SVY Solvay Pharma
LLY Lilly TAR Taro Pharmaceuticals
L&I Lilly Icos TP/ TAP Pharmaceutical Products
LSN Linson Pharma Inc TVN Teva Neuroscience
LUN Lundbeck Canada Inc VP3 Virco Pharma
M3Y Mayne Pharma (Canada) Inc WYE Wyeth Pharmaceuticals
MCC McNeil Consumer
126 Appendix
Glossary
Number of ad pages: the total number of pages of advertising devoted to a product or manufacturer.
Average compound growth rate: average annual growth rate between any two time periods.
CPA: indicates a product is co-detailed by a second sales force.
Detail: the presentation of a product to a physician by a sales representative.
Detail minutes: the physician’s perception of the time in minutes spent by a sales representative in detailing
a product to a physician.
Drug mentions: number of times a product is recommended by physicians in the given time period.
Ethical market: that part of the market which is driven by health care professionals. Most products, but not all,
require a prescription.
Evolution index: growth rate of a specific product, manufacturer or corporation when compared to the growth
rate of the class, corporation or market, respectively. For comparison purposes, the growth rate of the class,
corporation or market is given an index of 100.
Extended unit: smallest measurable unit of a product depending on the product form, e.g., tablet, millilitre, gram.
General discussion: no specific detailing occurs during a representative’s visit with a physician.
Institutional: describes company services or research but does not contain product-specific information.
Manufacturer not stated: activity recorded for a product where the manufacturer name is not provided at
the collection point.
Molecule: the chemical name for the active ingredient in a product.
Most productive specialty: the specialty or specialty group which makes the highest per capita number
of diagnoses or drug recommendations.
Patient visits: estimated number of patient/physician contacts in a given time period.
Patient visits with drugs: estimated number of patient/physician contacts where drug therapy is recommended.
Private label: a line of products specially manufactured and labelled for a drug store chain. This category reports
the combined activity of private labels for all drug store chains.
Rx: prescription.
Therapeutic class: a classification grouping products exhibiting similar therapeutic properties.
Total “Product Name”: shows the sum of the activity for all forms and strengths of the product.
Total promotional dollars: the sum of the costs of detailing and the costs of journal advertising.
Total purchases: the total estimated drug store and hospital purchases measured by IMS Health, Canada.
This includes all ethical products and some non-ethical (proprietary) products.
Appendix 127
Helping you stay

ABOUT IMS HEALTH
IMS HEALTH®
Industry Review


Toronto: (905) 816-5000

IMS Canada

Caricato da

Informazioni sul documento

Descrizione originale:

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

IMS Canada

Caricato da

Copyright:

Formati disponibili

Helping you stay

2006 Canadian Pharmaceutical ahead of the curve

2006 Canadian Pharmaceutical Industry Review

Contact your IMS representative to learn more

IMS Health Montreal: (514) 428-6000

2006 Canadian Pharmaceutical Industry Review

Contact your IMS representative to learn more

IMS Health Montreal: (514) 428-6000

I. Corporations and Manufacturers 17

II. Products and Molecules 47

III. Therapeutic Classes 67

Latin America 27.1 4.6 13.4 13.5

Sales and Growth in 10 Leading Markets 12 Months Ending September 2006

U.S.$ Bil Growth (%)

10 Key Markets 478.0 5.6

*Hospital Market Only, % Growth, Constant $ **Pharmacy Market Only

Leading Global Corporations

Top 10 Corporations 12 Months Ending September 2006

Worldwide 593.4 100.0 6.3 9.1

Source: IMS Health. MIDAS

Top 10 Brands by Global Pharmaceutical Sales

1 Lipitor (atorvastatin) 13.4 2.3 4.6 15.8

Source: IMS Health Midas. MAT Sep 2006

Direct-to-Consumer Advertising Expenditures 1997 to MAT September 2006

Drug Store and Hospital Purchases

Canadian Drug Store and Hospital Purchases 2006

Total $17.80 billion 7.8 100.0 9.5

Source: IMS Health. Canadian Drug Stores and Hospital Purchases.

Leading Therapeutic Classes in Drug Store and Hospital Purchases 2006

1 Cardiovasculars $2,470 6.2% 8.8%

Source: IMS Health. Canadian Drug Stores and Hospital Purchases

Top 10 Pharmaceutical Corporations by Sales

Canadian Ethical Market Top Ten Corporations, 2006

CANADA $17.79 100.0 7.8 9.5

Number of Listing Average Time to Concordance with

British Columbia 42 10 654 450 32/42

Generic Purchases – Drug Stores and Hospitals 2006

Source: IMS Health. Canadian Drug Stores and Hospital Purchases

Total Ethical Market 17,816,652 100.0 7.9 100 8

1 1 1 1 1 Pfizer 2,353,000 13.2 4.4 97 7

4 3 2 2 2 AstraZeneca 1,172,092 6.6 4.6 97 8

6 6 5 5 3 Apotex Inc 1,101,172 6.2 16.1 108 15

5 4 3 3 4 J&J 1,054,695 5.9 0.5 93 11

2 2 4 4 5 GlaxoSmithKline 994,406 5.6 3.4 96 1

9 9 8 7 6 sanofi-aventis Canada 675,831 3.8 8.1 100 10

8 7 7 6 7 Novartis 674,155 3.8 6.2 98 8

11 10 9 9 8 Wyeth 646,549 3.6 10.8 103 13

18 Corporations and Manufacturers

12 12 10 10 9 Lilly 620,957 3.5 8.7 101 12

14 14 13 13 10 Roche 600,857 3.4 27.7 118 17

10 11 12 12 11 Abbott 553,494 3.1 8.3 100 5

7 8 11 11 12 Bristol-Myers Squibb Canada 552,067 3.1 1.7 94 2

3 5 6 8 13 Merck Frosst 514,780 2.9 -14.5 79 -13

16 17 15 14 14 Novopharm 485,092 2.7 8.3 100 18

13 13 14 15 15 Schering-Plough 446,659 2.5 8.9 101 8

27 22 21 20 16 Amgen 373,366 2.1 23.9 115 44

18 16 16 18 17 Genpharm Pharma 365,097 2.0 9.4 101 15

Corporations and Manufacturers 19

17 18 17 17 18 Pharmascience 360,525 2.0 1.7 94 10

19 19 18 16 19 ratiopharm Inc 359,381 2.0 0.4 93 16

15 15 19 19 20 Bayer Inc 349,911 2.0 13.2 105 4

21 21 22 22 21 ALTANA Pharma Inc 305,761 1.7 14.0 106 16

20 20 20 21 22 Boehringer Ingelheim 298,852 1.7 10.9 103 13